<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis - Macfarlane, CL - 2019 | Cochrane Library</title> <meta content="Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis - Macfarlane, CL - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003753.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis - Macfarlane, CL - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003753.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003753.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis" name="citation_title"/> <meta content="Cara L Macfarlane" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="cara.macfarlane1@outlook.com" name="citation_author_email"/> <meta content="Shyam S Budhathoki" name="citation_author"/> <meta content="B P Koirala Institute of Health Sciences" name="citation_author_institution"/> <meta content="Samuel Johnson" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Marty Richardson" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Paul Garner" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD003753.pub4" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/01/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003753.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003753.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003753.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Albendazole [*therapeutic use]; Antigens, Helminth [blood]; Diethylcarbamazine [therapeutic use]; Drug Therapy, Combination; Elephantiasis, Filarial [*drug therapy, immunology]; Filaricides [*therapeutic use]; Ivermectin [therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003753.pub4&amp;doi=10.1002/14651858.CD003753.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6zFwvAqw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003753\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003753\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003753\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003753\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","fr","fa","zh_HANS"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD003753.pub4",title:"Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis",firstPublishedDate:"Jan 8, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003753.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003753.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003753.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003753.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003753.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003753.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003753.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003753.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003753.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003753.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11898 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003753.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-sec-0144"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-sec-0030"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-sec-0031"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-sec-0038"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-sec-0039"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-sec-0070"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-sec-0130"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/appendices#CD003753-sec-0149"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/table_n/CD003753StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/table_n/CD003753StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/information#CD003753-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Cara L Macfarlane</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/information#CD003753-cr-0003">Shyam S Budhathoki</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/information#CD003753-cr-0004">Samuel Johnson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/information#CD003753-cr-0005">Marty Richardson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003753.pub4/information#CD003753-cr-0006">Paul Garner</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/information/en#CD003753-sec-0155">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 January 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003753.pub4">https://doi.org/10.1002/14651858.CD003753.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003753-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003753-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003753-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003753-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003753-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003753-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003753-abs-0001" lang="en"> <section id="CD003753-sec-0001"> <h3 class="title" id="CD003753-sec-0001">Background</h3> <p>The Global Programme to Eliminate Lymphatic Filariasis recommends mass treatment of albendazole co‐administered with the microfilaricidal (antifilarial) drugs diethylcarbamazine (DEC) or ivermectin; and recommends albendazole alone in areas where loiasis is endemic. </p> </section> <section id="CD003753-sec-0002"> <h3 class="title" id="CD003753-sec-0002">Objectives</h3> <p>To assess the effects of albendazole alone, and the effects of adding albendazole to DEC or ivermectin, in people and communities with lymphatic filariasis. </p> </section> <section id="CD003753-sec-0003"> <h3 class="title" id="CD003753-sec-0003">Search methods</h3> <p>We searched the Cochrane Infectious Diseases Group Specialized Register, the Cochrane Central Register of Controlled Trials, MEDLINE (PubMed), Embase (OVID), LILACS (BIREME), and reference lists of included trials. We also searched the World Health Organization (WHO) International Clinical Trials Registry Platform and ClinicalTrials.gov to identify ongoing trials. We performed all searches up to 15 January 2018. </p> </section> <section id="CD003753-sec-0004"> <h3 class="title" id="CD003753-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) and cluster‐RCTs that compared albendazole to placebo or no placebo, or compared albendazole combined with a microfilaricidal drug to a microfilaricidal drug alone, given to people known to have lymphatic filariasis or communities where lymphatic filariasis was known to be endemic. We sought data on measures of transmission potential (microfilariae (mf) prevalence and density); markers of adult worm infection (antigenaemia prevalence and density, and adult worm prevalence detected by ultrasound); and data on clinical disease and adverse events. </p> </section> <section id="CD003753-sec-0005"> <h3 class="title" id="CD003753-sec-0005">Data collection and analysis</h3> <p>At least two review authors independently assessed the trials, evaluated the risks of bias, and extracted data. The main analysis examined albendazole overall, whether given alone or added to a microfilaricidal drug. We used data collected from all randomized individuals at time of longest follow‐up (up to 12 months) for meta‐analysis of outcomes. We evaluated mf density data up to six months and at 12 months follow‐up to ensure that we did not miss any subtle temporal effects. We conducted additional analyses for different follow‐up periods and whether trials reported on individuals known to be infected or both infected and uninfected. We analysed dichotomous data using the risk ratio (RR) with a 95% confidence interval (CI). We could not meta‐analyse data on parasite density outcomes and we summarized them in tables. Where data were missing, we contacted trial authors. We used GRADE to assess the certainty of evidence. </p> </section> <section id="CD003753-sec-0006"> <h3 class="title" id="CD003753-sec-0006">Main results</h3> <p>We included 13 trials (12 individually‐randomized and one small cluster‐randomized trial) with 8713 participants in total. No trials evaluated population‐level effects of albendazole in mass drug administration programmes. Seven trials enrolled people with a variety of inclusion criteria related to filarial infection, and six trials enrolled individuals from endemic areas. Outcomes were reported as end or change values. Mf and antigen density data were reported using the geometric mean, log mean and arithmetic mean, and reductions in density were variously calculated. Two trials discounted any increases in mf density in individuals at follow‐up by setting any density increase to zero. </p> <p>For mf prevalence over two weeks to 12 months, albendazole alone or added to another microfilaricidal drug makes little or no difference (RR 0.95, 95% CI 0.85 to 1.07; 5027 participants, 12 trials, high‐certainty evidence). For mf density there is no trend, with some trials reporting a greater reduction in mf density with albendazole and others a greater reduction with the control group. For mf density up to six months and at 12 months, we do not know if albendazole has an effect (one to six months: 1216 participants, 10 trials, very low‐certainty evidence<i>;</i> at 12 months: 1052 participants, 9 trials, very low‐certainty evidence). </p> <p>For antigenaemia prevalence between six to 12 months, albendazole alone or added to another microfilaricidal drug makes little or no difference (RR 1.04, 95% CI 0.97 to 1.12; 3774 participants, 7 trials, high‐certainty evidence). For antigen density over six to 12 months, the trend shows little or no effect of albendazole; but we do not know if albendazole has an effect on antigen density (1374 participants, 5 trials, very low‐certainty evidence). For adult worm prevalence detected by ultrasound at 12 months, albendazole added to a microfilaricidal drug may make little or no difference (RR 1.16, 95% CI 0.72 to 1.86; 165 participants, 3 trials, low‐certainty evidence). </p> <p>For people reporting adverse events, albendazole makes little or no difference (RR 0.97, 95% CI 0.84 to 1.13; 2894 participants, 6 trials, high‐certainty evidence). </p> <p>We also provide meta‐analyses and GRADE tables by drug, as operationally this may be of interest: for albendazole versus placebo (4 trials, 1870 participants); for albendazole with DEC compared to DEC alone (8 trials, 3405 participants); and albendazole with ivermectin compared to ivermectin alone (4 trials, 3438 participants). </p> </section> <section id="CD003753-sec-0007"> <h3 class="title" id="CD003753-sec-0007">Authors' conclusions</h3> <p>There is good evidence that albendazole makes little difference to clearing microfilaraemia or adult filarial worms in the 12 months post‐treatment. This finding is consistent in trials evaluating albendazole alone, or added to DEC or ivermectin. Trials reporting mf density included small numbers of participants, calculated density data variously, and gave inconsistent results. </p> <p>The review raises questions over whether albendazole has any important contribution to the elimination of lymphatic filariasis. To inform policy for areas with loiasis where only albendazole can be used, it may be worth conducting placebo‐controlled trials of albendazole alone. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003753-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003753-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003753-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003753-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003753-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003753-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD003753-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003753-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003753-abs-0004" lang="en"> <h3>Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis</h3> <p>In this Cochrane Review, Cochrane researchers examined the effects of using albendazole alone and albendazole added to antifilarial drugs to treat infected people and people who live in areas with lymphatic filariasis. After searching for relevant trials up to January 2018, we included 13 randomized controlled trials (RCTs), including one cluster‐RCT, with a total of 8713 participants. </p> <p><b>Lymphatic filariasis</b> </p> <p>Lymphatic filariasis, a disease common in tropical and subtropical areas, is spread by mosquitoes and caused by infection with parasitic filarial worms. After a person is infected from a mosquito bite, the worms grow into adults and mate to produce microfilariae (mf). The mf circulate in the blood so they can be collected by mosquitoes, and the infection can be spread to another person. Infection can be diagnosed by checking for the presence of circulating mf (microfilaraemia) or parasite antigens (antigenaemia), or by ultrasound imaging to detect live adult worms. </p> <p>The World Health Organization (WHO) recommends mass treatment of entire populations once a year for many years. Treatment is a two‐drug combination of albendazole and a microfilaricidal (antifilarial) drug, either diethycarbamazine (DEC) or ivermectin. Albendazole alone is recommended for people when DEC or ivermectin can not be used. </p> <p><b>What the research says</b> </p> <p>Albendazole alone or added to a microfilaricidal drug makes little or no difference to mf prevalence over two weeks to 12 months after treatment (high‐certainty evidence), but we do not know if albendazole alone or in combination reduces mf density between one to six months (very low‐certainty evidence) or at 12 months (very low‐certainty evidence). </p> <p>Treatment with albendazole alone or added to a microfilaricidal drug makes little or no difference to antigenaemia prevalence between six to 12 months (high‐certainty evidence). We do not know if albendazole alone or in combination reduces antigen density over six to 12 months (very low‐certainty evidence). Albendazole added to a microfilaricidal drug may make little or no difference to adult worm prevalence detected by ultrasound at 12 months (low‐certainty evidence). </p> <p>When given alone or added to a microfilaricidal drug, albendazole makes little or no difference to the number of people reporting an adverse event (high‐certainty evidence). </p> <p><b>Authors' conclusions</b> </p> <p>There is good evidence that albendazole, alone or added to DEC or ivermectin, delivers little or no benefit for totally clearing the mf or the adult worms up to 12 months after treatment. Evidence for an effect of albendazole in reducing the numbers of mf and adult worms is inconsistent. To inform policy for areas where ivermectin and DEC can not be given, further research could help determine whether there is any effect of albendazole alone. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003753-sec-0144" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003753-sec-0144">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003753-sec-0218">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003753-sec-0144"></div> <h3 class="title" id="CD003753-sec-0145">Implications for practice</h3> <section id="CD003753-sec-0145"> <p>There is good evidence from individually‐randomized trials that albendazole has little or no effect on completely clearing the mf or adult worms up to 12 months after treatment, and no convincing data across studies of an effect on mf density or adult worm viability. This finding is consistent in studies evaluating albendazole alone, or studies where albendazole is added to DEC or ivermectin‐ two drugs known to be effective in community treatment programmes. </p> <p>If there is a true but as yet unproven effect on parasite density, then it is possible that albendazole could have an effect on transmission in mass treatment programmes. There are no large cluster‐randomized studies to determine whether there is a population‐level effect, although these were called for in the initial WHO informal consultation in 1998 (<a href="./references#CD003753-bbs2-0098" title="Filariasis Elimination Programme (CDS/FIL). Report from informal consultation on albendazole research findings in lymphatic filariasis 13‐14 October 1998. Geneva: World Health Organization WHO/FIL/98.1941998. ">WHO 1998</a>). </p> <p>This review, and the earlier editions, raise fundamental questions around the evidence base of the effectiveness of albendazole and thus its inclusion in the global lymphatic filariasis elimination programme. Given that the drug is part of mainstream policy, and the WHO now recommend the triple‐drug regimen IDA (ivermectin, DEC, and albendazole), we are unlikely to see new research evaluating albendazole in combination with DEC or ivermectin. </p> <p>However, albendazole alone is recommended in areas endemic for <i>L loa</i>. In our view, this remains a priority for research through placebo‐controlled trials to know whether the drug is effective in these communities. </p> </section> <h3 class="title" id="CD003753-sec-0146">Implications for research</h3> <section id="CD003753-sec-0146"> <p>The key area that needs elucidation is whether albendazole has an independent effect on mf density, to guide treatment decisions for lymphatic filariasis in <i>L loa‐</i>endemic areas. </p> <p>Re‐analysis of the existing parasite density data as part of an individual patient data meta‐analysis would be theoretically helpful, but we have sought the data without success, and this does not look feasible. Future study authors should consider depositing their data and analyses in community‐recognized repositories, to make it possible to reproduce results and facilitate meta‐analysis. </p> <p>In further research, it would help if there were better standardization in field and analytical methods. Techniques for assessing mf in blood and outcome measures for mf densities should also be standardized, with complete reporting of all randomized individuals. The synthesis of data for mf density in this review proved to be challenging. In many studies, the authors applied log transformations to the data to be able to calculate geometric means, since data were skewed. It was not possible to meta‐analyse data for this outcome due to poor reporting of methods of analysis and results in the individual study reports. Firstly, many studies described methods to accommodate zero values (such as adding 1 to each value before taking the log of each value), but these methods were often not sufficiently detailed and referenced. Study authors should describe exactly how the method was applied (i.e. to all values or to zero values only), and exactly what summary measures are presented (i.e. geometric means, log means) and how these were calculated. </p> <p>For example, <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a> reports that “geometric mean intensities (mf GMIs) were calculated as antilog[(∑ log x + 1))/n] – 1”; this is perfectly sufficient detail, but many studies’ methods were not so clear. Secondly, several studies reported only the point estimates of the geometric mean, or the log mean, without any measure of variance or CIs. Studies should report measures of variance or CIs so that the amount of uncertainty in the estimate is clear; this would also enable study results to be included in meta‐analyses. Finally, some studies reported no transformation onto the log scale for skewness in the data; if data were skewed then summarizing using arithmetic means is not appropriate, and it then becomes impossible to combine studies which report arithmetic means with studies that report geometric or log means. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003753-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003753-sec-0030"></div> <div class="table" id="CD003753-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Albendazole alone or added to a microfilaricidal drug for lymphatic filariasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Albendazole alone or added to a microfilaricidal drug for lymphatic filariasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with lymphatic filariasis or communities where lymphatic filariasis is endemic<br/> <b>Setting:</b> Brazil, Ghana, Haiti, India, Papua New Guinea, Tanzania, and Zanzibar </p> <p><b>Intervention:</b> albendazole alone or in combination with a microfilaricidal drug<br/> <b>Comparison:</b> placebo or a single microfilaricidal drug </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment or a single microfilaricidal drug</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with albendazole alone or in combination with a microfilaricidal drug</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microfilaraemia (mf) prevalence<br/> follow‐up: range 2 weeks to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>174 per 1000<br/> (154 to 196) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95<br/> (0.85 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5027<br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole makes little or no difference to mf prevalence.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mf density<br/> follow‐up: range 1 month to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>In the included studies the effects of treatment with albendazole varied. The difference between treatment groups ranged from a 81.7% greater reduction with albendazole to 13.6% greater reduction with a single microfilaricidal drug.<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1216<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b,c,d</sup> </p> <p><i>Due to risk of bias, inconsistency, and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if albendazole has an effect on mf density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mf density<br/> follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>In the included studies the effects of treatment with albendazole varied. The difference between treatment groups ranged from a 55.5% greater reduction with albendazole to a 15.8% greater reduction with a single microfilaricidal drug.<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1052<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>c,f</sup> </p> <p><i>Due to inconsistency and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if albendazole has an effect on mf density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigenaemia prevalence<br/> follow‐up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>435 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>452 per 1000<br/> (422 to 487) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04<br/> (0.97 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3774<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole makes little or no difference to antigenaemia prevalence.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigen density<br/> follow‐up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>In the included studies treatment with albendazole had little or no effect on antigen density. There was a 1.5% to 17.1% greater reduction with albendazole in all studies except one; this study reported a 64.4% greater reduction in antigen density due to a small reduction with albendazole (16.9%) but a large increase in the placebo group.<sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1374<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>i,j,k</sup> </p> <p><i>Due to risk of bias and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if albendazole has an effect on antigen density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult worm prevalence detected by ultrasound<br/> follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>268 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>311 per 1000<br/> (193 to 499) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.16<br/> (0.72 to 1.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>l,m,n</sup> </p> <p><i>Due to indirectness and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole may make little or no difference to adult worm prevalence detected by ultrasound. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>184 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>178 per 1000<br/> (155 to 208) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.97<br/> (0.84 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2894<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>o</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole makes little or no difference to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> Abbreviations: CI: confidence interval; RR: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Eight studies reported geometric means, one study reported log mean, and one study reported the arithmetic mean. An effect of albendazole (P &lt; 0.05) on the geometric mean mf density was reported in three analyses in two studies. No effect of albendazole (P &gt; 0.05) was reported in six studies that used the geometric mean.<br/> <sup>b</sup>Downgraded by one for risk of bias: we judged the analytical methods used by <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> and <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> to obtain the change in density from baseline to follow‐up to be at high risk of bias.<br/> <sup>c</sup>Downgraded by one for inconsistency: the direction and magnitude of effect reported varied in favour of both albendazole and a microfilaricidal drug alone. We judged the effects of albendazole to be inconsistent.<br/> <sup>d</sup>Downgraded by two for imprecision: the optimal information size was met. There was considerable variation in the effects of albendazole, ranging from a statistically significant effect of albendazole (P &lt; 0.05) to little no effect. Authors reported mf density using geometric means, log means, and arithmetic means. We judged that the range of values that the effect estimate might take would likely include a meaningful effect and no effect.<br/> <sup>e</sup>Six studies reported geometric means, one study reported the log mean, and two studies reported the arithmetic mean. Five studies that assessed the geometric mean reported no effect was detected in six analyses (P &gt; 0.05).<br/> <sup>f</sup>Downgraded by two for imprecision: the optimal information size was met. There was considerable variation in the effects of albendazole; ranging from estimates with apparently large but underpowered effects (P &gt; 0.05) to estimates with little or no effect. Authors reported mf density using geometric means, log means, and arithmetic means. Given the differences in these measures, we are unable to judge the precision of the estimate of effect across the studies.<br/> <sup>g</sup>Not downgraded for risk of bias: most information is from studies at low or unclear risk of bias. Four studies had high risk of bias for attrition, but participant numbers at follow‐up were generally comparable between groups. We judge plausible bias unlikely to seriously alter the results.<br/> <sup>h</sup>Three studies reported geometric means, one study reported the log mean, and one study reported the arithmetic mean. Five analyses in three studies reported no effect of albendazole (P &gt; 0.05).<br/> <sup>i</sup>Downgraded by one for risk of bias: we judged the analytical methods used by <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> to obtain the change in density from baseline to follow‐up to be at high risk of bias.<br/> <sup>j</sup>Not downgraded for inconsistency: little to no benefit of albendazole was seen consistently across the studies. We judged the direction and the magnitude of effect to be consistent across studies.<br/> <sup>k</sup>Downgraded by two for imprecision: the optimal information size was met. Little to no effect of albendazole was consistently reported across the studies. All studies that reported a test for differences reported no statistically significant effect on geometric mean antigen density (P &gt; 0.05). We judged that the range of values would probably include little or no effect and exclude appreciable benefit or harm, but with no effect estimate or measure of precision we judged this to be seriously imprecise.<br/> <sup>l</sup>Not downgraded for risk of bias: all studies had unclear risk of bias for random sequence generation. The study contributing the most (68.7%) to the effect estimate had high risk of bias for attrition, but the number of participants followed up was comparable between groups. We judged plausible bias unlikely to seriously alter the results.<br/> <sup>m</sup>Downgraded by one for indirectness: this outcome was assessed only in men and boys (three studies). Two studies included adult men only, and one very small study included adults and children. We judged the evidence for this outcome to have serious indirectness due to the lack of applicability to the wider population of interest.<br/> <sup>n</sup>Downgraded by one for imprecision: there were insufficient events to meet optimal information size. The 95% CI around the pooled estimate of effect includes both no effect and appreciable benefit and harm, using a 25% relative risk reduction (RRR).<br/> <sup>o</sup>Not downgraded for risk of bias: for participant and personnel blinding, two studies had unclear risk of bias and one study was at high risk of bias. A large safety study contributing the most to the overall effect estimate (52.6%) had low risk of bias for blinding. We judged plausible bias unlikely to seriously alter the results. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003753-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Albendazole alone for lymphatic filariasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Albendazole alone for lymphatic filariasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with lymphatic filariasis or communities where lymphatic filariasis is endemic<br/> <b>Setting:</b> Ghana, Haiti and India<br/> <b>Intervention:</b> albendazole<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with albendazole</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microfilaraemia (mf) prevalence<br/> follow‐up: range 4 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>207 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>203 per 1000<br/> (168 to 246) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98<br/> (0.81 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1406<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole makes little or no difference to mf prevalence.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mf density<br/> follow‐up: range 4 months to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Trend favoured albendazole to a variable extent. Albendazole reduced the geometric mean mf density by 28.7% to 61.1%. Placebo reduced the geometric mean mf density up to 17.2%, but the density also increased by 20.6%.<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>d,e,f</sup> </p> <p><i>Due to risk of bias, inconsistency, and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if albendazole has an effect on mf density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mf density<br/> follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No trend. In one study that reported the geometric mean, albendazole reduced mf density by 68.5% and in the placebo group the reduction was 13%; however, the authors reported no significant difference with albendazole (P &gt; 0.05).<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>h,i</sup> </p> <p><i>Due to inconsistency and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if albendazole has an effect on mf density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigenaemia prevalence<br/> follow‐up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>355 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 per 1000<br/> (323 to 444) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.07<br/> (0.91 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1054<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole makes little or no difference to antigenaemia prevalence.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigen density<br/> follow‐up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Trend showed little or no effect of albendazole. Albendazole reduced the geometric mean antigen density by 3.2% to 16.9%, and the placebo group antigen density was reduced by 1.7% and also increased by 47.5%.<sup>j</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>371<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>k,l,m</sup> </p> <p><i>Due to risk of bias and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if albendazole has an effect on antigen density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult worm prevalence detected by ultrasound ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult worm prevalence detected by ultrasound was not measured for this comparison.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/> (65 to 157) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95<br/> (0.61 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>678<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>n,o</sup> </p> <p><i>Due to imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole probably makes little or no difference to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> Abbreviations: CI: confidence interval; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for risk of bias: most information is from studies at low or unclear risk of bias. Three studies had unclear or high risk of bias for attrition, but numbers of participants followed up were comparable between groups in each study. We judged plausible bias unlikely to seriously alter the results.<br/> <sup>b</sup>Not downgraded for imprecision: borderline sufficient events to meet optimal information size (289 total events), and the 95% CI around the pooled estimate of effect includes little or no effect and excludes clinically appreciable benefit and harm. We used a relative risk reduction (RRR) of 25% as a cut‐off for imprecision.<br/> <sup>c</sup>Of the three studies that reported the geometric mean; one study reported an effect of albendazole (P &lt; 0.05), one study reported no effect (P &gt; 0.05), and one study did not statistically test this. One study reporting the arithmetic mean suggested a large benefit with albendazole, but we judged this to be an inappropriate measure for skewed data.<br/> <sup>d</sup>Downgraded by one for risk of bias: we judged the analytical methods used by <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> and <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> to obtain the change in density from baseline to follow‐up to be at high risk of bias.<br/> <sup>e</sup>Downgraded by one for inconsistency: the benefit of albendazole and the magnitude of effect was inconsistent.<br/> <sup>f</sup>Downgraded by two for imprecision: the optimal information size was not met. There was considerable variation in the effects of albendazole on geometric mean mf density; ranging from an effect in one study (P &lt; 0.05), an apparently large effect in one study that was not statistically evaluated, and no effect in one study (P &gt; 0.05). One study reported the arithmetic mean. We judged that the range of values could include a meaningful effect and no effect.<br/> <sup>g</sup>One study reported the arithmetic mean and showed a large benefit with albendazole, but we judged it to be an inappropriate measure for skewed data.<br/> <sup>h</sup>Downgraded by one for inconsistency: two studies reported a greater reduction in mf density with albendazole, but the magnitude of effect was unclear. One study reported the geometric mean and reported no effect of albendazole (P &gt;0.05), and one study reported the arithmetic mean and did not test for differences.<br/> <sup>i</sup>Downgraded by two for imprecision: the optimal information size was not met. One study reported the geometric mean mf density and an apparently large but underpowered effect (P &gt; 0.05). One study suggested a large reduction in the arithmetic mean with albendazole and did not statistically evaluate the effect. We judged that the range of values could include a meaningful effect and no effect.<br/> <sup>j</sup>Both studies reported that there was no effect using albendazole (P &gt; 0.05).<br/> <sup>k</sup>Downgraded by one for risk of bias: we judged the analytical methods used by <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> to obtain the change in density from baseline to follow‐up to be at high risk of bias.<br/> <sup>l</sup>Not downgraded for inconsistency: we found little to no effect of albendazole consistently across the studies. We judged the direction and the magnitude of effect to be consistent across studies.<br/> <sup>m</sup>Downgraded by two for imprecision: the optimal information size was not met. Two studies reported geometric mean antigen density and no benefit of using albendazole (P &gt; 0.05). We judged that the range of values would likely include little or no effect and exclude appreciable benefit or harm, but we can not be certain with no effect estimate or measure of precision.<br/> <sup>n</sup>Not downgraded for indirectness: albendazole regimens differed, one study provided single dose 400 mg albendazole and one study provided daily dose 400 mg albendazole for seven days. However, we judge this does not have serious indirectness.<br/> <sup>o</sup>Downgraded by one for imprecision: insufficient events to meet optimal information size. The 95% CI around the pooled estimate of effect includes both no effect and appreciable benefit and harm, using a relative risk reduction (RRR) of 25%. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003753-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Albendazole added to DEC for lymphatic filariasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Albendazole added to DEC for lymphatic filariasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with lymphatic filariasis or communities where lymphatic filariasis is endemic<br/> <b>Setting:</b> Brazil, Haiti, India and Papua New Guinea<br/> <b>Intervention:</b> albendazole plus DEC<br/> <b>Comparison:</b> DEC </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with DEC</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with albendazole plus DEC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microfilaraemia (mf) prevalence<br/> follow‐up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>262 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>236 per 1000<br/> (197 to 286) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.90<br/> (0.75 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1102<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b</sup> </p> <p><i>Due to imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole probably makes little or no difference to mf prevalence.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mf density<br/> follow‐up: range 1 months to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No trend. The difference between the albendazole plus DEC and the DEC groups percentage reductions from baseline ranged from a 30% greater reduction with albendazole plus DEC to a 13.6% greater reduction with DEC alone.<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>559<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>d,e,f</sup> </p> <p><i>Due to risk of bias, inconsistency, and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if albendazole has an effect on mf density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mf density<br/> follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Trend showed little or no effect of albendazole. The difference between the albendazole plus DEC and the DEC groups percentage reductions from baseline ranged from a 5.6% greater reduction with albendazole plus DEC to a 15.8% greater reduction with DEC alone.<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>535<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>h,i</sup> </p> <p><i>Due to imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole may make little or no difference to mf density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigenaemia prevalence<br/> follow‐up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>503 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>518 per 1000<br/> (463 to 574) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/> (0.92 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>954<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>j</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole makes little or no difference to antigenaemia prevalence.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigen density<br/> follow up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Trend showed little or no effect of albendazole. The difference between the albendazole plus DEC and the DEC groups percentage reductions from baseline ranged from a 9.7% greater reduction in the geometric mean to a 10.7% greater reduction in the log mean with albendazole plus DEC.<sup>k</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>h,l,m</sup> </p> <p><i>Due to risk of bias and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if albendazole has an effect on antigen density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult worm prevalence detected by ultrasound<br/> follow up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>268 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>311 per 1000<br/> (193 to 499) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.16<br/> (0.72 to 1.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>n,o,p</sup> </p> <p><i>Due to indirectness and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole may make little or no difference to adult worm prevalence detected by ultrasound. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>240 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000<br/> (189 to 266) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.94<br/> (0.79 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1589<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>q</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole makes little or no difference to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> Abbreviations: CI: confidence interval; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for inconsistency: I<sup>2</sup> of 40% was explained through subgroup analysis. The heterogeneity was a result of one study which used a more intensive treatment regimen (daily dose for 12 days) compared to the other six studies (single dose). We therefore judged inconsistency does not seem to be a serious issue.<br/> <sup>b</sup>Downgraded by one for imprecision: insufficient events to meet optimal information size (276 total events). Using a relative risk reduction (RRR) of 25% as a cut‐off for imprecision, the 95% CI around the pooled estimate of effect includes no effect and no clinically appreciable harm, but the upper boundary of the CI represents a 25% RRR. We therefore judge that the 95% CI around the pooled estimate of effect could include clinically appreciable benefit if the optimal information size had been met.<br/> <sup>c</sup>One study reported an effect of adding albendazole to DEC (P &lt; 0.05) and four studies reported no effect (P &gt; 0.05). Five studies reported geometric means and one study reported the log mean.<br/> <sup>d</sup>Downgraded by one for risk of bias: we judged the analytical methods used by <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> to obtain the change in density from baseline to follow‐up to be at high risk of bias.<br/> <sup>e</sup>Downgraded by one for inconsistency: the direction and magnitude of effect reported varied in favour of both albendazole plus DEC and DEC alone. We judged the effects of adding albendazole to DEC to be inconsistent.<br/> <sup>f</sup>Downgraded by two for imprecision: the optimal information size was met. The effect of adding albendazole to DEC varied considerably. One trial reported an effect of adding albendazole (P &lt; 0.05) and no effect was reported in the others (P &gt; 0.05). We judged that the range of values would likely include a meaningful effect and no effect.<br/> <sup>g</sup>Four studies reporting the geometric mean reported no effect of adding albendazole to DEC (P &gt; 0.05). One study reported the log mean and one study reported the arithmetic mean, no effect was seen.<br/> <sup>h</sup>Not downgraded for inconsistency: the direction and magnitude of the effect was consistent; we found no benefit of adding albendazole to DEC consistently across the studies.<br/> <sup>i</sup>Downgraded by two for imprecision: the optimal information size was met. No effect of adding albendazole to DEC was consistently reported across the studies; all studies reported no effect on geometric mean mf density (P &gt; 0.05). We judged that the range of values would likely include little or no effect and exclude appreciable benefit or harm, but we can not be certain as there is no estimate of effect or measure of precision.<br/> <sup>j</sup>Not downgraded for risk of bias: most information was at low or unclear risk of bias. Three studies had high risk of bias for attrition, but the number of participants followed up was comparable between groups in the studies. We judged plausible bias unlikely to alter the results.<br/> <sup>k</sup>One study reported the geometric mean, one study reported the log mean and one study reported the arithmetic mean; two studies reported no effect of adding albendazole to DEC (P &gt; 0.05).<br/> <sup>l</sup>Downgraded by one for risk of bias: we judged the analytical methods used by <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> to obtain the change in density from baseline to follow‐up to be at high risk of bias.<br/> <sup>m</sup>Downgraded by two for imprecision: the optimal information size was not met. Two studies reported no effect of albendazole added to DEC (P &gt; 0.05). One study reported geometric mean, one study reported log mean and one study reported arithmetic mean. Given the differences in these measures and small number of participants, we are unable to judge the precision of the estimate of effect across the studies.<br/> <sup>n</sup>Not downgraded for risk of bias: all studies had unclear risk of bias for random sequence generation. The study contributing the most (68.7%) to the effect estimate had high risk of bias for attrition, but the number of participants followed up was comparable between groups. We judged plausible bias unlikely to seriously alter the results.<br/> <sup>o</sup>Downgraded by one for indirectness: this outcome was assessed only in men and boys (three studies). Two studies included adult men only, and one study included adults and children. We judged the evidence for this outcome to have serious indirectness due to the lack of applicability to the wider population of interest.<br/> <sup>p</sup>Downgraded by one for imprecision: there were insufficient events to meet optimal information size (47 total events). The 95% CI around the pooled estimate of effect includes both no effect and appreciable benefit and harm, using a relative risk reduction (RRR) of 25%.<br/> <sup>q</sup>Not downgraded for risk of bias: for participant and personnel blinding, one study had unclear risk of bias and one study was at high risk of bias; however, a large safety study contributing the most to the overall effect estimate (73.1%) was at low risk of bias. We judged plausible bias unlikely to seriously alter the results. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003753-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Albendazole added to ivermectin for lymphatic filariasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Albendazole added to ivermectin for lymphatic filariasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with lymphatic filariasis or communities where lymphatic filariasis is endemic<br/> <b>Setting:</b> Ghana, Haiti, Tanzania and Zanzibar<br/> <b>Intervention:</b> albendazole plus ivermectin<br/> <b>Comparison:</b> ivermectin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ivermectin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with albendazole plus ivermectin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microfilaraemia (mf) prevalence<br/> follow‐up: range 2 weeks to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>108 per 1000<br/> (70 to 169) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.84<br/> (0.54 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2519<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b,c</sup> </p> <p><i>Due to imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole probably makes little or no difference to mf prevalence.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mf density<br/> follow‐up: range 4 months to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No trend. The difference between the albendazole plus ivermectin and the ivermectin groups percentage reductions from baseline ranged from a 3% to 22.8% greater reduction with albendazole plus ivermectin.<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>372<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>e,f,g</sup> </p> <p><i>Due to risk of bias, inconsistency, and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if albendazole has an effect on mf density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mf density<br/> follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Trend showed little or no effect of albendazole. The difference between the albendazole plus ivermectin and the ivermectin groups percentage reductions from baseline ranged from a 6.7% to 9.1% greater reduction with albendazole plus ivermectin.<sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>i,j,k</sup> </p> <p><i>Due to imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole may make little or no difference to mf density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigenaemia prevalence<br/> follow up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>462 per 1000<br/> (418 to 516) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04<br/> (0.94 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1766<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole makes little or no difference to antigenaemia prevalence.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigen density<br/> follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Trend showed little or no effect of albendazole. The difference between the albendazole plus ivermectin and the ivermectin groups percentage reductions from baseline ranged from a 10.9% to 17.1% greater reduction with albendazole plus ivermectin.<sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>733<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>i,j,l</sup> </p> <p><i>Due to imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole may make little or no difference to antigen density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult worm prevalence detected by ultrasound ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult prevalence detected by ultrasound was not measured for this comparison.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>122 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>142 per 1000<br/> (94 to 212) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.16<br/> (0.77 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>627<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>m,n</sup> </p> <p><i>Due to imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole probably makes little or no difference to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> Abbreviations: CI: confidence interval; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for risk of bias: most information is from studies at low or unclear risk of bias. Two studies had high risk and one had unclear risk of bias for attrition, but the number of participants followed up were comparable between groups in most of the studies. We judged plausible bias unlikely to seriously alter the results.<br/> <sup>b</sup>Not downgraded for inconsistency: although we found heterogeneity between studies (I<sup>2</sup> = 65%), a subgroup analysis for length of follow‐up showed no statistical variability when two studies with earlier follow‐up time points (two weeks and four months) and two studies with later follow‐up time points (12 months) were analysed as subgroups. Overall, we judged that the effect estimate is not inconsistent.<br/> <sup>c</sup>Downgraded by one for imprecision: the optimal information size was met. The 95% CI around the pooled estimate of effect includes both no effect and appreciable benefit and harm, using a relative risk reduction (RRR) of 25%.<br/> <sup>d</sup>One small study reported an effect of adding albendazole to ivermectin (P &lt; 0.05), one study reported no effect (P &gt; 0.05), and one study did not clearly report the outcome of the statistical analyses.<br/> <sup>e</sup>Downgraded by one for risk of bias: we judged the analytical methods used by <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> to obtain the change in density from baseline to follow‐up to be at high risk of bias.<br/> <sup>f</sup>Downgraded by one for inconsistency: the magnitude of the effect of adding albendazole to ivermectin varied and we judged it to be inconsistent.<br/> <sup>g</sup>Downgraded by two for imprecision: the optimal information size was not met. The effect of adding albendazole to ivermectin showed considerable variability; ranging from an effect in one study (P &lt; 0.05) and little or no effect (P &gt; 0.05) in another. We judged that the range of values could include a meaningful effect and no effect.<br/> <sup>h</sup>One study reported no effect of adding albendazole to ivermectin (P &gt; 0.05), and one study did not clearly report the outcome of the statistical analyses.<br/> <sup>i</sup>Not downgraded for risk of bias: most information is from studies at low or unclear risk of bias. Two studies had high risk or unclear risk of bias for attrition, but losses between groups were generally comparable in the studies. We judged plausible bias unlikely to seriously alter the results.<br/> <sup>j</sup>Not downgraded for inconsistency: we judged the direction and magnitude of effect to be consistent across studies.<br/> <sup>k</sup>Downgraded by two for imprecision: the optimal information size was not met. Two studies reported little or no effect with albendazole; statistically evaluated in one study (P &gt; 0.05). We judged that the range of values would likely include little or no effect and exclude appreciable benefit or harm, but we can not be certain as there is no estimate of effect or measure of precision.<br/> <sup>l</sup>Downgraded by two for imprecision: the optimal information size was met. Two studies reported little or no effect of albendazole; statistically evaluated in one study (P &gt; 0.05). We judged that the range of values would likely include little or no effect and exclude appreciable benefit or harm, but we can not be certain as there is no estimate of effect or measure of precision.<br/> <sup>m</sup>Not downgraded for risk of bias: most information was at low and unclear risk of bias. The study had unclear risk of bias for participant and personnel blinding and unclear risk of bias for attrition. However, for this outcome 90% of individuals were followed up. We judged plausible bias unlikely to seriously alter the results.<br/> <sup>n</sup>Downgraded by one for imprecision: insufficient events to meet optimal information size (83 total events). The 95% CI around the pooled estimate of effect includes both no effect and appreciable harm, using a 25% relative risk reduction (RRR). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003753-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003753-sec-0031">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003753-sec-0165">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD003753-sec-0031"></div> <section id="CD003753-sec-0032"> <h3 class="title" id="CD003753-sec-0032">Epidemiology</h3> <p>Lymphatic filariasis is a parasitic infection of threadlike filarial worms and is endemic in 72 countries. Globally, 856 million people in 52 countries require preventive chemotherapy to stop the spread of infection (<a href="./references#CD003753-bbs2-0109" title="World Health Organization. Lymphatic filariasis. www.who.int/news‐room/fact‐sheets/detail/lymphatic‐filariasis (accessed 11 October 2018). ">WHO 2018a</a>). Bancroftian filariasis, caused by <i>Wuchereria bancrofti</i>, is responsible for over 90% of infections, and occurs in tropical regions of Asia, Africa, the Pacific islands, and in parts of the Caribbean and South America (<a href="./references#CD003753-bbs2-0104" title="World Health Organization. Global programme to eliminate lymphatic filariasis: progress report, 2015. Weekly Epidemiological Record2016;91(39):441‐60. ">WHO 2016</a>). Brugian filariasis is less common, with <i>Brugia malayi</i> occurring in parts of Asia, and <i>Brugia timori</i> in Indonesia (<a href="./references#CD003753-bbs2-0089" title="TaylorMJ , HoeraufA , BockarieM . Lymphatic filariasis and onchocerciasis. Lancet2010;376(9747):1175‐85. ">Taylor 2010</a>). The implications of lymphatic filariasis for individuals and societies are manifold. Clinical severity and progression of the disease can lead to chronic health complications and disability, which may be accompanied by mental health issues and social stigma, while the resultant reduced productivity causes nearly USD 1.3 billion per year in economic losses (<a href="./references#CD003753-bbs2-0042" title="ContehL , EngelsT , MolyneuxDH . Socioeconomic aspects of neglected tropical diseases. Lancet2010;375(9710):239–47. ">Conteh 2010</a>). </p> <p>Filariasis is transmitted by female mosquitoes from several genera, including <i>Culex</i> ,<i>Anopheles</i> ,<i>Mansonia</i> , and <i>Aedes</i> (<a href="./references#CD003753-bbs2-0036" title="BockarieMJ , PedersenEM , WhiteGB , MichaelE . Role of vector control in the global program to eliminate lymphatic filariasis. Annual Review of Entomology2009;54:469‐87. ">Bockarie 2009</a>). The mosquito vectors become infected when they take blood meals from people with early stage larvae, which are termed microfilariae (mf). The larvae develop for about 12 to 15 days in the mosquito to a third‐stage infective larvae (L3 larvae) (<a href="./references#CD003753-bbs2-0082" title="ScottAL . Lymphatic‐dwelling filariae. In: NutmanBT editor(s). Lymphatic Filariasis. London: Imperial College Press, 2000:5‐39. ">Scott 2000</a>). When the mosquito takes a subsequent blood meal, the larvae enter the skin, migrate to the lymph vessels, and develop into adult worms (macrofilariae) in the lymph nodes, where male and female worms pair. Female worms then produce mf, which migrate to the blood causing microfilaraemia. The time between being infected and adult worms producing microfilaraemia is estimated to be about 12 months (<a href="./references#CD003753-bbs2-0068" title="MahoneyLE , KesselJF . Treatment failure in filariasis mass treatment programmes. Bulletin of the World Health Organization1971;45(1):35‐42. ">Mahoney 1971</a>). </p> <p>Microfilariae move in and out of circulating peripheral blood according to a daily cycle. In most species, levels peak during the night, between 10 pm and 4 am (<a href="./references#CD003753-bbs2-0085" title="SimonsenPE , NiemannL , MeyrowitschDW . Wuchereria bancrofti in Tanzania: microfilarial periodicity and effect of blood sampling time on microfilarial intensities. Tropical Medicine &amp; International Health1997;2(2):153‐8. ">Simonsen 1997</a>), a time when mosquito vectors are actively feeding. In the diurnal subperiodic strain of <i>W bancrofti</i>, found only in the South Pacific region, mf are continuously circulating but peak during the day (<a href="./references#CD003753-bbs2-0036" title="BockarieMJ , PedersenEM , WhiteGB , MichaelE . Role of vector control in the global program to eliminate lymphatic filariasis. Annual Review of Entomology2009;54:469‐87. ">Bockarie 2009</a>). </p> </section> <section id="CD003753-sec-0033"> <h3 class="title" id="CD003753-sec-0033">Diagnosis and clinical features</h3> <p>Historically, filarial infection has been diagnosed by examination of a blood smear for mf using microscopy. However, even if blood is taken at night when mf are in the peripheral blood, not all infections are detected because mf levels are very low in many people. Adult worms may also be present but not yet producing mf, or there may be only a single unmated worm in a lymph node. Antigen‐detection assays for <i>W bancrofti</i> circulating filarial antigen (CFA) became available for field use during the 1990s. The assays can be used for sensitive diagnosis of infection at any time of day (<a href="./references#CD003753-bbs2-0095" title="WeilGJ , LammiePJ , WeissN . The ICT Filariasis Test: A rapid‐format antigen test for diagnosis of bancroftian filariasis. Parasitology Today1997;13(10):401‐4. ">Weil 1997</a>), as they indicate the presence of the adult worm and do not depend on the temporal presence of mf. A point‐of‐care rapid diagnostic test for bancroftian filariasis, the Filariasis Test Strip (FTS), is used by the Global Programme to Eliminate Lymphatic Filariasis (GPELF) to detect the presence of filarial antigens (<a href="./references#CD003753-bbs2-0103" title="World Health Organization. Global programme to eliminate lymphatic filariasis: progress report, 2014. Weekly Epidemiological Record2015;90(38):489–504. ">WHO 2015</a>). Parasite antigen levels can be measured using the Og4C3 Filariasis Ag ELISA, and the circulating antigen density is thought to be correlated with the numbers of adult <i>W bancrofti</i> worms (<a href="./references#CD003753-bbs2-0061" title="HarnettW , WormsMJ , GraingerM , PykeSD , ParkhouseRM . Association between circulating antigen and parasite load in a model filarial system, Acanthocheilonema viteae in jirds. Parasitology1990;101(Pt 3):435‐44. ">Harnett 1990</a>; <a href="./references#CD003753-bbs2-0094" title="WeilGJ , ChandrashekarR , LiftisF , McVayCS , BosshardtSC , KleiTR . Circulating parasite antigen in Brugia pahangi‐infected jirds. Journal of Parasitology1990;76(1):78‐84. ">Weil 1990</a>). Ultrasound imaging can demonstrate the presence of live adult worms (<a href="./references#CD003753-bbs2-0048" title="DreyerG , AmaralF , NorõesJ , MedeirosZ , AddissD . A new tool to assess in vivo the adulticidal efficacy of antifilarial drugs for bancroftian filariasis. Transactions of the Royal Society of Tropical Medicine and Hygiene1995;89(2):225‐6. ">Dreyer 1995</a>). </p> <p>Many people with filariasis are asymptomatic, even when there are high parasite densities. However, even people without clinical symptoms often have lymphatic changes, including lymphangiectasia (widening of the lymphatic vessels) and thickening of the spermatic cord (<a href="./references#CD003753-bbs2-0031" title="AddissD , DreyerG . Treatment of lymphatic filariasis. In: NutmanBT editor(s). Lymphatic Filariasis. London: Imperial College Press, 2000:151‐99. ">Addiss 2000</a>; <a href="./references#CD003753-bbs2-0051" title="DreyerG , NorõesJ , Figueredo‐SilvaJ , PiessensWF . Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective. Parasitology Today2000;16(12):544‐8. ">Dreyer 2000</a>), which can be detected using ultrasound. </p> <p>People can experience acute inflammatory episodes, including acute filarial lymphangitis (AFL), believed to be triggered by the death of the adult worm, and acute dermatolymphangioadenitis (ADLA), linked with secondary bacterial infection (<a href="./references#CD003753-bbs2-0050" title="DreyerG , MedeirosZ , NettoMJ , LealNC , DeCastroLG , PiessensWF . Acute attacks in the extremities of persons living in an area endemic for bancroftian filariasis: differentiation of two syndromes. Transactions of the Royal Society of Tropical Medicine and Hygiene1999;93(4):413‐7. ">Dreyer 1999</a>). An AFL episode presents with lymphangitis that spreads distally or in a ‘retrograde' manner along the lymphatic vessel, creating a palpable ‘cord' (<a href="./references#CD003753-bbs2-0032" title="AddissDG , BradyMA . Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature. Filaria Journal2007;6:2. ">Addiss 2007</a>). ADLA episodes reportedly may last up to 16 days and cause malaise, fever, chills, pain, and swelling, with episodes typically recurring several times a year (<a href="./references#CD003753-bbs2-0032" title="AddissDG , BradyMA . Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature. Filaria Journal2007;6:2. ">Addiss 2007</a>). Symptoms of ADLA are more severe and occur much more frequently compared to AFL (<a href="./references#CD003753-bbs2-0050" title="DreyerG , MedeirosZ , NettoMJ , LealNC , DeCastroLG , PiessensWF . Acute attacks in the extremities of persons living in an area endemic for bancroftian filariasis: differentiation of two syndromes. Transactions of the Royal Society of Tropical Medicine and Hygiene1999;93(4):413‐7. ">Dreyer 1999</a>). Recurrent ADLA attacks are a major factor in the progression to chronic lymphoedema. Clinical symptoms and signs of chronic conditions include hydrocoele (excess fluid inside the scrotal sac), lymphoedema (swelling and enlargement of affected areas of the body), and elephantiasis (long‐standing enlargement and swelling of the limbs, scrota, or breasts associated with skin thickening). </p> <p>How the filarial worm causes disease is not well understood. The following have been proposed: adult worms living in and damaging lymph vessels; immunological reactions to the presence and death of filarial worms; secondary infections of affected areas, which contribute significantly to both acute and chronic disease manifestations; and host genetics (<a href="./references#CD003753-bbs2-0051" title="DreyerG , NorõesJ , Figueredo‐SilvaJ , PiessensWF . Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective. Parasitology Today2000;16(12):544‐8. ">Dreyer 2000</a>; <a href="./references#CD003753-bbs2-0045" title="CuencoKT , OttesenEA , WilliamsSA , NutmanTB , SteelC . Heritable factors play a major role in determining host responses to Wuchereria bancrofti infection in an isolated South Pacific island population. Journal of Infectious Diseases2009;200(8):1271‐8. ">Cuenco 2009</a>). A major contributor to inflammation is the release of lipoproteins from the bacterial endosymbiont <i>Wolbachia</i>, which is found within the cells of filarial worms (<a href="./references#CD003753-bbs2-0087" title="TaylorMJ , CrossHF , FordL , MakundeWH , PrasadGB , BiloK . Wolbachia bacteria in filarial immunity and disease. Parasite Immunology2001;23(7):401‐9. ">Taylor 2001</a>; <a href="./references#CD003753-bbs2-0091" title="TurnerJD , LangleyRS , JohnstonKL , GentilK , FordL , WuB , et al. Wolbachia lipoprotein stimulates innate and adaptive immunity through toll‐like receptors 2 and 6 to induce disease manifestations of filariasis. Journal of Biological Chemistry2009;284(33):22364‐79. ">Turner 2009</a>). Some or all of these processes may be important in pathogenesis and immunopathogenesis (<a href="./references#CD003753-bbs2-0034" title="BabuS , NutmanTB . Immunopathogenesis of lymphatic filarial disease. Seminars in Immunopathology2012;34(6):847‐61. ">Babu 2012</a>). </p> </section> <section id="CD003753-sec-0034"> <h3 class="title" id="CD003753-sec-0034">Control and elimination</h3> <p>The main strategy used by the GPELF consists of community‐wide mass drug administration (MDA) to entire populations at risk in order to interrupt transmission of the disease and prevent morbidity due to infection. Preventive chemotherapy is considered necessary where the total population in an implementation unit (province, district, or smaller unit) of a given country has an infection prevalence of 1% or higher. Preventive chemotherapy aims to interrupt transmission by sustainably reducing community microfilaraemia below a critical threshold or by completely clearing the mf (<a href="./references#CD003753-bbs2-0076" title="OttesenEA . Lymphatic filariasis: treatment, control and elimination. Advances in Parasitology2006;61:395‐441. ">Ottesen 2006</a>). </p> <p>The GPELF recommends yearly, single‐dose, two‐drug regimens (albendazole plus diethylcarbamazine (DEC) or albendazole plus ivermectin) for at least five years (corresponding to the reproductive lifespan of the adult worm), with coverage of at least 65% of the total at‐risk population to prevent transmission. More recently, for special settings the WHO has recommended the use of annual treatment with the triple‐drug therapy of ivermectin, DEC, and albendazole (termed IDA) rather than two‐drug therapy of albendazole and DEC (<a href="./references#CD003753-bbs2-0105" title="World Health Organization. Guideline: alternative mass drug administration regimens to eliminate lymphatic filariasis. Guideline: Alternative Mass Drug Administration Regimens to Eliminate Lymphatic Filariasis. Geneva: World Health Organization, 2017. ">WHO 2017a</a>). Overall mf prevalence rates are believed to be relatively stable over time in endemic communities in the absence of treatment because of reinfection and new adult worms producing mf (<a href="./references#CD003753-bbs2-0071" title="MeyrowitschDW , SimonsenPE , MakundeWH . A 16‐year follow‐up study on bancroftian filariasis in three communities of north‐eastern Tanzania. Annals of Tropical Medicine and Parasitology1995;89(6):665‐75. ">Meyrowitsch 1995</a>). </p> <p>The transmission assessment survey (TAS) is used to determine when infection prevalence (estimated from the number of CFA‐positive or antibody‐positive cases in children) is below critical cut‐off thresholds and MDA can stop, and also as a surveillance tool in order to validate elimination (<a href="./references#CD003753-bbs2-0100" title="World Health Organization. Lymphatic filariasis: monitoring and epidemiological assessment of mass drug administration: A manual for national elimination programmes. Lymphatic Filariasis: Monitoring and Epidemiological Assessment of Mass Drug Administration: A Manual for National Elimination Programmes. Geneva: World Health Organization, 2011. [WHO/HTM/NTD/PCT/2011.4] ">WHO 2011</a>). Palau, Vietnam, Wallis and Futuna, the Republic of the Marshall Islands, and Tonga eliminated lymphatic filariasis as a public health problem in 2018 and 2017 (<a href="./references#CD003753-bbs2-0106" title="World Health Organization. Republic of the Marshall Islands eliminates lymphatic filariasis as a public health problem. www.wpro.who.int/mediacentre/releases/2017/20170330/en/ (accessed 1 April 2017). ">WHO 2017b</a>; <a href="./references#CD003753-bbs2-0107" title="World Health Organization. Tonga eliminates lymphatic filariasis as a public health problem. www.who.int/neglected_diseases/news/Tonga_eliminates_lymphatic_filariasis/en/ (accessed 1 September 2017). ">WHO 2017c</a>; <a href="./references#CD003753-bbs2-0110" title="World Health Organization. Three more countries eliminate lymphatic filariasis. www.who.int/westernpacific/news/detail/08‐10‐2018‐three‐more‐countries‐eliminate‐lymphatic‐filariasis (accessed 12 October 2018). ">WHO 2018b</a>), along with Togo, the first country in sub‐Saharan Africa (<a href="./references#CD003753-bbs2-0108" title="World Health Organization. Togo: first country in sub‐Saharan Africa to eliminate lymphatic filariasis. www.who.int/neglected_diseases/news/Togo_saying_goodbye_lymphatic_filariasis/en/ (accessed 1 May 2017). ">WHO 2017d</a>), and Egypt, the first country in the Eastern Mediterranean region (<a href="./references#CD003753-bbs2-0111" title="World Health Organization. Egypt: first country in Eastern Mediterranean region to eliminate lymphatic filariasis. www.who.int/neglected_diseases/news/Egypt_first_EMRO_country_eliminate_LF/en/ (accessed 14 March 2018). ">WHO 2018c</a>). They join six countries validated as having achieved elimination in 2016 (<a href="./references#CD003753-bbs2-0104" title="World Health Organization. Global programme to eliminate lymphatic filariasis: progress report, 2015. Weekly Epidemiological Record2016;91(39):441‐60. ">WHO 2016</a>), and China and the Republic of Korea in 2007 and 2008, respectively. </p> <p>Transmission dynamics may show variable efficiency depending on the vector species in the locality; in processes referred to as limitation, facilitation, and proportionality (<a href="./references#CD003753-bbs2-0102" title="World Health Organization. Lymphatic Filariasis: A Handbook of Practical Entomology for National Lymphatic Filariasis Elimination Programmes. Geneva: World Health Organization, 2013. [WHO/HTM/NTD/PCT/2013.10] ">WHO 2013</a>; <a href="./references#CD003753-bbs2-0059" title="GravesPM , WoodP , BossinHC . Lymphatic filariasis in Oceania. In: LoukasA editor(s). Neglected Tropical Diseases ‐ Oceania. Switzerland: Springer, 2016:101‐42. ">Graves 2016</a>). Higher treatment coverage for longer periods or other strategies such as vector control may be required in areas where vectors are responsible for a high proportion of transmission (<a href="./references#CD003753-bbs2-0038" title="BurkotTR , TaleoG , ToeasoV , IchimoriK . Progress towards, and challenges for, the elimination of filariasis from Pacific‐island communities. Annals of Tropical Medicine and Parasitology2002;96 Suppl 2:S61‐9. ">Burkot 2002</a>; <a href="./references#CD003753-bbs2-0077" title="PichonG . Limitation and facilitation in the vectors and other aspects of the dynamics of filarial transmission: the need for vector control against Anopheles‐transmitted filariasis. Annals of Tropical Medicine and Parasitology2002;96 Suppl 2:S143‐52. ">Pichon 2002</a>). Vector control for lymphatic filariasis can enhance the impact on transmission during and after MDA (<a href="./references#CD003753-bbs2-0102" title="World Health Organization. Lymphatic Filariasis: A Handbook of Practical Entomology for National Lymphatic Filariasis Elimination Programmes. Geneva: World Health Organization, 2013. [WHO/HTM/NTD/PCT/2013.10] ">WHO 2013</a>), and elimination has also been achieved in some areas such as the Solomon Islands and Australia using vector control methods (<a href="./references#CD003753-bbs2-0038" title="BurkotTR , TaleoG , ToeasoV , IchimoriK . Progress towards, and challenges for, the elimination of filariasis from Pacific‐island communities. Annals of Tropical Medicine and Parasitology2002;96 Suppl 2:S61‐9. ">Burkot 2002</a>; <a href="./references#CD003753-bbs2-0077" title="PichonG . Limitation and facilitation in the vectors and other aspects of the dynamics of filarial transmission: the need for vector control against Anopheles‐transmitted filariasis. Annals of Tropical Medicine and Parasitology2002;96 Suppl 2:S143‐52. ">Pichon 2002</a>). </p> <p>In addition to ‘microfilaricidal’ drugs DEC and ivermectin, ‘macrofilaricidal’ drugs that kill the adult worms have also been shown to be effective. Antibiotics, such as doxycycline, target the <i>Wolbachia</i> obligate endosymbiont in the parasite, leading to long‐term sterility and a gradual, sustained killing of adult worms (<a href="./references#CD003753-bbs2-0088" title="TaylorMJ , MakundeWH , McGarryHF , TurnerJD , MandS , HoeraufA . Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double‐blind, randomised placebo‐controlled trial. Lancet2005;365(9477):2116‐21. ">Taylor 2005</a>; <a href="./references#CD003753-bbs2-0046" title="DebrahAY , MandS , Marfo‐DebrekyeiY , BatsaL , PfarrK , ButtnerM , et al. Macrofilaricidal effect of 4 weeks of treatment with doxycycline on Wuchereria bancrofti. Tropical Medicine &amp; International Health2007;12(12):1433‐41. ">Debrah 2007</a>). Doxycycline is not currently used in community‐based treatment programmes due to the logistics of longer treatment regimens and contraindications in pregnant women and children. </p> </section> <section id="CD003753-sec-0035"> <h3 class="title" id="CD003753-sec-0035">DEC and ivermectin</h3> <p>Both ivermectin and DEC rapidly clear mf from the blood and suppress their reappearance (<a href="./references#CD003753-bbs2-0086" title="StolkWA , VanOortmarssenGJ , PaniSP , DeVlasSJ , SubramanianS , DasPK , et al. Effects of ivermectin and diethylcarbamazine on microfilariae and overall microfilaria production in bancroftian filariasis. American Journal of Tropical Medicine and Hygiene2005;73(5):881‐7. ">Stolk 2005</a>; <a href="./references#CD003753-bbs2-0056" title="GearyTG , WooK , McCarthyJS , MackenzieCD , HortonJ , PrichardRK , et al. Unresolved issues in anthelmintic pharmacology for helminthiases of humans. International Journal for Parasitology2010;40(1):1‐13. ">Geary 2010</a>). Reductions of 90% from pre‐treatment mf levels have been seen after a single dose of DEC or ivermectin, even one year after treatment (<a href="./references#CD003753-bbs2-0075" title="OttesenEA , IsmailMM , HortonJ . The role of albendazole in programmes to eliminate lymphatic filariasis. Parasitology Today1999;15(9):382‐6. ">Ottesen 1999</a>). Microfilaraemia can therefore be effectively reduced by DEC or ivermectin (<a href="./references#CD003753-bbs2-0089" title="TaylorMJ , HoeraufA , BockarieM . Lymphatic filariasis and onchocerciasis. Lancet2010;376(9747):1175‐85. ">Taylor 2010</a>). However, the limited effects on adult worm viability cause new mf infections to replace those whose microfilaraemia subsides (<a href="./references#CD003753-bbs2-0093" title="VanamailP , SubramanianS , DasPK , PaniSP , RajagopalanPK . Estimation of fecundic life span of Wuchereria bancrofti from longitudinal study of human infection in an endemic area of Pondicherry (south India). Indian Journal of Medical Research1990;91:293‐7. ">Vanamail 1990</a>; <a href="./references#CD003753-bbs2-0096" title="WeilGJ , RamzyRM , ElSetouhyM , KandilAM , AhmedES , FarisR . A longitudinal study of Bancroftian filariasis in the Nile Delta of Egypt: baseline data and one‐year follow‐up. American Journal of Tropical Medicine and Hygiene1999;61(1):53‐8. ">Weil 1999</a>). </p> <p>DEC has been in use for filariasis for more than 50 years. In the early years of control the recommended regimen for DEC was 6 mg/kg daily for 12 days (<a href="./references#CD003753-bbs2-0097" title="World Health Organization Expert Committee on Filariasis. Lymphatic Filariasis: Fourth Report of the WHO Expert Committee on Filariasis [meeting held in Geneva from 31 October to 8 November 1983]; Technical Report Series no. 702. Geneva: World Health Organization, 1984. ">WHO 1984</a>). Later, clinical and community trials determined that single doses given at various intervals − weekly, monthly, twice a year, and annually − were equally effective (<a href="./references#CD003753-bbs2-0052" title="EberhardML , LammiePJ , RobertsJM , LowrieRCJr . Effectiveness of spaced doses of diethylcarbamazine citrate for the control of bancroftian filariasis. Tropical Medicine and Parasitology1989;40(2):111‐3. ">Eberhard 1989</a>; <a href="./references#CD003753-bbs2-0069" title="MataikaJU , KimuraE , KoroivuetaJ , KaisuvaJN , BrownM , TuivagaJ , et al. Comparison of the efficacy of diethylcarbamazine between 5 rounds of annual single‐dose treatment and an intensive 28‐dose treatment spread over 2 years against diurnally subperiodic Wuchereria bancrofti in Fiji. Fiji Medical Journal1993;19:2‐6. ">Mataika 1993</a>; <a href="./references#CD003753-bbs2-0033" title="AndradeLD , MedeirosZ , PiresML , PimentelA , RochaA , Figueredo‐SilvaJ , et al. Comparative efficacy of three different diethylcarbamazine regimens in lymphatic filariasis. Transactions of the Royal Society of Tropical Medicine and Hygiene1995;89(3):319‐21. ">Andrade 1995</a>; <a href="./references#CD003753-bbs2-0084" title="SimonsenPE , MeyrowitschDW , MakundeWH , MagnussenP . Selective diethylcarbamazine chemotherapy for control of Bancroftian filariasis in two communities of Tanzania: compared efficacy of a standard dose treatment and two semi‐annual single dose treatments. American Journal of Tropical Medicine and Hygiene1995;53(3):267‐72. ">Simonsen 1995</a>). There is reasonable evidence from ultrasound and clinical observations that DEC kills some adult worms after single doses (<a href="./references#CD003753-bbs2-0053" title="Figueredo‐SilvaJ , JungmannP , NorõesJ , PiessensWF , CoutinhoA , BritoC , et al. Histological evidence for adulticidal effect of low doses of diethylcarbamazine in bancroftian filariasis. Transactions of the Royal Society of Tropical Medicine and Hygiene1996;90(2):192‐4. ">Figueredo‐Silva 1996</a>; <a href="./references#CD003753-bbs2-0073" title="NorõesJ , DreyerG , SantosA , MendesVG , MedeirosZ , AddissD . Assessment of the efficacy of diethylcarbamazine on adult Wuchereria bancrofti in vivo. Transactions of the Royal Society Tropical Medicine and Hygiene1997;9(1):78‐81. ">Norões 1997</a>; <a href="./references#CD003753-bbs2-0031" title="AddissD , DreyerG . Treatment of lymphatic filariasis. In: NutmanBT editor(s). Lymphatic Filariasis. London: Imperial College Press, 2000:151‐99. ">Addiss 2000</a>). </p> <p>Ivermectin is used for the treatment and community control of onchocerciasis (caused by another filarial worm, <i>Onchocerca volvulus</i>). It has also been effective in community control programmes for lymphatic filariasis (<a href="./references#CD003753-bbs2-0040" title="CartelJL , SechanY , BoutinJP , CelerierP , PlichartR , RouxJF . Ivermectin for treatment of bancroftian filariasis French Polynesia: efficacy in man, effect on transmission by vector Aedes polynesiensis. Tropical Medicine and Parasitology1990;41(3):241‐4. ">Cartel 1990</a>; <a href="./references#CD003753-bbs2-0043" title="CoutinhoAD , DreyerG , MedeirosZ , LopesE , MachadoG , GaldinoE , et al. Ivermectin treatment of bancroftian filariasis in Recife, Brazil. American Journal of Tropical Medicine and Hygiene1994;50(3):339‐48. ">Coutinho 1994</a>; <a href="./references#CD003753-bbs2-0039" title="CaoWC , Van derPloegCP , PlaisierAP , Van derSluijsIJ , HabbemaJD . Ivermectin for the chemotherapy of bancroftian filariasis: a meta‐analysis of the effect of single treatment. Tropical Medicine &amp; International Health1997;2(4):393‐403. ">Cao 1997</a>). Ivermectin is used in areas where both onchocerciasis and lymphatic filariasis coexist, as DEC can result in eye damage if given to individuals with onchocerciasis. Ivermectin is not known to have any macrofilaricidal activity, and ultrasound studies have shown that adult worms are not killed by ivermectin even at high doses over a period of six months (<a href="./references#CD003753-bbs2-0049" title="DreyerG , AddissD , NoroesJ , AmaralF , RochaA , CoutinhoA . Ultrasonographic assessment of the adulticidal efficacy of repeat high‐dose ivermectin in bancroftian filariasis. Tropical Medicine &amp; International Health1996;1(4):427‐32. ">Dreyer 1996</a>; <a href="./references#CD003753-bbs2-0031" title="AddissD , DreyerG . Treatment of lymphatic filariasis. In: NutmanBT editor(s). Lymphatic Filariasis. London: Imperial College Press, 2000:151‐99. ">Addiss 2000</a>). </p> <p>In areas of Central and West Africa co‐endemic for lymphatic filariasis and <i>Loa loa</i> , the filarial eye worm causing loiasis, treatment with ivermectin or DEC can cause serious adverse events (SAEs) when there are high <i>L loa</i> mf densities (more than 30,000 mf/mL) (<a href="./references#CD003753-bbs2-0037" title="BoussinesqM , GardonJ . Prevalences of Loa loa microfilaraemia throughout the area endemic for the infection. Annals of Tropical Medicine and Parasitology1997;91(6):573‐89. ">Boussinesq 1997</a>; <a href="./references#CD003753-bbs2-0055" title="GardonJ , Gardon‐WendelN , KamgnoJ , ChippauxJP , BoussinesqM . Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet1997;350(9070):18‐22. ">Gardon 1997</a>). In these areas, albendazole alone given twice a year with vector control is recommended if ivermectin has not already been distributed for either onchocerciasis or lymphatic filariasis (<a href="./references#CD003753-bbs2-0101" title="World Health Organization. Provisional Strategy for Interrupting Lymphatic Filariasis Transmission in Loiasis‐Endemic Countries: Report of the Meeting on Lymphatic Filariasis, Malaria and Integrated Vector Management [Accra, Ghana, 5 – 9 March 2012]. Geneva: World Health Organization, 2012. [WHO/HTM/NTD/PCT/2012.6] ">WHO 2012</a>; <a href="./references#CD003753-bbs2-0105" title="World Health Organization. Guideline: alternative mass drug administration regimens to eliminate lymphatic filariasis. Guideline: Alternative Mass Drug Administration Regimens to Eliminate Lymphatic Filariasis. Geneva: World Health Organization, 2017. ">WHO 2017a</a>). Ivermectin can also cause SAEs in people with onchocerciasis and high <i>L loa</i> densities; however, treatment with ivermectin was recommended for onchocerciasis meso‐ and high‐endemic areas following one of three strategies to manage complications, should they occur (<a href="./references#CD003753-bbs2-0070" title="Mectizan® Expert Committee, The Technical Consultative Committee. Recommendations for the Treatment of Onchocerciasis with Mectizan® in Areas Co‐endemic for Onchocerciasis and Loiasis. Georgia (USA): Mectizan® Expert Committee/The Mectizan® Donation Program, 2004. ">Mectizan Expert Committee 2004</a>). See <a href="#CD003753-tbl-0005">Table 1</a>. </p> <div class="table" id="CD003753-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Mass drug administration (MDA) programmes for filariasis</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Endemic for</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Drug recommendation</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Lymphatic filariasis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Onchocerciasis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Loiasis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Albendazole</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ivermectin</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Diethylcarbamazine</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Regimen</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twice per year<sup>b,c</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annual<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twice per year<sup>b,c</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annual<sup>c</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annual<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annual</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>In areas where <i>L loa</i> is endemic, ivermectin must be used with caution as people with high <i>L loa</i> microfilaraemia are at greater risk of experiencing serious adverse effects (SAEs). Albendazole alone given twice per year is recommended when mass drug administration with ivermectin has not yet occurred. Where mass drug administration with ivermectin has already occurred for either lymphatic filariasis or onchocerciasis, ivermectin distribution can continue under current guidance on the use of ivermectin for onchocerciasis in areas co‐endemic for loiasis. For further information, see reference c.<br/> <sup>b</sup><a href="./references#CD003753-bbs2-0105" title="World Health Organization. Guideline: alternative mass drug administration regimens to eliminate lymphatic filariasis. Guideline: Alternative Mass Drug Administration Regimens to Eliminate Lymphatic Filariasis. Geneva: World Health Organization, 2017. ">WHO 2017a</a><br/> <sup>c</sup><a href="./references#CD003753-bbs2-0070" title="Mectizan® Expert Committee, The Technical Consultative Committee. Recommendations for the Treatment of Onchocerciasis with Mectizan® in Areas Co‐endemic for Onchocerciasis and Loiasis. Georgia (USA): Mectizan® Expert Committee/The Mectizan® Donation Program, 2004. ">Mectizan Expert Committee 2004</a><br/> <sup>d</sup>Annual treatment with the triple‐drug therapy of ivermectin, DEC and albendazole is recommended in specified settings. </p> </div> </div> <p>Adverse effects of antifilarial drugs can be serious (although rarely fatal) and prevent people from starting or completing treatment. The most serious appear to be due to a host immunologic reaction induced by the rapid killing of mf, and associated with the release of inflammatory <i>Wolbachia</i> lipoproteins (<a href="./references#CD003753-bbs2-0044" title="CrossHF , HaarbrinkM , EgertonG , YazdanbakhshM , TaylorMJ . Severe reactions to filarial chemotherapy and release of Wolbachia endosymbionts into blood. Lancet2001;358(9296):1873‐5. ">Cross 2001</a>; <a href="./references#CD003753-bbs2-0091" title="TurnerJD , LangleyRS , JohnstonKL , GentilK , FordL , WuB , et al. Wolbachia lipoprotein stimulates innate and adaptive immunity through toll‐like receptors 2 and 6 to induce disease manifestations of filariasis. Journal of Biological Chemistry2009;284(33):22364‐79. ">Turner 2009</a>)<i>.</i> Adverse effects include fever, headache, malaise, muscle pain, and blood in urine. Local effects include localized pain, tender nodules, lymphadenitis (inflammation of the lymph nodes), and lymphangitis (inflammation of lymph vessels) (<a href="./references#CD003753-bbs2-0031" title="AddissD , DreyerG . Treatment of lymphatic filariasis. In: NutmanBT editor(s). Lymphatic Filariasis. London: Imperial College Press, 2000:151‐99. ">Addiss 2000</a>). </p> </section> <section id="CD003753-sec-0036"> <h3 class="title" id="CD003753-sec-0036">Albendazole</h3> <p>Albendazole has been used widely to treat intestinal parasites since the late 1980s and may have a potential role in lymphatic filariasis control (<a href="./references#CD003753-bbs2-0075" title="OttesenEA , IsmailMM , HortonJ . The role of albendazole in programmes to eliminate lymphatic filariasis. Parasitology Today1999;15(9):382‐6. ">Ottesen 1999</a>). In an early study on albendazole for lymphatic filariasis, a high (400 mg) dose taken twice a day for 21 days was believed to be macrofilaricidal due to the serious adverse reactions the authors attributed to adult worm death (<a href="./references#CD003753-bbs2-0017" title="JayakodyRL , DeSilvaCS , WeerasingheWM . Treatment of bancroftian filariasis with albendazole: evaluation of efficacy and adverse reactions. Tropical Biomedicine1993;10:19‐24. ">Jayakody 1993</a>). A report from an informal consultation organized by the WHO went on to suggest that repeated high doses of albendazole have a killing or sterilizing effect on <i>W bancrofti</i> adult worms (<a href="./references#CD003753-bbs2-0041" title="Filariasis Elimination Programme (CDS/FIL). Division of Control of Tropical Diseases, Communicable Diseases. Report from Informal Consultation on Albendazole Research Findings in Lymphatic Filariasis; WHO/FIL/98.194; (closed document). Geneva: World Health Organization, 1998. ">CDS/FIL 1998</a>). However, it was unclear whether adding albendazole to either DEC or ivermectin improves cure, prevents further transmission, or influences the occurrence of adverse events (<a href="./references#CD003753-bbs2-0113" title="AddissD , GambleCL , GarnerP , GelbandH , EjereHOD , CritchleyJA . Albendazole for lymphatic filariasis. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD003753.pub3] ">Addiss 2005</a>). </p> <p>In 2000, a narrative review by <a href="./references#CD003753-bbs2-0064" title="HortonJ . Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology2000;121 Suppl:S113‐32. ">Horton 2000</a> from GlaxoSmithKline, which manufactures albendazole, did not demonstrate that adding albendazole to either drug increased the frequency or severity of adverse events. GlaxoSmithKline stated that albendazole does not have a role in morbidity management − it will not treat the symptoms in people already affected by filariasis (<a href="./references#CD003753-bbs2-0057" title="GlaxoSmithKline . Lymphatic filariasis programme: eliminating lymphatic filariasis. web.archive.org/web/20020414025235/www.gsk.com/filariasis/eliminating.htm (accessed 1 May 2017). ">GlaxoSmithKline 2002</a>). A recent trial reported that a significant proportion of children with <i>W bancrofti</i> infection had their lymphatic pathology reversed when given the combination of albendazole and DEC annually (<a href="./references#CD003753-bbs2-0066" title="KarSK , DwibediB , DasBK , AgrawalaBK , RamachandranCP , HortonJ . Lymphatic pathology in asymptomatic and symptomatic children with Wuchereria bancrofti infection in children from Odisha, India and its reversal with DEC and albendazole treatment. PLoS Neglected Tropical Diseases2017;11(10):e0005631. ">Kar 2017</a>). We therefore include the effectiveness of albendazole for reducing disease progression and incidence of new symptoms as a secondary outcome. </p> <p>The use of albendazole in MDA programmes for lymphatic filariasis is considered to have ‘beyond filariasis' benefits, as it additionally addresses ‘polyparasitism’ through treatment of intestinal helminth infections (<a href="./references#CD003753-bbs2-0083" title="ShenoyRK , BockarieMJ . Lymphatic filariasis in children: clinical features, infection burdens and future prospects for elimination. Parasitology2011;138(12):1559‐68. ">Shenoy 2011</a>). However, a narrative review by <a href="./references#CD003753-bbs2-0065" title="HortonJ . The development of albendazole for lymphatic filariasis. Annals of Tropical Medicine and Parasitology2009;103(Supp 1):33‐40. ">Horton 2009</a> stated "while there is no doubt about the efficacy of albendazole for the treatment of many helminth diseases, as a single agent it could never be recommended for filariasis". In 2005, a systematic review concluded "the addition of albendazole to DEC or ivermectin does not appear to improve the effectiveness of either drug alone, and therefore may not directly benefit the transmission elimination aspect of the lymphatic filariasis control programme" (<a href="./references#CD003753-bbs2-0090" title="TischDJ , MichaelE , KazuraJW . Mass chemotherapy options to control lymphatic filariasis: a systematic review. Lancet Infectious Diseases2005;5(8):514‐23. ">Tisch 2005</a>). The authors also commented on the insufficiency of existing data for comparing the efficacy of drug regimens against bancroftian filariasis, and highlighted the need for more evidence from comparative randomized controlled studies. Conversely, an expert opinion review that included meta‐analyses and observational data (also published in 2005) concluded that co‐administration of albendazole was more effective in reducing mf prevalence than one antifilarial drug alone (<a href="./references#CD003753-bbs2-0060" title="GyapongJO , KumaraswamiV , BiswasG , OttesenEA . Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opinion on Pharmacotherapy2005;6(2):179‐200. ">Gyapong 2005</a>). </p> </section> <section id="CD003753-sec-0037"> <h3 class="title" id="CD003753-sec-0037">Why it is important to do this review</h3> <p>Since the GPELF's inception, interventions for lymphatic filariasis have prevented or cured an estimated 97 million cases and obviated over USD 100 billion in economic losses over the lifetimes of the beneficiaries (<a href="./references#CD003753-bbs2-0078" title="RamaiahKD , OttesenEA . Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease. PLOS Neglected Tropical Diseases2014;8(11):e3319. ">Ramaiah 2014</a>; <a href="./references#CD003753-bbs2-0092" title="TurnerHC , BettisAA , ChuBK , McFarlandDA , HooperPJ , OttesenEA , et al. The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000–2014). Infectious Diseases of Poverty2016;5(1):54. ">Turner 2016</a>). The combined therapy (albendazole with either ivermectin or DEC) has been endorsed for nearly two decades by the WHO and GPELF, as well as the Global Alliance to Eliminate Lymphatic Filariasis (GAELF), who currently state that "the combination of albendazole with either Mectizan® or DEC has been proven to enhance the efficacy of the individual‐drug treatments in reducing the numbers of parasites in the blood" (<a href="./references#CD003753-bbs2-0054" title="Global Alliance to Eliminate LymphaticFilariasis . Community management. Planning an implementation programme. www.filariasis.org/about‐lf/community‐management/planning‐implementation‐programme (accessed 1 October 2018). ">GAELF 2018</a>). More recently, researchers have been investigating higher or more frequent dosing with albendazole (<a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>; <a href="./references#CD003753-bbs2-0018" title="KarSK , DwibediB , KerketaAS , MaharanaA , PandaSS , MohantyPC , et al. A randomized controlled trial of increased dose and frequency of albendazole with standard dose DEC for treatment of Wuchereria bancrofti microfilaremics in Odisha, India. PLoS Neglected Tropical Diseases2015;9(3):e0003583. ">Kar 2015</a>), as well as the effectiveness of the single‐dose triple therapy IDA (<a href="./references#CD003753-bbs2-0027" title="ThomsenEK , KumarJA , SanukuN , BaeaM , SatofanS , MakiE , et al. Efficacy, safety and pharmacokinetics of coadministered diethylcarbamazine, albendazole and ivermectin for the treatment of Wuchereria bancrofti. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl. 1):368. ThomsenEK , SanukuN , BaeaM , SatofanS , MakiE , LomboreB , et al. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis. Clinical Infectious Diseases2016;62(3):334‐41. ">Thomsen 2016</a>; <a href="./references#CD003753-bbs2-0019" title="KingCL , SuamaniJ , SanukuN , ChengYC , SatofanS , MancusoB . A trial of a triple‐drug treatment for lymphatic filariasis. New England Journal of Medicine2018;379(19):1801‐10. NCT01975441 . Eval 3‐drug therapy diethylcarbamize, albendazole and ivermectin that could accelerate LF elimination outside of Africa. clinicaltrials.gov/ct2/show/NCT01975441 (first received 4 November 2013). ">King 2018</a>). </p> <p>However, despite policy recommending the addition of albendazole to ivermectin or DEC, or albendazole monotherapy in <i>L loa</i> co‐endemic areas, it remains unclear whether its addition is of any benefit specifically for lymphatic filariasis. </p> <p>The previous published version of this Cochrane Review concluded that there was not enough evidence on the effectiveness of the drug albendazole, either alone or in combination with antifilarial drugs, for killing or interrupting transmission of the worms that cause lymphatic filariasis (<a href="./references#CD003753-bbs2-0113" title="AddissD , GambleCL , GarnerP , GelbandH , EjereHOD , CritchleyJA . Albendazole for lymphatic filariasis. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD003753.pub3] ">Addiss 2005</a>). In light of this, we aimed to summarize the evidence for the effects of albendazole alone or combined with a microfilaricidal drug for both individual treatment and transmission control, updating the previous edition with new methods and including new trials. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003753-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003753-sec-0038">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003753-sec-0172">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003753-sec-0038"></div> <p>To assess the effects of albendazole alone, and the effects of adding albendazole to DEC or ivermectin, in people and communities with lymphatic filariasis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003753-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003753-sec-0039">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003753-sec-0173">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003753-sec-0039"></div> <section id="CD003753-sec-0040"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003753-sec-0041"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs), including those randomized by cluster.</p> </section> <section id="CD003753-sec-0042"> <h4 class="title">Types of participants</h4> <p> <ul id="CD003753-list-0001"> <li> <p>Adults or children with filarial infection defined by the presence of mf in the blood, filarial antigens in the blood, or ultrasound detection of adult worms in lymphatic vessels. </p> </li> <li> <p>Populations normally resident in endemic communities and who are eligible for treatment, regardless of microfilaraemia status. </p> </li> </ul> </p> </section> <section id="CD003753-sec-0043"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD003753-list-0002"> <li> <p>Albendazole alone versus placebo or no placebo.</p> </li> <li> <p>Albendazole plus DEC versus DEC alone (DEC dose and regimen same in both arms).</p> </li> <li> <p>Albendazole plus ivermectin versus ivermectin alone (ivermectin dose and regimen same in both arms). </p> </li> </ul> </p> </section> <section id="CD003753-sec-0044"> <h4 class="title">Types of outcome measures</h4> <section id="CD003753-sec-0045"> <h5 class="title">Primary outcomes</h5> <section id="CD003753-sec-0046"> <h6 class="title">Measures of transmission potential</h6> <p> <ul id="CD003753-list-0003"> <li> <p>Mf prevalence.</p> </li> <li> <p>Mf density (individual or average community density in community trials).</p> </li> </ul> </p> </section> </section> <section id="CD003753-sec-0047"> <h5 class="title">Secondary outcomes</h5> <section id="CD003753-sec-0048"> <h6 class="title">Markers of adult worm infection</h6> <p> <ul id="CD003753-list-0004"> <li> <p>Antigenaemia prevalence.</p> </li> <li> <p>Antigen density.</p> </li> <li> <p>Adult worm prevalence (macrofilariae viability detected by ultrasound).</p> </li> </ul> </p> </section> <section id="CD003753-sec-0049"> <h6 class="title">Clinical disease</h6> <p> <ul id="CD003753-list-0005"> <li> <p>Acute filariasis (fever plus clinical evidence of inflammation of the lymphatic system, as defined by primary investigators). </p> </li> <li> <p>Appearance or disappearance of hydrocoele or lymphoedema.</p> </li> <li> <p>Reduction in size (or severity or grade) of hydrocoele or lymphoedema.</p> </li> </ul> </p> </section> <section id="CD003753-sec-0050"> <h6 class="title">Adverse events</h6> <p> <ul id="CD003753-list-0006"> <li> <p>Adverse events that prevent daily activities or require hospitalization.</p> </li> <li> <p>Systemic adverse events (e.g. fever, headache, malaise, myalgia, or haematuria).</p> </li> <li> <p>Local adverse events (e.g. localized pain and inflammation, tender nodules, lymphadenitis, or lymphangitis). </p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD003753-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003753-sec-0052"> <h4 class="title">Electronic searches</h4> <p>We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress). </p> <p>We searched the following databases using the search terms and strategy described in <a href="./appendices#CD003753-sec-0150">Appendix 1</a>. </p> <p> <ul id="CD003753-list-0007"> <li> <p>Cochrane Infectious Diseases Group Specialized Register (up to 15 January 2018).</p> </li> <li> <p>MEDLINE (PubMed, 1966 to 15 January 2018).</p> </li> <li> <p>Embase (OVID, 1974 to 15 January 2018).</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) published in the Cochrane Library (Issue 1, 2018). </p> </li> <li> <p>Latin American and Caribbean Health Sciences Literature (LILACS) (BIREME, 1982 to 15 January 2018). </p> </li> </ul> </p> <p>We also searched the WHO International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/ictrp/search/en/</a>) and <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>, to identify ongoing trials using the terms: filariasis; albendazole; benzimidazole. </p> </section> <section id="CD003753-sec-0053"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all included trials to identify relevant studies.</p> </section> </section> <section id="CD003753-sec-0054"> <h3 class="title" id="CD003753-sec-0054">Data collection and analysis</h3> <section id="CD003753-sec-0055"> <h4 class="title">Selection of studies</h4> <p>Two review authors, Cara Macfarlane (CM) and Shyam Budhathoki (SB), screened titles and abstracts identified from the search strategy, obtained full‐text copies of all potentially relevant trials and checked each trial report for evidence of multiple publications from the same data set. CM and SB independently assessed each trial for inclusion using an eligibility form based on the inclusion criteria and resolved any disagreements through discussion or, where necessary, by consulting a third review author, Paul Garner (PG). We contacted trial authors when we required further information. We planned to contact authors of unpublished trials. We listed excluded studies and the reasons for their exclusion in the ‘<a href="./references#CD003753-sec-0163" title="">Characteristics of excluded studies</a>’ table, and studies awaiting classification in the ‘<a href="./references#CD003753-bbs1-0003" title="">Studies awaiting classification</a>’ table along with any known details. We illustrated the study selection process in a PRISMA diagram. </p> </section> <section id="CD003753-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (CM and SB) independently extracted data on trial characteristics, including methods, participants, interventions (including dose and treatment frequency), and outcomes using a pretested data extraction form. We resolved any differences in data extraction through discussion or by consulting a third review author (PG). In the case of unclear or missing data, we attempted to contact the primary investigators for further information. We recorded the number of participants randomized in each treatment group and the number of participants that were analysed for each outcome of interest, and reported the loss to follow‐up in each group. When data were shown in figures but were not reported in the article text, we extracted data using WebPlotDigitizer software (Version 3.12) (<a href="./references#CD003753-bbs2-0080" title="RohatgiA . WebPlotDigitizer. Version 3.12. Austin: Ankit Rohatgi, 2017. ">Rohatgi 2017</a>). </p> <section id="CD003753-sec-0057"> <h5 class="title">RCTs that randomized individuals</h5> <p>For dichotomous outcomes, we recorded the number of participants experiencing the event and the total number of participants in each treatment group. For continuous outcomes, we aimed to extract geometric means and confidence intervals (CIs), together with the numbers of participants in each group. Where these were not reported, we extracted the summary measure used (geometric mean, log mean, or arithmetic mean) and standard deviations (SDs) or CIs where possible, along with the numbers of participants in each group. Where change from baseline results were presented alongside results purely based on the end value, we only extracted the change from baseline results. </p> </section> <section id="CD003753-sec-0058"> <h5 class="title">RCTs that randomized clusters</h5> <p>For cluster‐RCTs that met the inclusion criteria, we attempted to extract the cluster unit, the number of clusters in the trial, the average size of clusters, and the unit of randomization (such as household). We extracted the statistical methods used to analyse the trial along with details describing whether these methods adjusted for clustering or other covariates. We attempted to extract the intra‐cluster correlation coefficient (ICC) for the cluster‐RCT, as if this was reported we could adjust the analyses. </p> <p>We aimed to extract the cluster‐adjusted results when a cluster‐RCT adjusted for clustering in their analysis. When the trial did not account for clustering in their analysis, we extracted the same data as for trials that randomize individuals. </p> </section> </section> <section id="CD003753-sec-0059"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (CM and SB) independently assessed the risks of bias for each included trial using the Cochrane ‘Risk of bias' tool (<a href="./references#CD003753-bbs2-0063" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. ">Higgins 2011</a>), and resolved differences of opinion through discussion with Samuel Johnson (SJ) and PG. For RCTs that randomized individuals we assessed six components: sequence generation; allocation concealment; blinding (of participants, personnel, and outcome assessors); incomplete outcome data; selective outcome reporting; and other potential biases. For the cluster‐RCT, we addressed additional components: recruitment bias; baseline imbalance; loss of clusters; incorrect analysis; and compatibility with RCTs randomized by individual. </p> <p>For sequence generation and allocation concealment, we reported the methods used. For blinding, we described who was blinded and the blinding method. For incomplete outcome data, we reported the percentage and proportion of participants lost to follow‐up. For selective outcome reporting, we stated any discrepancies between the methods used and the results in terms of the outcomes measured or the outcomes reported. For other biases, we described any other trial features that could have affected the trial result (for example, if the trial was stopped early). </p> <p>We categorized our ‘Risk of bias' judgements as either ‘low’, ‘high’, or ‘unclear’. We displayed the results in ‘Risk of bias' tables, a ‘Risk of bias' summary, and a ‘Risk of bias' graph. </p> </section> <section id="CD003753-sec-0060"> <h4 class="title">Measures of treatment effect</h4> <p>We used the risk ratio (RR) to compare the treatment and control groups for dichotomous outcomes, and presented the treatment effects with 95% CIs. </p> <p>For continuous data summarized using geometric means, we planned to report the geometric mean ratios. Due to the variability in the summary measures reported and the lack of reporting of CIs or measures of variance in the trials, we could not synthesize data to obtain pooled treatment effects. We report continuous outcomes in ‘Additional tables', and we compare the difference in the intervention and the control groups' percentage reductions in parasitaemia from baseline. </p> </section> <section id="CD003753-sec-0061"> <h4 class="title">Unit of analysis issues</h4> <p>For a particular cluster‐RCT when the analyses had not been adjusted for clustering, we planned to try and adjust the results for clustering by estimating the design effect calculated as 1+(m‐1)*ICC, where m is the average cluster size and ICC is the ICC. When the true ICC was unknown, we planned to estimate it from other included cluster‐RCTs. As we were unable to estimate the ICC due to the inclusion of a single cluster‐RCT, we presented the trial authors' unadjusted data in <a href="./appendices#CD003753-sec-0151">Appendix 2</a>. </p> </section> <section id="CD003753-sec-0062"> <h4 class="title">Dealing with missing data</h4> <p>We aimed to conduct a complete‐case analysis in this review, such that all participants with a recorded outcome were included in the analysis. When necessary, we made extensive efforts to obtain clarification over aspects of the parasite density data and to obtain the original data from the trial authors. </p> </section> <section id="CD003753-sec-0063"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity using Chi<sup>2</sup> and I<sup>2</sup> statistics (<a href="./references#CD003753-bbs2-0062" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>), and judged any heterogeneity using values of I<sup>2</sup> greater than 50% and a Chi<sup>2</sup> P value of 0.10 or less to indicate moderate to substantial statistical heterogeneity (<a href="./references#CD003753-bbs2-0047" title="DeeksJJ , HigginsJPT , AltmanDG , (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from training.cochrane.org/handbook. ">Deeks 2017</a>). </p> </section> <section id="CD003753-sec-0064"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess the possibility of publication bias by examining funnel plots for asymmetry, but there were too few trials. </p> </section> <section id="CD003753-sec-0065"> <h4 class="title">Data synthesis</h4> <p>One review author (CM) analysed the data using Review Manager 5 (<a href="./references#CD003753-bbs2-0079" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). The main analysis examined albendazole alone or added to a microfilaricidal drug. We sought to identify evidence of an overall effect of albendazole; in the presence of high heterogeneity of effects between albendazole alone or added to either of the microfilaricidal drugs, we would then proceed to analysis of individual comparisons to see if this explained the heterogeneity. However, no such inconsistency was apparent. Nevertheless, we included additional comparisons of albendazole alone or in combination versus the background drug, be that placebo, DEC, or ivermectin. We provide this to summarize the reliable evidence for policy‐makers interested in the effectiveness of albendazole regimens for global lymphatic filariasis programmes. </p> <p>We directly compared treatments using pairwise comparisons. Some trials randomized infected and uninfected individuals, but only analysed subgroups of participants who were infected at baseline. The primary analysis for each outcome included the number of individuals randomized as the denominator, where possible. When a trial reported data at multiple time points we included data collected at the longest follow‐up time up to 12 months in the analysis. The exception to this was data for mf density, which we analysed by longest follow‐up time up to six months and at 12 months to seek evidence of any temporally‐dependent effects. Within the individual drug comparator groups (e.g. albendazole versus placebo), we also conducted meta‐analyses for different follow‐up time points, and included data from subgroups of individuals known to be infected or participants who were both infected and uninfected. </p> <p>We planned to combine RCTs that randomized individuals and cluster‐RCTs that adjusted for clustering using meta‐analysis. When a cluster‐RCT did not adjust for clustering and could not be combined with RCTs, we reported the results of the cluster‐RCT in an appendix. We used a fixed‐effect meta‐analysis when the assessments of heterogeneity did not reveal heterogeneity. In the presence of statistical heterogeneity we used random‐effects meta‐analysis. </p> <p>For continuous data, we presented data that could not be meta‐analysed in ‘Additional tables' and reported on these in each section under the relevant outcome heading. For the parasite density data, we examined the summary measure used (geometric, log, or arithmetic mean), the methods that were used to estimate this and the change in density post‐treatment, and whether the analysis included the whole population or only infected participants. We sought approaches to allow meta‐analysis of the density data, but this was not possible due to the variability in the summary measures reported and the lack of reporting of CIs or measures of variance. We were also unable to calculate measures of treatment effect for individual studies, due to the lack of reported measures of variances or CIs. We therefore reported on the trial authors' statistical tests of significance. </p> <p>Where trial authors provided geometric or log estimates of percentage reduction for parasite density outcomes (as an average across participants), we took the estimated percentage reduction in the intervention and the estimated percentage reduction in the control and calculated the percentage difference in density reduction between intervention and control. Whilst we could not conduct meta‐analyses to assess the treatment effect, it gave a measure of the direction of the possible effect. </p> <section id="CD003753-sec-0066"> <h5 class="title">Certainty of the evidence</h5> <p>We assessed the certainty of the evidence for each important outcome using the GRADE approach (<a href="./references#CD003753-bbs2-0081" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editors. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Updated October 2013. The GRADE Working Group, 2013. Hamilton (ON): McMaster University, Available from: gdt.gradepro.org/app/handbook/handbook.html (accessed 1 June 2018). ">Schünemann 2013</a>). All review authors participated in the GRADE assessment through several meetings. For the main outcomes in each comparison, we used GRADE profiler to assess five domains: risk of bias; inconsistency; indirectness; imprecision; and publication bias (<a href="./references#CD003753-bbs2-0058" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 28 September 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro 2015</a>). </p> <p>We assessed the overall certainty of the evidence using four categories (high, moderate, low, or very low). The baseline for each outcome was set as high‐certainty evidence, as all studies were RCTs. Each GRADE domain could be downgraded by one or two levels if we judged it to have serious or very serious concerns, and we detailed the justification for downgrading in footnotes. </p> <p>We displayed the GRADE rating of the certainty of evidence and justification for downgrading in the ‘Summary of findings' tables. </p> </section> <section id="CD003753-sec-0067"> <h5 class="title">‘Summary of findings' tables</h5> <p>We interpreted results using ‘Summary of findings' tables, which provide key information about the certainty of the evidence for the included trials in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on the main outcomes. Using GRADE profiler (<a href="./references#CD003753-bbs2-0058" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 28 September 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro 2015</a>), we imported data from Review Manager 5 (<a href="./references#CD003753-bbs2-0079" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We present the main outcomes for the review in the ‘Summary of findings' tables. When there was no pooled effect estimate for an outcome, we presented a narrative synthesis of quantitative data. </p> </section> </section> <section id="CD003753-sec-0068"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In the presence of statistically significant heterogeneity, we planned to explore the following potential sources of heterogeneity using subgroup analyses: drug dose (comparing regimens where there are significant variations in drug dose), participant age (children only, adults only, or whole populations), and length of follow‐up. We conducted subgroup analyses for drug dose and length of follow‐up only, as this appeared to explain the heterogeneity. </p> </section> <section id="CD003753-sec-0069"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out sensitivity analyses including only those trials with a low risk of bias for allocation concealment. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003753-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003753-sec-0070"></div> <section id="CD003753-sec-0071"> <h3 class="title">Description of studies</h3> <section id="CD003753-sec-0072"> <h4 class="title">Results of the search</h4> <p>See PRISMA flow diagram (<a href="#CD003753-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD003753-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003753-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We included 13 trials (8713 participants), reported in 18 articles (see <a href="./references#CD003753-sec-0162" title="">Characteristics of included studies</a>). In this Cochrane Review update, we dropped two comparisons (albendazole versus DEC and albendazole versus ivermectin), so we re‐screened all included, excluded, and ongoing studies from the last published version (<a href="./references#CD003753-bbs2-0113" title="AddissD , GambleCL , GarnerP , GelbandH , EjereHOD , CritchleyJA . Albendazole for lymphatic filariasis. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD003753.pub3] ">Addiss 2005</a>), in addition to 149 records identified from the update search. We were unable to locate one record cited in the previous version of this review, which was a two‐year follow‐up to <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>. </p> <p>We excluded 15 studies (reported in 20 records) at full‐text screening stage (see <a href="./references#CD003753-sec-0163" title="">Characteristics of excluded studies</a>). One study we excluded that was listed in a trial register (NCT01975441) published the full‐text article after we conducted the search in 15 January 2018 (<a href="./references#CD003753-bbs2-0019" title="KingCL , SuamaniJ , SanukuN , ChengYC , SatofanS , MancusoB . A trial of a triple‐drug treatment for lymphatic filariasis. New England Journal of Medicine2018;379(19):1801‐10. NCT01975441 . Eval 3‐drug therapy diethylcarbamize, albendazole and ivermectin that could accelerate LF elimination outside of Africa. clinicaltrials.gov/ct2/show/NCT01975441 (first received 4 November 2013). ">King 2018</a>). One trial, <a href="./references#CD003753-bbs2-0029" title="PurkaitB , SinghV , SankhwarSN , SinhaRJ , KumarM , BhaskarV , et al. Efficacy and safety of multi drugs combination therapy in Filarial Chyluria; a prospective randomized controlled trial. Indian Journal of Urology2017;33(Suppl 1):S43‐178. ">Purkait 2017</a>, is awaiting classification (see <a href="./references#CD003753-sec-0164" title="">Characteristics of studies awaiting classification</a>). We excluded one trial included in the previous published review, as it no longer meets the inclusion criteria due to the removal of a comparison (albendazole versus DEC) (<a href="./references#CD003753-bbs2-0017" title="JayakodyRL , DeSilvaCS , WeerasingheWM . Treatment of bancroftian filariasis with albendazole: evaluation of efficacy and adverse reactions. Tropical Biomedicine1993;10:19‐24. ">Jayakody 1993</a>). </p> </section> <section id="CD003753-sec-0073"> <h4 class="title">Included studies</h4> <section id="CD003753-sec-0074"> <h5 class="title">Location</h5> <p>The included trials were undertaken in eight different countries: India (<a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>; <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a>; <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>), Haiti (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>), Brazil (<a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>; <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>), Papua New Guinea (<a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>), Zanzibar (<a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a>), Ghana (<a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>), Tanzania (<a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>), and Kenya (<a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a>). All trials were conducted in endemic regions. </p> </section> <section id="CD003753-sec-0075"> <h5 class="title">Participants</h5> <p>Three trials were school‐based and recruited children and adolescents (5 to 18 years old) from school populations (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>); five trials were conducted in community settings and recruited adults and children (<a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a>; <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>; <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a>). Three studies were hospital‐based and recruited only children and adolescents (9 to 19 years of age) (<a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>), only adult men (<a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>), or adults and children (<a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>). Two trials recruited mf‐positive adults from endemic villages (<a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a>; <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>). </p> <p>Seven trials enrolled people with a variety of inclusion criteria related to filarial infection; four only enrolled individuals who were mf‐positive (<a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007;</a><a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013;</a><a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>); <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a> enrolled individuals with detectable filaria dance sign (FDS); <a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a> enrolled individuals who had either microfilaraemia or who were amicrofilaraemic with clinical disease; and <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a> enrolled individuals if one or more members of a household were microfilaraemic. </p> <p>Six trials enrolled individuals irrespective of their infection status at baseline (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>; <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>). <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a> enrolled 1403 participants for a safety study and included 103 men in a separate analysis of efficacy at 3, 6, and 12 months follow‐up. Forty‐three of the 103 participants in the smaller efficacy analysis were mf‐positive, 30 had clinical disease, and 30 were mf‐negative and asymptomatic. For subsequent assessments at 12, 24, and 36 months follow‐up, men and women from the safety study who were mf‐positive at baseline were also included (155 participants). </p> </section> <section id="CD003753-sec-0076"> <h5 class="title">Intervention</h5> <p>Four trials assessed albendazole alone versus placebo (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>; <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>; <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a>), eight trials assessed albendazole plus DEC versus DEC alone (<a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>; <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>, <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>; <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>; <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a>; <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>) and four trials assessed albendazole plus ivermectin versus ivermectin alone (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>; <a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a>; <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>). </p> <p>Twelve trials used the same albendazole dose (400 mg) (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>; <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>; <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>; <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>; <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a>; <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a>; <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>), and <a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a> did not report the dose. Drug dose information for <a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a> appeared to be reported in the appendices, which were not included in our copy of the thesis. We contacted the author of <a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a> and the library where the thesis was deposited to obtain the appendices, but received no response. As albendazole is usually given as a standard 400 mg single dose and there was no indication that a non‐standard dose was used, we included this trial. In the four placebo‐controlled trials, <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a> and <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a> described tablets as identical or matching albendazole‐placebo, while <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> and <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> provided 250 mg vitamin C tablets. </p> <p>All trials used a 6 mg/kg dose of DEC except for <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>, where 300 mg DEC was given. <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a> also provided a placebo for 12 days following treatment with DEC and with albendazole plus DEC. </p> <p>Of the four trials that included ivermectin, three trials used doses varying from 200 to 400 μg/kg (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>) and 150 to 200 μg/kg (<a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>). <a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a> did not report the ivermectin dose, but the thesis discussion indicated the dosage was similar to 200 μg/kg. </p> <p>In nine trials the drugs were given as a single‐dose treatment (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>; <a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a>; <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>; <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>; <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>); <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a> and <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a> provided three annual single doses. Two trials used more intensive treatment regimens; <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a> provided albendazole daily for seven days, and <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a> provided albendazole plus DEC or DEC daily for 12 days. </p> </section> <section id="CD003753-sec-0077"> <h5 class="title">Study design</h5> <p>Twelve trials were individually‐RCTs, and <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a> was a cluster‐RCT. The cluster‐RCT used households as the unit of randomization, and included 64 households containing 205 adults and children. </p> <p>The length of follow‐up varied between trials. <a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a> followed up participants for two weeks; <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> for four months; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> for six months; <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>, <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>, <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>, <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>, <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a>, and <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a> for 12 months; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a> and <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a> for 24 months; and <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a> and <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a> for 36 months. </p> </section> <section id="CD003753-sec-0078"> <h5 class="title">Outcomes</h5> <section id="CD003753-sec-0079"> <h6 class="title">Measures of transmission potential</h6> <p>All trials reported on mf prevalence and density, but the methods of measurement varied. <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> and <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> assessed 20 μL of blood with thick smear microscopy. <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>, <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>, and <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a> assessed 100 μL of blood using a counting chamber, and <a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a> assessed 200 μL of blood using a counting chamber. Seven trials assessed 1 mL blood using membrane filtration (<a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>; <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>; <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>; <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a>; <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>). <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a> also assessed prevalence in 60 μL of blood with thick smear microscopy. </p> </section> <section id="CD003753-sec-0080"> <h6 class="title">Markers of adult worm infection</h6> <p>Eight trials reported antigenaemia prevalence (<a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>; <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a>; <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>), of which all except <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a> also reported on antigen density. Five trials assessed antigenaemia using the TropBio Og4C3 ELISA (<a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>; <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a>); <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a> used the BinaxNOW Filariasis ICT; and <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a> and <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a> used both the ELISA and the immunochromatographic card test (ICT). Three trials also assessed the effect of treatment on adult worm FDS by ultrasound scan in male participants (<a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>; <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>). </p> </section> <section id="CD003753-sec-0081"> <h6 class="title">Clinical disease</h6> <p><a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a> reported on the effect of treatment on clinical disease (lymphoedema or hydrocoele), including the reduction in grade or disappearance of clinical disease, the increase in clinical disease grade, and the appearance of new clinical disease at 12 months follow‐up. </p> </section> <section id="CD003753-sec-0082"> <h6 class="title">Adverse events</h6> <p>Twelve trials reported on adverse events, but the reporting varied between trials. Some trials reported the proportion of participants experiencing adverse events (<a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>; <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>; <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a>; <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a>; <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>), while some also reported the incidence of specific systemic adverse events (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999;</a><a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a>; <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000;</a><a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>; <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>), tolerability (<a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>), or calculated scores based on severity and intensity (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999;</a><a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>). <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a> reported appearance of intrascrotal nodules in adult worm nests of male participants as a ‘sensitive reaction' to treatment. <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a> did not mention adverse events post‐treatment. </p> </section> </section> <section id="CD003753-sec-0083"> <h5 class="title">Reported statistical analysis</h5> <section id="CD003753-sec-0084"> <h6 class="title">Individually‐randomized trials</h6> <p>The statistical analyses used in the trials for density data are reported in <a href="#CD003753-tbl-0006">Table 2</a>, and detailed further here. The methods used to calculate mf density and antigen density and the percentage reductions from baseline to follow‐up were inconsistently reported across trials, and SDs or CIs for density data were absent in all but one study reporting the geometric mean (<a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>), and two studies reporting the arithmetic mean (<a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>). We obtained CIs from the investigators of <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>, and CIs for density data reported in <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> were obtained by the authors of the last published version of this review (<a href="./references#CD003753-bbs2-0113" title="AddissD , GambleCL , GarnerP , GelbandH , EjereHOD , CritchleyJA . Albendazole for lymphatic filariasis. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD003753.pub3] ">Addiss 2005</a>). As so few trials reported any measure of variance or CIs, and the summary measures presented differed between and within trials (such as arithmetic means, geometric means, and log means), we could not pool results for changes in parasite density. Results quoted in this review are the original trial author's calculations. </p> <div class="table" id="CD003753-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Parasitaemia density data: reported statistical analysis</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study details </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Reported statistical analysis </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of people enrolled</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mf density outcome denominator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CFA density outcome denominator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Explicit about method used to accommodate people with zero counts </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Explicit about method used to calculate % reduction in density</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>If density increased post‐ treatment, authors set change to zero </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infected and uninfected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infected and uninfected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All CFA‐positive<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All CFA‐positive<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> <p>(“n+1”)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All CFA‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All FDS‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All individuals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infected and uninfected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All CFA‐positive<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> <p>Calculation provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>e</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infected and uninfected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All CFA‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> <p>(“n+1”)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>e</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infected and uninfected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>e</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All individuals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GM and AM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> <p>(“n+1”)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infected and uninfected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All CFA‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> <p>Calculation provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>e</sup> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: AM: arithmetic mean; CFA: circulating filarial antigen; FDS: filarial dance sign; GM: geometric mean; LM: log mean; Mf: microfilariae; NA: not applicable; NR: not reported.<br/> <sup>a</sup>Mf density and percentage reduction in density were reported for all participants irrespective of their pre‐treatment infection status only at the 24‐month follow‐up. Details were not provided in the Methods, but the standard percentage change calculation was used.<br/> <sup>b</sup>Antigen density was reported as number of antigenaemic participants with high antigenaemia decreasing to low or to negative, and number with low antigenaemia converting to negative only at 24‐month follow‐up.<br/> <sup>c</sup>Authors provided further details on request; for mf density the "n+1" formula before log transforming values was used, and % reduction was calculated using method reported in <a href="./references#CD003753-bbs2-0030" title="AddissDG , EberhardML , LammiePJ , McNeeleyMB , LeeSH , McNeeleyDF , et al. Comparative efficacy of clearing‐dose and single high‐dose ivermectin and diethylcarbamazine against Wuchereria bancrofti microfilaremia. American Society of Tropical Medicine and Hygiene1993;48(2):178‐85. ">Addiss 1993</a>.<br/> <sup>d</sup>Authors also reported mf and CFA unit geometric mean densities for individuals who were negative for the markers at baseline and positive at 12 months; however, the change or reduction in population mf or CFA densities for all enrolled individuals was not reported.<br/> <sup>e</sup>Details were not provided in the Methods, but the standard percentage change calculation was used.<br/> <sup>f</sup>Authors used the arithmetic mean and only assessed participants who remained mf‐positive at follow‐ups; participants who had previously been mf‐positive but converted to negative were excluded from density calculations.<br/> <sup>g</sup>The last version of this review, <a href="./references#CD003753-bbs2-0113" title="AddissD , GambleCL , GarnerP , GelbandH , EjereHOD , CritchleyJA . Albendazole for lymphatic filariasis. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD003753.pub3] ">Addiss 2005</a>, reported further details were provided by <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a> on request; this trial calculated a William's mean (a modified geometric mean to take into account zero counts). </p> </div> </div> <p>Six trials enrolled individuals irrespective of their infection status at baseline (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>; <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>), and none reported the overall change in mf density or antigen density in the total population enrolled up to 12 months; only <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a> provided a measure of the impact on community mf density at 24 months post‐treatment. Most trials reported geometric mean mf density (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>; <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>; <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>; <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>), and geometric mean antigen density (<a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>); <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a> reported the log mean mf density and log mean antigen density; the arithmetic mean was also used for mf density (<a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>; <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a>), and for antigen density in <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>. <a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a> reported mf density data by intensity categories ("1‐20mff, 21‐39 mff, 40‐59 mff, &gt;60mff"), and <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a> reported that they calculated geometric mean mf intensity, but reported log mean mf densities that had not been adjusted for clustering. We did not include parasite density data from <a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a> and <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a> in our analyses. </p> <p>Four studies were not explicit about the method used to accommodate zero counts (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>; <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>; <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>), but <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a> and <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a> provided further details on request; the authors calculated a William's mean (a modification of the geometric mean to accommodate zero values) (<a href="./references#CD003753-bbs2-0112" title="WilliamsCB . The use of logarithms in the interpretation of certain entomological problems. Annals of Applied Biology1937;24(2):404‐14. ">Willams 1937</a>; <a href="./references#CD003753-bbs2-0035" title="BasáñezMG , BoussinesqM , Prod'honJ , FrontadoH , VillamizarNJ , MedleyGF , et al. Density‐dependent processes in the transmission of human onchocerciasis: intensity of microfilariae in the skin and their uptake by the simuliid host. Parasitology1994;108(Pt 1):115‐27. ">Basáñez 1994</a>). Five trials reported using the "n+1" formula before log transforming the data. Seven trials were not explicit about the method used to calculate the percentage reduction for density data (<a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>; <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a>), but five of these trials used the standard percentage change calculation (<a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>; <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a>). <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a> provided further details on request; this trial used the method described by <a href="./references#CD003753-bbs2-0030" title="AddissDG , EberhardML , LammiePJ , McNeeleyMB , LeeSH , McNeeleyDF , et al. Comparative efficacy of clearing‐dose and single high‐dose ivermectin and diethylcarbamazine against Wuchereria bancrofti microfilaremia. American Society of Tropical Medicine and Hygiene1993;48(2):178‐85. ">Addiss 1993</a>. <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> and <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> calculated the geometric mean mf density and antigen density reduction by dividing the difference between densities before and after treatment by the pretreatment mf density and log transforming the results. If pretreatment mf density was less than the density after treatment, the reduction was deemed to be zero. The trialists performed this adjustment to eliminate the problem of log transforming a negative value, but this method may bias estimates of treatment effectiveness, as increases in mf density after treatment are set to zero. </p> <p>Two trials reported inappropriate statistical methods for assessing differences in mf density or antigen density between treatment groups. <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a> reported use of a paired t‐test, which is an unsuitable test for comparing different groups. <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a> estimated the combined effect on both mf density and antigen density over the one‐year follow‐up period using repeated measures ANOVA, and used pairwise contrast tests to examine differences between groups at specific time points; however, repeated measures ANOVA is unsuitable for comparing groups, and results of pairwise contrast tests were not reported. </p> </section> <section id="CD003753-sec-0085"> <h6 class="title">Cluster‐randomized trials</h6> <p>One cluster‐RCT reported the use of a multilevel mixed‐effects regression model that adjusted for the cluster design (<a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a>); however, the primary and secondary outcomes of the review were not adjusted using this model and the authors reported on subgroups of microfilaraemic or antigenaemic individuals at follow‐up. It was not possible to adjust the results for clustering by estimating the design effect, as the average cluster size and ICC were not reported. We also could not estimate the ICC, as no other cluster‐RCTs were included. No outcomes from this trial were therefore suitable for meta‐analysis or comparative analysis, and we present the authors' unadjusted results in <a href="./appendices#CD003753-sec-0151">Appendix 2</a>. </p> </section> </section> <section id="CD003753-sec-0086"> <h5 class="title">Dealing with missing data</h5> <p>We attempted to clarify aspects of the parasite density data and to obtain the original data from the authors, but we could not acquire most of the data that we required from the primary studies for our analysis. We contacted authors of <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>, <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>, <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>, <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>, <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>, and <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>, and also attempted to contact <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>, but the email addresses that we obtained from recently published articles were inactive. At our request, the authors of <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a> provided us with CIs and SDs of log‐transformed density data and the number of participants reporting adverse events, and the authors of <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a> gave us the raw data files. We contacted the authors of <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> and <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> to obtain the raw study data in order to recalculate the percentage reduction in density from baseline to follow‐up. We received no response from the authors of <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>. The authors of <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> were unable to provide this at the time of preparing the review, due to issues with the file formats. We hope to incorporate new data analyses from <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> into any future updates of this Cochrane Review. </p> </section> </section> <section id="CD003753-sec-0087"> <h4 class="title">Excluded studies</h4> <p>We excluded 15 trials (reported in 20 records) at the full‐text screening stage, because they did not include the comparison groups or participant population sought for the review, the methods and results were not coherent or clearly expressed, the number of participants randomized for each group was very small with differential losses to follow‐up between treatment groups, or they were not an RCT. See <a href="./references#CD003753-sec-0163" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD003753-sec-0088"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD003753-fig-0002">Figure 2</a> and <a href="#CD003753-fig-0003">Figure 3</a> for ‘Risk of bias' summaries, and <a href="./references#CD003753-sec-0162" title="">Characteristics of included studies</a> section for details of the risks of bias and methods used in each trial. </p> <div class="figure" id="CD003753-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="‘Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003753-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>‘Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD003753-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="‘Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003753-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>‘Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD003753-sec-0089"> <h4 class="title">Allocation</h4> <p>All trials described themselves as randomized. We judged the risk of bias to be low in six trials that described a method of randomization (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>; <a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a>; <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>; <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>), and unclear in seven trials that did not provide further details (<a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>; <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>; <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a>; <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a>; <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>). </p> <p>We judged eight trials to be at low risk of bias for allocation concealment (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>; <a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a>; <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>; <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013)</a>. We judged <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a> to be at high risk of bias, as allocation of participants was not concealed. We judged four trials to be at unclear risk, due to insufficient information (<a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>; <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a>; <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>). </p> </section> <section id="CD003753-sec-0090"> <h4 class="title">Blinding</h4> <p>Nine trials described themselves as "double blind". For blinding of participants and personnel, five studies described blinding and we judged these to be at low risk of bias (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>; <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>; <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a>). We judged <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a> to be at high risk of bias, as they did not use blinding. We judged details of blinding to be unclear in seven trials (<a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a>; <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>; <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a>; <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>). </p> <p>For blinding of outcome assessors, seven trials described blinding of outcome assessment and we judged these to be at low risk of bias (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>; <a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a>; <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>; <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>). Six trials did not provide details of outcome assessor blinding and we judged risk of bias to be unclear (<a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>; <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a>; <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a>; <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>). </p> </section> <section id="CD003753-sec-0091"> <h4 class="title">Incomplete outcome data</h4> <p>About half the included studies (6/13) reported that more than 85% of all randomized individuals had been followed up, and we judged these studies to be at low risk of bias (<a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a>; <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>; <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>; <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a>; <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>). We judged six studies to be at high risk of bias due to attrition, as losses or exclusions of participants during the follow‐up period were considerable (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>; <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>; <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a>). We judged <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a> to be at unclear risk. </p> <p>We judged <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>, <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>, <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>, and <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a> to be at high risk of bias, as they excluded randomized participants who did not have pre‐ and post‐treatment blood samples. We judged <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a> to be at high risk of bias as the authors included a very small subset of randomized participants in a separate efficacy analysis. <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a> (cluster‐RCT) did not clearly report the number of individuals that were analysed among those randomized. <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a> analysed 1181 of 1425 participants (17.1% lost) at 12 months, with losses attributed to participant absence during survey times and some being unwilling to have repeated finger pricks. Sixty‐seven of the 340 mf‐positive participants (20%) were also lost to follow‐up. </p> </section> <section id="CD003753-sec-0092"> <h4 class="title">Selective reporting</h4> <p>Eight trials had no obvious evidence of selective reporting and we judged these to be at low risk of bias (<a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a>; <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>; <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>; <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a>; <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>). Four trials had evidence of selective reporting and we judged them to be at high risk of bias (<a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>; <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a>). We judged <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> to be at unclear risk, as not all the adverse events prespecified in the Methods were reported. </p> </section> <section id="CD003753-sec-0093"> <h4 class="title">Other potential sources of bias</h4> <p>We judged three studies to be at high risk of bias due to other potential sources of bias (<a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a>; <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a>). <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a> reported an inappropriate statistical analysis (paired t‐test) for testing for differences between treatments, which could bias interpretation of the intervention effects. <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a> did not report the findings of statistical tests for differences between groups at specific time points, but reported a significant effect for the intervention over time using repeated measures ANOVA. We rated one cluster‐RCT at high risk of bias due to incorrect analysis (some data were not adjusted for clustering) and the number of clusters and participants followed up or included in the analyses was not clearly reported (<a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a>). </p> <p>We judged two studies to have unclear risk of bias (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>). For parasite density data outcomes, the authors of <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> and <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> omitted increases in density prior to estimating the percentage reduction between baseline and follow‐up. This simply provides an assessment of the decrease in density only in people experiencing a decrease. Whilst this rule was applied to both intervention and control groups, we were uncertain of the effect of this on the estimate, or exactly what the estimate was measuring. </p> </section> </section> <section id="CD003753-sec-0094"> <h3 class="title" id="CD003753-sec-0094">Effects of interventions</h3> <p>See: <a href="./full#CD003753-tbl-0001"><b>Summary of findings for the main comparison</b> Albendazole alone or added to a microfilaricidal drug for lymphatic filariasis</a>; <a href="./full#CD003753-tbl-0002"><b>Summary of findings 2</b> Albendazole alone for lymphatic filariasis</a>; <a href="./full#CD003753-tbl-0003"><b>Summary of findings 3</b> Albendazole added to DEC for lymphatic filariasis</a>; <a href="./full#CD003753-tbl-0004"><b>Summary of findings 4</b> Albendazole added to ivermectin for lymphatic filariasis</a> </p> <p>The first set of analyses examine albendazole given alone or added to a microfilaricidal drug; and the subsequent analyses are grouped by the different background drugs (placebo, DEC, ivermectin). </p> <p>For each comparison, we present the results at the longest follow‐up (up to 12 months) from each study, and include all individuals enrolled as the denominator where possible. </p> <p>Within each different background drug analysis, we also analysed different follow‐up time points and stratified by the following. </p> <p> <ul id="CD003753-list-0008"> <li> <p>People known to be infected</p> </li> <li> <p>People both infected and uninfected in community studies</p> </li> </ul> </p> <p>The data on mf density and antigen density are presented in ‘Additional tables'; this was expressed differently across studies, often with no measure of variance, and we therefore summarized it narratively in the text. </p> <section id="CD003753-sec-0095"> <h4 class="title">Overall effect</h4> <section id="CD003753-sec-0096"> <h5 class="title">Albendazole alone or added to a microfilaricidal drug</h5> <p>One cluster‐randomized trial randomized households, and then only reported on people found to be infected and who gave blood at baseline (<a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a>). The authors reported the mean log density in a graph but this was complicated by interaction, and a logistic regression analysis was not clear as to who was included, and so further interpretation was not possible (see <a href="#CD003753-sec-0071">Description of studies</a> above). The results are in <a href="./appendices#CD003753-sec-0151">Appendix 2</a>. </p> <section id="CD003753-sec-0097"> <h6 class="title">Mf prevalence</h6> <p>Treatment with albendazole had no effect on mf prevalence at the longest follow‐up up to 12 months (5027 participants, 12 trials; <a href="./references#CD003753-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD003753-sec-0098"> <h6 class="title">Mf density</h6> <p>Eleven trials reported the effects of albendazole on mf density. <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>, <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>, <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a>, and <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a> only enrolled mf‐positive people at baseline; <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a> only enrolled people with adult worms detected by ultrasound, irrespective of mf status; <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>, <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>, <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>, <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>, <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>, and <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a> recruited mf‐positive and ‐negative participants, but only reported density in people who were mf‐positive at baseline; none reported the overall change in mf density in the total population enrolled. </p> <p>Overall, albendazole was associated with inconsistent reductions in mf density up to six months (1216 participants, 10 trials; <a href="#CD003753-tbl-0007">Table 3</a>) and at 12 months (1052 participants, 9 trials; <a href="#CD003753-tbl-0008">Table 4</a>). </p> <div class="table" id="CD003753-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Microfilarial density: up to 6 months follow‐up</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Background drug </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of bias: analysis used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial (follow‐up)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Intervention (albendazole) </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Control </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Difference between groups post‐treatment </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing (% reduction)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing: mf density</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Dunyo-2000" target="_blank">Dunyo 2000</a><sup>a,b,c,d</sup> </p> <p>(6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1783 (95% CI 1215 to 2617) to 693 (95% CI 335 to 1431)</p> <p>(61.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2277 (95% CI 1576 to 3289) to 2745 (95% CI 1505 to 5007)</p> <p>(20.6% increase)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.7%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>High risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Beach-1999" target="_blank">Beach 1999</a><sup>a,d,e</sup> </p> <p>(4 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.1 to 5.1</p> <p>(28.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.3 to 5.3</p> <p>(17.2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Fox-2005" target="_blank">Fox 2005</a><sup>a,d,e</sup> </p> <p>(6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.1 (95% CI 10.3 to 14.2) to 4.4 (95% CI 3.7 to 5.3)</p> <p>(34.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.3 (95% CI 14.5 to 20.6) to 11.2 (95% CI 9.2 to 13.7)</p> <p>(10.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>* (P &lt; 0.05)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>* (P &lt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Gayen-2013" target="_blank">Gayen 2013</a><sup>a,f,g</sup> </p> <p>(4 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3942.32 to 821.88</p> <p>(79%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4460.7 to 4390.7</p> <p><i>(1.6%)</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>DEC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Pani-2002" target="_blank">Pani 2002</a><sup>a,d,f</sup> </p> <p>(6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.4, post‐treatment NR</p> <p><i>(81%)</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.3, post‐treatment NR</p> <p><i>(74.7%)</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Dreyer-2006" target="_blank">Dreyer 2006</a><sup>d,f</sup> </p> <p>(1 month)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.9 to 12.7</p> <p>(53.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129.5 to 18.8</p> <p>(67.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−13.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.83)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Rizzo-2007" target="_blank">Rizzo 2007</a><sup>a,d,f</sup> </p> <p>(6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232.6 to 17.7</p> <p>(92.4%)</p> <p>[2.36 (95% CI 2.16 to 2.57) to 1.27 (95% CI 0.94 to 1.60)]<sup>i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182.6 to 10.5</p> <p>(94.2%)</p> <p>[2.26 (95% CI 2.04 to 2.49) to 1.09 (95% CI 0.74 to 1.43)]<sup>i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Bockarie-2007" target="_blank">Bockarie 2007</a><sup>d,f</sup> </p> <p>(6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.4 to 4.46</p> <p><i>(82.4%)</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.4 to 7.49</p> <p><i>(69.3%)</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.21)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-De-Britto-2015" target="_blank">De Britto 2015</a><sup>a,f,j</sup> </p> <p>(6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.26 (± 0.57) to 0.15 (± NR)</p> <p>(<i>99.2%</i>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.22 (± 0.52) to 0.83 (± NR)</p> <p>(<i>96%</i>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Fox-2005" target="_blank">Fox 2005</a><sup>a,d,e</sup> </p> <p>(6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.4 (95% CI 11.4 to 15.8) to 0.76 (95% CI 0.7 to 0.9)</p> <p>(80.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.9 (95% CI 11.0 to 15.2) to 2.8 (95% CI 2.3 to 3.4)</p> <p>(50.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>* (P = 0.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>* (P &lt;0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Ivermectin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Dunyo-2000" target="_blank">Dunyo 2000</a><sup>a,b,c,d</sup> </p> <p>(6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1585 (95% CI 1069 to 2350) to 110 (95% CI 50 to 239)</p> <p>(93.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2055 (95% CI 1389 to 3041) to 204 (95% CI 91 to 451)</p> <p>(90.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.71)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Simonsen-2004" target="_blank">Simonsen 2004</a><sup>a,b,d</sup> </p> <p>(6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>812.6 to 29.8</p> <p>(96.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>763.5 to 150</p> <p>(80.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>k</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>k</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Beach-1999" target="_blank">Beach 1999</a><sup>a,d,e</sup> </p> <p>(4 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.7 to 0.3</p> <p>(98.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5 to 1.5</p> <p>(76.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>*** (P &lt; 0.001)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>* (P &lt; 0.05)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Microfilariae (mf) density data and significance testing for differences between groups at baseline and follow‐up, as reported by study authors. We calculated the percentage reduction when this was not reported by the authors (values are italicized), and also the difference between the percentage reductions in the intervention and control groups. We judged the risk of bias as high when studies used analytical methods that could affect the interpretation of the data, and low or unclear risk when there was no obvious analytical issues.<br/> Abbreviations: CI: confidence interval; mf: microfilariae; NR: not reported; NS: not significant; * (P &lt; 0.05): significant; *** (P &lt; 0.001): significant; ±: standard deviation.<br/> <sup>a</sup>Only participants positive for mf at baseline.<br/> <sup>b</sup>Measured in 100 µL blood using counting chamber, and expressed as mf/mL.<br/> <sup>c</sup>Only in those individuals with over 100 mf/mL blood before treatment.<br/> <sup>d</sup>Reported as geometric mean.<br/> <sup>e</sup>Measured in 20 µL thick smear.<br/> <sup>f</sup>Measured in 1 mL blood by membrane filtration, and expressed as mf/mL.<br/> <sup>g</sup>Reported as arithmetic mean.<br/> <sup>h</sup>Authors reported "a significant difference between the control and the treated groups (P &lt; 0.05)" using paired t‐test for analysis; however, this statistical test is inappropriate for comparing different groups.<br/> <sup>i</sup>Data within square brackets [ ] indicates log mean intensity data and CIs provided by authors of <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>.<br/> <sup>j</sup>Reported as log mean.<br/> <sup>k</sup>Authors reported statistical analysis by paired t‐test and repeated‐measures ANOVA for correlated samples, and use of pairwise contrast tests to examine differences between groups at specific time points; results of pairwise tests for differences between groups do not appear to be reported. </p> </div> </div> <div class="table" id="CD003753-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Microfilarial density: 12 months follow‐up</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Background drug</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of bias: analysis used</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Intervention (albendazole)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Difference between groups post‐treatment </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing: % reduction</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing: mf density</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>798 to 251</p> <p>(68.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>971 to 845</p> <p>(13%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a><sup>a,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3942.32 to 432.64</p> <p>(89%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4460.7 to 4245</p> <p>(<i>4.8%</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>DEC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a><sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.4, post‐treatment NR</p> <p>(95.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.3, post‐treatment NR</p> <p>(89.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a><sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.9 to 6.1</p> <p>(69.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129.5 to 4.8</p> <p>(85.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−15.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.21)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.87)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a><sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232.6 to 5.2</p> <p>(<i>97.8%</i>) </p> <p>[2.36 (95% CI 2.16 to 2.57) to 0.74 (95% CI 0.44 to 1.03)]<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182.6 to 3.6</p> <p>(<i>98%</i>) </p> <p>[2.26 (95% CI 2.04 to 2.49) to 0.65 (95% CI 0.35 to 0.95)]<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a><sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.4 to 3.47</p> <p>(<i>86.3%</i>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.4 to 4.27</p> <p>(<i>82.5%</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.6)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a><sup>a,d,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.26 (± 0.57) to 0.07 (± NR)</p> <p>(<i>99.4%</i>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.22 (± 0.52) to 0.52 (± NR)</p> <p>(<i>98%</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a><sup>a,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR to 249.2 (± 276.1)</p> <p>(NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR to 245.9 (± 314.8)</p> <p>(NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ivermectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>614 to 78</p> <p>(87.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>640 to 124</p> <p>(80.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.80)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>812.6 to 59.4</p> <p>(92.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>763.5 to 124.9</p> <p>(83.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>i</sup> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Microfilariae (mf) density data and significance testing for differences between groups at baseline and follow‐up, as reported by study authors. We calculated the percentage reduction when this was not reported by the authors (values are italicized), and also the difference between the percentage reductions in the intervention and control groups. We judged the risk of bias as high when studies used analytical methods that could affect the interpretation of the data, and low or unclear risk when there was no obvious analytical issues. </p> <p>Abbreviations: mf: microfilariae; NR: not reported; NS: not significant; ±: standard deviation; CI: confidence interval.<br/> <sup>a</sup>Only participants positive for mf at baseline.<br/> <sup>b</sup>Measured in 100 µL blood using counting chamber, and expressed as mf/mL.<br/> <sup>c</sup>Reported as geometric mean.<br/> <sup>d</sup>Measured in 1 mL blood by membrane filtration, and expressed as mf/mL.<br/> <sup>e</sup>Reported as arithmetic mean.<br/> <sup>f</sup>Authors reported "a significant difference between the control and the treated groups (P &lt; 0.05)" using paired t‐test for analysis; however, this statistical test is inappropriate for comparing different groups.<br/> <sup>g</sup>Data within square brackets [ ] indicates log mean intensity data and CIs provided by authors of <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>.<br/> <sup>h</sup>Reported as log mean.<br/> <sup>i</sup>Authors reported statistical analysis by paired t‐test and repeated‐measures ANOVA for correlated samples, and use of pairwise contrast tests to examine differences between groups at specific time points; results of pairwise tests for differences between groups do not appear to be reported. </p> </div> </div> <p>Up to six months, there were four studies that gave albendazole alone, and we assessed three of these as being at high risk of bias (<a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a> used the arithmetic mean, <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> and <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> excluded increases in mf density post‐treatment). One study (119 participants), assessed as low or unclear risk of bias, suggested an effect on density although this was not evaluated statistically (<a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>); and the other studies are difficult to interpret, given the risks of bias. When albendazole was used with other drugs, the results were similarly inconsistent or problematic to interpret. </p> <p>At 12 months, a similar pattern emerged with albendazole alone, where we rated one study at high risk of bias (<a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a> used the arithmetic mean), and an effect on density was suggested in <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>, although this was not statistically significant (P = 0.10). When used with other drugs, the results showed little or no effect of albendazole. </p> </section> <section id="CD003753-sec-0099"> <h6 class="title">Antigenaemia prevalence</h6> <p>Treatment with albendazole had no effect on antigen prevalence at the longest follow‐up (3774 participants, 7 trials; <a href="./references#CD003753-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD003753-sec-0100"> <h6 class="title">Antigen density</h6> <p>Five trials reported the effects of albendazole on antigen density. <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a> and <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a> only enrolled people mf‐positive at baseline; <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>, <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>, and <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> recruited infected and uninfected participants, but only reported density in people who were antigen‐positive at baseline; none reported the overall change in antigen density in the total population enrolled. </p> <p>Overall, albendazole was not associated with greater reductions in antigen density between six and 12 months post‐treatment (1374 participants, 5 trials; <a href="#CD003753-tbl-0009">Table 5</a>). </p> <div class="table" id="CD003753-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Antigen density: longest follow‐up (up to 12 months)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Background drug</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of bias: analysis used</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial</b> </p> <p><b>(follow‐up)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Intervention (albendazole)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Difference between groups post‐treatment </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing: % reduction</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing: CFA density</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a><sup>a,b</sup> </p> <p>(12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1370 to 1139</p> <p>(16.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1869 to 2757</p> <p>(47.5% increase)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a><sup>a,c</sup> </p> <p>(6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2640 (95% CI 2279 to 3058) to 2428 (95% CI 2071 to 2847)</p> <p>(3.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2298 (95% CI 1951 to 2706) to 2479 (95% CI 2105 to 2919)</p> <p>(1.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>DEC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a><sup>a,d</sup> </p> <p>(12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.88 (± 0.48) to 2.89 (± NR) (<i>89.8%</i>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.58 (± 0.69) to 2.9 (± NR) (<i>79.1%</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.750)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a><sup>a,c</sup> </p> <p>(6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2116 (95% CI 1798 to 2490) to 1350 (95% CI 1176 to 1549)</p> <p>(26.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2194 (95% CI 1842 to 2613) to 1597 (95% CI 1375 to 1855)</p> <p>(17%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a><sup>e</sup> </p> <p>(12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.47 (± 0.18) to 0.08 (± 0.15) (<i>83%</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39 (± 0.21) to 0.07 (± 0.15) (<i>82.1%</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ivermectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a><sup>a,b</sup> </p> <p>(12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1404 to 834</p> <p>(40.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1689 to 1187</p> <p>(29.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.80)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a><sup>a,b</sup> </p> <p>(12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>247</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1338.4 to 986.6</p> <p>(26.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>266</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1026.3 to 931.6</p> <p>(9.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>f</sup> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Circulating filarial antigen (CFA) density data and significance testing for differences between groups at baseline and follow‐up, as reported by study authors. We calculated the percentage reduction when this was not reported by the authors (values are italicized), and also the difference between the percentage reductions in the intervention and control groups. We judged the risk of bias as high when studies used analytical methods that could affect the interpretation of the data, and low or unclear risk when there was no obvious analytical issues. </p> <p>Abbreviations: CFA: circulating filarial antigen; CI: confidence interval; DEC: diethylcarbamazine; mf: microfilariae; NR: not reported; NS: not significant; ±: standard deviation.<br/> <sup>a</sup>Only participants positive for CFA at baseline.<br/> <sup>b</sup>Measured in fingerprick blood, expressed as CFA unit geometric mean intensity.<br/> <sup>c</sup>Measured in fingerprick blood, expressed as geometric mean CFA units/mL.<br/> <sup>d</sup>Volume of blood not reported, expressed as log mean CFA units.<br/> <sup>e</sup>Measured in 50 µL blood, expressed as arithmetic mean CFA optical density value.<br/> <sup>f</sup>Authors reported statistical analysis by paired t‐test and repeated‐measures ANOVA for correlated samples, and use of pairwise contrast tests to examine differences between groups at specific time points; results of pairwise tests for differences between groups do not appear to be reported. </p> </div> </div> <p>Two studies gave albendazole alone; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> was assessed at high risk of bias (the authors excluded increases in antigen density post‐treatment) and <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a> at low or unclear risk of bias. <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a> included 208 participants and suggested a large difference in the antigen density percentage reductions between albendazole and placebo; however, albendazole alone reduced density by 16.9% while the placebo group increased by 47.5%, and the difference was not statistically significant (P = 0.11). The results showed little or no effect of albendazole when used with other drugs. </p> </section> <section id="CD003753-sec-0101"> <h6 class="title">Adult worm prevalence detected by ultrasound</h6> <p>There was no difference associated with adding albendazole to DEC for reducing adult worm prevalence in men examined for FDS by ultrasonography at the longest follow‐up up to 12 months (165 participants, 3 trials; <a href="./references#CD003753-fig-0006" title="">Analysis 1.3</a>). However, the individual trials were all small and underpowered. </p> </section> <section id="CD003753-sec-0102"> <h6 class="title">Clinical disease: new and pre‐existing</h6> <p>Treatment with albendazole had no effect on new (535 participants, 1 trial; <a href="./references#CD003753-fig-0007" title="">Analysis 1.4</a>) or existing clinical disease (85 participants, 1 trial; <a href="./references#CD003753-fig-0008" title="">Analysis 1.5</a>); however, the trial was underpowered for clinical outcomes. </p> </section> <section id="CD003753-sec-0103"> <h6 class="title">Adverse events</h6> <p>Treatment with albendazole had no effect on the number of participants experiencing adverse events (2894 participants, 6 trials; <a href="./references#CD003753-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD003753-sec-0104"> <h6 class="title">Sensitivity analysis</h6> <p>In the sensitivity analyses including only trials where the risk of bias for allocation concealment was low, no difference between intervention and control groups in mf prevalence, antigenaemia prevalence, adult worm prevalence detected by ultrasound, or adverse events was evident. We do not present the sensitivity analyses here, as the results did not differ from those in the primary analyses. </p> </section> </section> </section> <section id="CD003753-sec-0105"> <h4 class="title">Effects stratified by background drug</h4> <p>In the absence of any substantive evidence for an overall effect of albendazole, this became our main finding. However, we provide comparisons of albendazole grouped by background drug, as countries and policy‐makers may want to scrutinize the effectiveness of individual treatment regimens. </p> <section id="CD003753-sec-0106"> <h5 class="title">Albendazole versus placebo</h5> <p>No trials assessed adult worm prevalence (FDS) using ultrasound.</p> <section id="CD003753-sec-0107"> <h6 class="title">Mf prevalence</h6> <p>Treatment with albendazole had no effect on mf prevalence at the longest follow‐up (1406 participants, 4 trials; <a href="./references#CD003753-fig-0010" title="">Analysis 2.1</a>). </p> <p>Treatment with albendazole had no effect on mf prevalence up to six months (<a href="./references#CD003753-fig-0011" title="">Analysis 2.2</a>), or at 12 months (<a href="./references#CD003753-fig-0012" title="">Analysis 2.3</a>), irrespective of baseline infection status. </p> </section> <section id="CD003753-sec-0108"> <h6 class="title">Mf density</h6> <p>Four trials reported the effects of albendazole on mf density. <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a> only enrolled people mf‐positive at baseline; <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>, <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>, and <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> recruited mf‐positive and ‐negative participants, but only reported density in people mf‐positive at baseline; none reported the overall change in mf density in the total population enrolled. </p> <p>Albendazole was associated with greater reductions in mf density up to six months (285 participants, 4 trials; <a href="#CD003753-tbl-0007">Table 3</a>) and 12 months (169 participants, 2 trials; <a href="#CD003753-tbl-0008">Table 4</a>). </p> <p>Up to six months, there were four studies that assessed albendazole against placebo, but the magnitude of the effect of albendazole varied. One study (119 participants) suggested an effect on density (<a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>), but this was not statistically evaluated. Three studies were at high risk of bias: <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> and <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> excluded increases in mf density post‐treatment, and <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a> used the arithmetic mean; and could not be meaningfully interpreted. </p> <p>At 12 months, there were two studies that gave albendazole; <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a> included 143 participants and reported an effect of albendazole on density but this was not statistically significant (P = 0.10); the results of <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a> were difficult to interpret, as this study included 33 participants and was at high risk of bias. </p> </section> <section id="CD003753-sec-0109"> <h6 class="title">Antigenaemia prevalence</h6> <p>Treatment with albendazole had no effect on antigen prevalence at the longest follow‐up (1054 participants, 2 trials; <a href="./references#CD003753-fig-0013" title="">Analysis 2.4</a>). </p> <p>Treatment with albendazole had no effect on antigen prevalence in people who were infected and uninfected at six months (<a href="./references#CD003753-fig-0014" title="">Analysis 2.5</a>) and 12 months (<a href="./references#CD003753-fig-0015" title="">Analysis 2.6</a>) post‐treatment; and no effect at 12 months follow‐up in participants who were antigenaemic at baseline (<a href="./references#CD003753-fig-0015" title="">Analysis 2.6</a>). </p> </section> <section id="CD003753-sec-0110"> <h6 class="title">Antigen density</h6> <p>Two trials reported the effects of albendazole on antigen density (<a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>). Both trials recruited antigen‐positive and ‐negative participants, but only reported density in people antigen‐positive at baseline; none reported the overall change in antigen density in the total population enrolled. </p> <p>Albendazole was not associated with significantly greater reductions in antigen density between six and 12 months post‐treatment (371 participants, 2 trials; <a href="#CD003753-tbl-0009">Table 5</a>). </p> <p><a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a> included 208 participants and density was reduced by 16.9% with albendazole, while density increased by 47.5% with placebo, but the difference was not statistically significant (P = 0.11). <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> reported no difference with albendazole in a study including 163 participants (P &gt; 0.05), but we judged it to be at high risk of bias (the authors excluded increases in mf density post‐treatment). </p> </section> <section id="CD003753-sec-0111"> <h6 class="title">Clinical disease: new and pre‐existing</h6> <p>Treatment with albendazole had no effect on new (255 participants, 1 trial; <a href="./references#CD003753-fig-0016" title="">Analysis 2.7</a>: subgroup 1) or existing clinical disease (<a href="./references#CD003753-fig-0016" title="">Analysis 2.7</a>: subgroups 2 and 3); however, <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a> was underpowered for clinical outcomes. </p> </section> <section id="CD003753-sec-0112"> <h6 class="title">Adverse events</h6> <p>Treatment with albendazole had no effect on the number of participants experiencing adverse events (678 participants, 2 trials; <a href="./references#CD003753-fig-0017" title="">Analysis 2.8</a>). </p> <p><a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> and <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> did not provide data in a form that we could use in the meta‐analysis. <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> reported adverse reactions as generally mild and well tolerated, with no significant difference between participants receiving placebo or albendazole. <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> reported statistically significant reductions (P &lt; 0.05) in myalgias and cough for albendazole compared with placebo, but no statistically significant differences in headache, fever, or mean treatment impact score. </p> <p><a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>, <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>, and <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> reported that no localized inflammatory reactions were detected following treatment, and <a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a> did not report this. No serious adverse events were reported in any trials. </p> </section> <section id="CD003753-sec-0113"> <h6 class="title">Sensitivity analysis</h6> <p>In the sensitivity analyses including only trials where the risk of bias for allocation concealment was low, no difference between albendazole and placebo groups in mf prevalence, antigenaemia prevalence, or adverse events was evident. We do not present the sensitivity analyses here, as the results did not differ from those in the primary analyses. </p> </section> </section> <section id="CD003753-sec-0114"> <h5 class="title">Albendazole plus DEC versus DEC</h5> <p>No trials assessed new or pre‐existing clinical manifestations post‐treatment.</p> <p>One cluster‐randomized trial randomized households, and then only reported on people found to be infected and who gave blood at baseline (<a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a>). The trial authors reported the mean log density in a graph but a logistic regression analysis was not clear as to who was included, and was complicated by interaction, so further interpretation was not possible (see <a href="#CD003753-sec-0071">Description of studies</a> above). The results are in <a href="./appendices#CD003753-sec-0151">Appendix 2</a>. </p> <section id="CD003753-sec-0115"> <h6 class="title">Mf prevalence</h6> <p>Adding albendazole to DEC had no effect on mf prevalence at the longest follow‐up (1102 participants, 7 trials; <a href="./references#CD003753-fig-0018" title="">Analysis 3.1</a>). </p> <p>There was no benefit of adding albendazole to DEC up to six months (<a href="./references#CD003753-fig-0019" title="">Analysis 3.2</a>) or at 12 months post‐treatment (<a href="./references#CD003753-fig-0020" title="">Analysis 3.3</a>), irrespective of baseline infection status. There was moderate to substantial heterogeneity detected up to six months (<a href="./references#CD003753-fig-0019" title="">Analysis 3.2</a>; I<sup>2</sup> = 79%) and at 12 months (<a href="./references#CD003753-fig-0020" title="">Analysis 3.3</a>; I<sup>2</sup> = 61%) in the microfilaraemic participant subgroups, but subgroup analysis for dose seemed to explain this. There were not enough trials to formally investigate the source of heterogeneity. </p> <p>There was no difference in mf prevalence at 24 months follow‐up in participants who were all mf‐ or all antigen‐positive at baseline (<a href="./references#CD003753-fig-0021" title="">Analysis 3.4</a>). There was no benefit of adding albendazole to DEC for individuals infected and uninfected at baseline after a single dose or two annual doses; or at 36 months after three annual doses (<a href="./references#CD003753-fig-0022" title="">Analysis 3.5</a>). </p> </section> <section id="CD003753-sec-0116"> <h6 class="title">Mf density</h6> <p>Seven trials reported the effects of adding albendazole to DEC on mf density. <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>, <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>, and <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a> only enrolled microfilaraemic individuals; <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a> only enrolled individuals with FDS irrespective of mf status; and <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>, <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>, and <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a> recruited mf‐positive and ‐negative participants, but only reported density in subsets of individuals enrolled at baseline; none reported the overall change in mf density in the total population enrolled up to 12 months follow‐up. </p> <p>Overall, albendazole was associated with inconsistent effects on mf density up to six months (559 participants, 6 trials; <a href="#CD003753-tbl-0007">Table 3</a>), and was not associated with greater reductions in mf density at 12 months (535 participants, 6 trials; <a href="#CD003753-tbl-0008">Table 4</a>). </p> <p>Up to six months, there were six studies that compared albendazole added to DEC to DEC alone. Five studies showed little or no effect with albendazole, and one study reported a slightly greater reduction with DEC alone (<a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>); there was no significant difference (P &gt; 0.05) in the four trials that statistically evaluated this. One study assessed at high risk of bias (<a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> excluded increases in mf density post‐treatment) reported a significant reduction (P = 0.02) with the addition of albendazole, but this is difficult to interpret given the risk of bias. </p> <p>At 12 months, there were five studies at low or unclear risk of bias that showed no effect of adding albendazole, and <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a> reported a slightly greater reduction with DEC alone; there was no statistically significant difference (P &gt; 0.05) in four studies that tested this. </p> <p>At 24 months, there was no effect of adding albendazole to DEC in two studies after one dose (<a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>), and one study after two annual doses (<a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>); reported as not significant in two studies (P &gt; 0.05) (795 participants, 3 trials; <a href="#CD003753-tbl-0010">Table 6</a>). At 36 months, two very small trials at high risk of bias reported no effect with albendazole after one annual dose (<a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>), or three annual doses (<a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a>) (57 participants, 2 trials; <a href="#CD003753-tbl-0010">Table 6</a>). </p> <div class="table" id="CD003753-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Microfilarial density: 24 months and 36 months follow‐up</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Background drug</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of bias:</b> </p> <p><b>Analysis used</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial</b> </p> <p><b>(follow‐up)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Intervention (albendazole)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Difference between groups post‐treatment </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing: % reduction</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing: mf density</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>DEC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a><sup>a,b</sup> </p> <p>(24 months)<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR to 0.5</p> <p>(83.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>381</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR to 0.7</p> <p>(87.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−3.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.53)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>High risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a><sup>d,e</sup> </p> <p>(24 months)<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 (± 57) to <i>0.52</i> (± NR) (<i>99.5%</i>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133 (± 157) to <i>0.94</i> (± NR) </p> <p>(<i>99.3%</i>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a><sup>d,e</sup> </p> <p>(24 months)<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR to 109.5 (± 143.3) (NR)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR to 99.5 (± 119.3)</p> <p>(NR)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a><sup>d,e</sup> </p> <p>(36 months)<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 (± 57) to 0</p> <p>(<i>100%</i>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133 (± 157) to 0</p> <p>(<i>100%</i>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a><sup>d,e</sup> </p> <p>(36 months)<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR to 57.6 (± 56.0)</p> <p>(NR)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR to 60.3 (± 61.5)</p> <p>(NR)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Microfilariae (mf) density (mf/mL) data and significance testing for differences between groups at baseline and follow‐up, as reported by study authors. We calculated the percentage reduction when this was not reported by the authors (values are italicized), and also the difference between the percentage reductions in the intervention and control groups. We judged the risk of bias as high when studies used analytical methods that could affect the interpretation of the data, and low or unclear risk when there was no obvious analytical issues. </p> <p>Abbreviations: DEC: diethylcarbamazine; mf: microfilariae; NR: not reported; NS: not significant; ±: standard deviation.<br/> <sup>a</sup>All evaluable participants irrespective of baseline mf status.<br/> <sup>b</sup>Reported as geometric mean.<br/> <sup>c</sup>After one annual dose albendazole plus DEC and DEC provided.<br/> <sup>d</sup>Only participants positive for mf at baseline.<br/> <sup>e</sup>Reported as arithmetic mean.<br/> <sup>f</sup>After two annual doses albendazole plus DEC and DEC provided.<br/> <sup>g</sup>After three annual doses albendazole plus DEC and DEC provided. </p> </div> </div> </section> <section id="CD003753-sec-0117"> <h6 class="title">Antigenaemia prevalence</h6> <p>There was no effect of adding albendazole to DEC in reducing antigen prevalence at the longest follow‐up (954 participants, 5 trials; <a href="./references#CD003753-fig-0023" title="">Analysis 3.6</a>). </p> <p>There was no benefit of albendazole plus DEC at six months (<a href="./references#CD003753-fig-0024" title="">Analysis 3.7</a>) or at 12 months (<a href="./references#CD003753-fig-0025" title="">Analysis 3.8</a>) post‐treatment, irrespective of baseline infection status. Treatment with albendazole plus DEC had no additive effect at 24 months follow‐up (<a href="./references#CD003753-fig-0026" title="">Analysis 3.9</a>) after either one annual dose or two annual doses; and no effect at 36 months (<a href="./references#CD003753-fig-0027" title="">Analysis 3.10</a>) after either one annual dose or three annual doses. </p> </section> <section id="CD003753-sec-0118"> <h6 class="title">Antigen density</h6> <p>Three trials reported the effects of adding albendazole to DEC on antigen density. <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a> and <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a> only recruited mf‐positive participants; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> recruited antigen‐positive and ‐negative participants and reported density in people antigenaemic at baseline, not the overall change in antigen density in the total population enrolled. </p> <p>Adding albendazole to DEC was not associated with greater reductions in antigen density between six and 12 months (270 participants, 3 trials; <a href="#CD003753-tbl-0009">Table 5</a>). </p> <p>One study was at low or unclear risk of bias (<a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>), and two studies were at high risk of bias (<a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> excluded increases in mf density post‐treatment; <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a> used the arithmetic mean). All three studies reported little or no effect of adding albendazole to DEC, reported as not significant (P &gt; 0.05) in two studies that statistically evaluated this. </p> <p>At 24 and 36 months after a single treatment, one small study at high risk of bias reported density was near pre‐treatment levels in both groups after 24 months (<a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>), and at 36 months density had increased in the albendazole plus DEC group but remained at pre‐treatment levels with DEC alone (35 participants, 1 trial; <a href="#CD003753-tbl-0011">Table 7</a>). At 24 months after a single treatment, <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a> reported antigen concentration decreased from high to low in 16 (18.8%) participants with albendazole plus DEC, and 9 (14.7%) participants with DEC alone. </p> <div class="table" id="CD003753-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Antigen density: 24 months and 36 months follow‐up</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Background drug</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of bias: analysis used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial (follow‐up)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Intervention (albendazole)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Difference between groups post‐treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing: % reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing: CFA density</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>DEC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a><sup>a,b</sup> </p> <p>(24 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 to 0.48</p> <p>(4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39 to 0.44</p> <p>(12.8% increase)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a><sup>a,b</sup> </p> <p>(36 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 to 1.2</p> <p>(140% increase)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39 to 0.79</p> <p>(102.6% increase)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−37.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Circulating filarial antigen (CFA) density data and significance testing for differences between groups at baseline and follow‐up, as reported by study authors. Data was reported as the arithmetic mean and presented by the authors in graphs only; we extracted this information using WebPlotDigitizer software. We calculated the percentage reduction after treatment, and the difference between the percentage reductions in the intervention and control groups. We judged the risk of bias as high when studies used analytical methods that could affect the interpretation of the data, and low or unclear risk when there was no obvious analytical issues. </p> <p>Abbreviations: CFA: circulating filarial antigen; DEC: diethylcarbamazine; mf: microfilariae; NR: not reported.<br/> <sup>a</sup>Only participants positive for mf at baseline.<br/> <sup>b</sup>Volume of blood not reported, expressed as arithmetic mean CFA optical density value. </p> </div> </div> </section> <section id="CD003753-sec-0119"> <h6 class="title">Adult worm prevalence detected by ultrasound</h6> <p>There was no difference with albendazole plus DEC for reducing adult worm prevalence in men examined for FDS by ultrasound at the longest follow‐up (165 participants, 3 trials; <a href="./references#CD003753-fig-0028" title="">Analysis 3.11</a>). However, the individual trials were all small and underpowered. </p> <p>There was no benefit of adding albendazole to DEC at six months (<a href="./references#CD003753-fig-0029" title="">Analysis 3.12</a>) or at 12 months (<a href="./references#CD003753-fig-0030" title="">Analysis 3.13</a>) post‐treatment, or at 24 months (<a href="./references#CD003753-fig-0031" title="">Analysis 3.14</a>) after single dose or two annual doses, irrespective of baseline infection status. </p> </section> <section id="CD003753-sec-0120"> <h6 class="title">Adverse events</h6> <p>Treatment with albendazole plus DEC had no effect on the number of participants experiencing adverse events (1589 participants, 4 trials; <a href="./references#CD003753-fig-0032" title="">Analysis 3.15</a>). Adverse events were systemic in three trials and <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a> did not provide details. </p> <p>There was no difference in adverse events that interfered with daily activity when albendazole was added to DEC (<a href="./references#CD003753-fig-0033" title="">Analysis 3.16</a>: subgroup 2). One small trial reported localized inflammatory reactions following treatment, but no difference between treatment groups (<a href="./references#CD003753-fig-0033" title="">Analysis 3.16</a>: subgroup 3). One small trial that enrolled only men with FDS reported intrascrotal nodules (a "sensitive reaction" to antifilarial drugs) at seven days post‐treatment; nodules were detected at the site of 21 (46.7%) adult worm nests with DEC alone compared to 2 (6.1%) with albendazole plus DEC (P = 0.002) (<a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>). </p> <p><a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a> did not report adverse events, and <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> did not did not provide data in a form that we could use in meta‐analysis. <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> reported that adverse reactions were generally mild and well tolerated, with no statistically significant differences in specific symptoms or treatment impact scores between groups. <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a> also assessed a smaller subset of individuals from the large safety study who were retreated at 12 months and 24 months, but differences between groups were not reported. </p> <p>No life‐threatening adverse events or adverse events requiring hospitalization were reported in any trials. </p> </section> <section id="CD003753-sec-0121"> <h6 class="title">Sensitivity analysis</h6> <p>In the sensitivity analyses including only trials where the risk of bias for allocation concealment was low, no difference between albendazole plus DEC and DEC groups in mf prevalence, antigenaemia prevalence, adult worm prevalence by ultrasound, or adverse events was evident. We do not present the sensitivity analyses here, as the results did not differ from those in the primary analyses. </p> </section> </section> <section id="CD003753-sec-0122"> <h5 class="title">Albendazole plus ivermectin versus ivermectin</h5> <p>No trials assessed adult worm prevalence (FDS) by ultrasound.</p> <section id="CD003753-sec-0123"> <h6 class="title">Mf prevalence</h6> <p>Treatment with albendazole plus ivermectin had no effect on mf prevalence at the longest follow‐up (2519 participants, 4 trials; <a href="./references#CD003753-fig-0034" title="">Analysis 4.1</a>). There was moderate heterogeneity detected (I<sup>2</sup> = 65%) in this analysis, but subgroup analysis for length of follow‐up seemed to explain this. There were not enough trials to formally investigate the source of heterogeneity. </p> <p>Treatment with albendazole plus ivermectin did not have a statistically significant effect on mf prevalence up to six months (<a href="./references#CD003753-fig-0035" title="">Analysis 4.2</a>) or at 12 months (<a href="./references#CD003753-fig-0036" title="">Analysis 4.3</a>), irrespective of baseline infection status. Moderate to substantial heterogeneity was also detected within the subgroups of microfilaraemic participants (I<sup>2</sup> = 75%) and infected and uninfected participants (I<sup>2</sup> = 63%) at six months (<a href="./references#CD003753-fig-0035" title="">Analysis 4.2</a>). This also appeared to be explained by length of follow‐up, but could not be formally investigated. </p> </section> <section id="CD003753-sec-0124"> <h6 class="title">Mf density</h6> <p>Four trials reported the effects of adding albendazole to ivermectin on mf density. <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>, <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>, and <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a> recruited mf‐positive and mf‐negative participants, but only reported density in people mf‐positive at baseline; none reported the overall change in the population mf density post‐treatment. <a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a> assessed mf density by density categories and we did not include these data in our analysis. </p> <p>Adding albendazole to ivermectin was associated with inconsistent reductions in mf density up to six months (372 participants, 3 trials; <a href="#CD003753-tbl-0007">Table 3</a>), and was not associated with greater reductions at 12 months (348 participants, 2 trials; <a href="#CD003753-tbl-0008">Table 4</a>). </p> <p>Up to six months, there were three studies that gave albendazole with ivermectin, and one of these was assessed at high risk of bias (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> excluded increases in mf density post‐treatment). Two studies, <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a> and <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>, which we assessed as at low or unclear risk of bias, reported little or no effect on density with albendazole. <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> reported a significant effect (P &lt; 0.001) but what this means is unclear, given the risk of bias. </p> <p>At 12 months, there were two trials at low or unclear risk of bias (<a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>). There was little or no difference in density with albendazole, reported as not significant (P = 0.80) in one study that statistically tested this. </p> </section> <section id="CD003753-sec-0125"> <h6 class="title">Antigenaemia prevalence</h6> <p>There was no difference in antigen prevalence at the longest follow‐up up to 12 months (1766 participants, 2 trials; <a href="./references#CD003753-fig-0037" title="">Analysis 4.4</a>). </p> <p>There was no benefit of adding albendazole to ivermectin at six months (<a href="./references#CD003753-fig-0038" title="">Analysis 4.5</a>) or 12 months post‐treatment (<a href="./references#CD003753-fig-0039" title="">Analysis 4.6</a>), irrespective of baseline infection status. </p> </section> <section id="CD003753-sec-0126"> <h6 class="title">Antigen density</h6> <p>Two trials reported the effects of adding albendazole to ivermectin on antigen density (<a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>). Both trials recruited antigen‐positive and ‐negative participants, but only reported density in people antigen‐positive at baseline; none reported the overall change in the population antigen density post‐treatment. </p> <p>Albendazole was associated with marginal reductions in antigen density at 12 months (733 participants, 2 trials; <a href="#CD003753-tbl-0009">Table 5</a>). </p> <p>A slightly greater reduction in density with albendazole was reported in <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a> (10.9% difference) and <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a> (17.1% difference); the antigen density post‐treatment with albendazole was not significantly different (P &gt; 0.80) in <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>. </p> </section> <section id="CD003753-sec-0127"> <h6 class="title">Clinical disease</h6> <p>At 12 months post‐treatment, adding albendazole to ivermectin had no effect on new (280 participants, 1 trial; <a href="./references#CD003753-fig-0040" title="">Analysis 4.7</a>: subgroup 1) or existing clinical disease (<a href="./references#CD003753-fig-0040" title="">Analysis 4.7</a>: subgroups 2 and 3); however, <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a> was underpowered for clinical outcomes. </p> </section> <section id="CD003753-sec-0128"> <h6 class="title">Adverse events</h6> <p>Treatment with albendazole plus ivermectin had no effect on the number of participants experiencing adverse events (627 participants, 1 trial; <a href="./references#CD003753-fig-0041" title="">Analysis 4.8</a>). </p> <p><a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>, <a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a>, and <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a> did not provide data in a form that we could use in meta‐analysis. <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a> did not report the number of participants with adverse events in each group, but reported that all reactions were mild, and no significant relationship between headache or fever and the treatment given (P = 0.42 and P = 0.96). <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> reported that adverse reactions were generally mild, with no significant differences (P &gt; 0.05) in the frequency or severity of symptoms between groups. <a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a> reported significant differences in fever (P = 0.045) and dizziness (P = 0.029) with ivermectin alone, and significant differences (P = 0.012) in headaches were reported with the combination treatment. </p> <p>No serious or severe adverse reactions were reported in any of the trials. No localized inflammatory reactions were observed in <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> and <a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>, and <a href="./references#CD003753-bbs2-0003" title="DahomaMJ . A randomized community trial on safety and efficacy of co‐administration of albendazole and ivermectin on lymphatic filariasis and its secondary effects on geohelminths in Zanzibar. http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/15692000. ">Dahoma 2000</a> and <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a> did not report this. </p> </section> <section id="CD003753-sec-0129"> <h6 class="title">Sensitivity analysis</h6> <p>In the sensitivity analyses including only trials where the risk of bias for allocation concealment was low, no difference between albendazole plus ivermectin and ivermectin groups in mf prevalence, antigenaemia prevalence, or adverse events was evident. We do not present the sensitivity analyses here, as the results did not differ from those in the primary analyses. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003753-sec-0130" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003753-sec-0130">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003753-sec-0204">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003753-sec-0130"></div> <section id="CD003753-sec-0131"> <h3 class="title" id="CD003753-sec-0131">Summary of main results</h3> <p>Albendazole given alone or added to a microfilaricidal drug makes little or no difference to mf prevalence over two weeks to 12 months post‐treatment (high‐certainty evidence), but we do not know if there is an effect on mf density over one to six months (very‐low certainty evidence), or at 12 months follow‐up (very low‐certainty evidence). For antigenaemia prevalence between six to 12 months, albendazole alone or in combination makes little or no difference (high‐certainty evidence). For antigen density over six to 12 months, we do not know if albendazole has an effect (very low‐certainty evidence). For adult worm prevalence detected by ultrasound at 12 months, albendazole may make little or no difference (low‐certainty evidence). Albendazole alone or added to a microfilaricidal drug makes little or no difference to adverse events (high‐certainty evidence). See <a href="./full#CD003753-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>Albendazole given alone makes little or no difference to mf prevalence over four to 12 months post‐treatment (high‐certainty evidence), but we do not know if there is an effect on mf density after four to six months (very low‐certainty evidence), or at 12 months follow‐up (very low‐certainty evidence). For antigenaemia prevalence over six to 12 months post‐treatment, albendazole makes little or no difference (high‐certainty evidence). For antigen density over six to 12 months, we do not know if albendazole has an effect (very low‐certainty evidence). For adult worm prevalence detected by ultrasound, the effect of albendazole was not measured. Albendazole probably makes little or no difference to adverse events (moderate‐certainty evidence). See <a href="./full#CD003753-tbl-0002">summary of findings Table 2</a>. </p> <p>Albendazole added to DEC probably makes little or no difference to mf prevalence over six to 12 months post‐treatment (moderate‐certainty evidence). For mf density between one to six months, we do not know if there is an effect (very low‐certainty evidence), but albendazole co‐administered with DEC may make little or no difference to mf density at 12 months (low‐certainty evidence). For antigenaemia prevalence between six to 12 months post‐treatment, albendazole makes little or no difference (high‐certainty evidence). For antigen density over six to 12 months, we do not know if albendazole has an effect (very low‐certainty evidence). For adult worm prevalence detected by ultrasound at 12 months, albendazole plus DEC may make little or no difference (low‐certainty evidence). Albendazole added to DEC makes little or no difference to adverse events (high‐certainty evidence). See <a href="./full#CD003753-tbl-0003">summary of findings Table 3</a>. </p> <p>Albendazole added to ivermectin probably makes little or no difference to mf prevalence over two weeks to 12 months post‐treatment (moderate‐certainty evidence). For mf density between four to six months, we do not know if there is an effect (very low‐certainty evidence), but albendazole co‐administered with ivermectin may make little or no difference at 12 months (low‐certainty evidence). For antigenaemia prevalence at 12 months, albendazole makes little or no difference (high‐certainty evidence). For antigen density at 12 months, the albendazole plus ivermectin combination may make little or no difference (low‐certainty evidence). For adult worm prevalence detected by ultrasound, the effect of albendazole plus ivermectin versus ivermectin was not measured. Albendazole added to ivermectin probably makes little or no difference to adverse events (moderate‐certainty evidence). See <a href="./full#CD003753-tbl-0004">summary of findings Table 4</a>. </p> </section> <section id="CD003753-sec-0132"> <h3 class="title" id="CD003753-sec-0132">Overall completeness and applicability of evidence</h3> <section id="CD003753-sec-0133"> <h4 class="title">Measures of transmission potential</h4> <p>In people with lymphatic filariasis and people from lymphatic filariasis‐endemic communities, treatment with albendazole alone or albendazole added to antifilarial drugs, DEC or ivermectin, had little or no effect on mf prevalence. All trials included in the review assessed mf prevalence, and the evidence for the lack of effect comes from trials that were conducted in a variety of locations and settings, included both adults and children, and included both infected and uninfected individuals. </p> <p>The trials used a range of methods to measure and calculate changes in mf density, and the reported efficacy of albendazole given alone or in combination with a microfilaricidal drug ranged from showing an effect to no effect, with greater inconsistency seen up to six months post‐treatment. All trials measured mf density, but trial authors mainly reported the results of small subgroups of microfilaraemic individuals at follow‐up, rather than all randomized individuals. The benefit of albendazole regimens when given to endemic communities could not be assessed. </p> <p>No trials included in the review assessed treatment twice per year with albendazole, so we could not determine whether the WHO recommendation for albendazole alone twice per year to treat lymphatic filariasis in loiasis‐endemic areas is supported (<a href="./references#CD003753-bbs2-0101" title="World Health Organization. Provisional Strategy for Interrupting Lymphatic Filariasis Transmission in Loiasis‐Endemic Countries: Report of the Meeting on Lymphatic Filariasis, Malaria and Integrated Vector Management [Accra, Ghana, 5 – 9 March 2012]. Geneva: World Health Organization, 2012. [WHO/HTM/NTD/PCT/2012.6] ">WHO 2012</a>). Other studies have reported a benefit of an increased dose or frequency of albendazole for individual treatment and community control, but these were either not placebo‐controlled trials (<a href="./references#CD003753-bbs2-0023" title="PionSD , ChesnaisCB , BopdaJ , LouyaF , FischerPU , MajewskiAC . The impact of two semiannual treatments with albendazole alone on lymphatic filariasis and soil‐transmitted helminth infections: a community‐based study in the Republic of Congo. American Journal of Tropical Medicine and Hygiene2015;92(5):959‐66. PionSD , ChesnaisCB , WeilGJ , FischerPU , MissamouF , BoussinesqM . Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil‐transmitted helminth infections: a community‐based study in Republic of the Congo. Lancet Infectious Diseases2017;17(7):763‐9. ">Pion 2015</a>), or were not designed to assess the effects of albendazole alone (<a href="./references#CD003753-bbs2-0018" title="KarSK , DwibediB , KerketaAS , MaharanaA , PandaSS , MohantyPC , et al. A randomized controlled trial of increased dose and frequency of albendazole with standard dose DEC for treatment of Wuchereria bancrofti microfilaremics in Odisha, India. PLoS Neglected Tropical Diseases2015;9(3):e0003583. ">Kar 2015</a>; <a href="./references#CD003753-bbs2-0026" title="TafatathaTT , NgwiraBM , TaegtmeyerM , PhiriAJ , WilsonTP , BandaLG . Randomised controlled clinical trial of increased dose and frequency of albendazole and ivermectin on Wuchereria bancrofti microfilarial clearance in northern Malawi. Transactions of the Royal Society of Tropical Medicine and Hygiene2015;109(6):393‐9. ">Tafatatha 2015</a>). </p> </section> <section id="CD003753-sec-0134"> <h4 class="title">Markers of adult worm infection</h4> <p>Albendazole is thought to have some macrofilaricidal properties when given at high doses over several weeks (<a href="./references#CD003753-bbs2-0017" title="JayakodyRL , DeSilvaCS , WeerasingheWM . Treatment of bancroftian filariasis with albendazole: evaluation of efficacy and adverse reactions. Tropical Biomedicine1993;10:19‐24. ">Jayakody 1993</a>). However, a single 400 mg dose of albendazole (the dose used in MDA programmes), given either as monotherapy or as a combination therapy, had little or no effect on adult worm prevalence after six to 12 months. </p> <p>Evidence for an overall effect of albendazole for reducing adult worm viability was limited to comparing the antigen density reductions and the trial authors' statistical interpretation, but no studies reported a significant effect (P &lt; 0.05) of albendazole alone or when added to a microfilaricidal drug. The trials were individually‐randomized and primarily assessed subgroups of antigenaemic individuals, and so we could not evaluate the effect of albendazole on CFA density at the community level. </p> <p>Three trials also assessed adult worm (filarial dance sign) prevalence using ultrasound with male participants treated with albendazole co‐administered with DEC or DEC alone. The limited current evidence suggests that albendazole may give little or no additional benefit over DEC alone. One trial included in this review reported that the addition of albendazole appeared to decrease the macrofilaricidal effect of DEC against <i>W bancrofti</i> (<a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>)<i>.</i> However, these trials were small and so we can not completely rule out any macrofilaricidal effect. </p> </section> <section id="CD003753-sec-0135"> <h4 class="title">Clinical disease</h4> <p>The effect of albendazole, either alone or when added to ivermectin for clinical disease, was not remarkable. This is not surprising as effect sizes for clinical outcomes were small and the one trial that assessed this was not powered to detect small clinical benefits (<a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a>). </p> </section> <section id="CD003753-sec-0136"> <h4 class="title">Adverse events</h4> <p>Nearly all trials reported on adverse events, with treatment with albendazole alone or combined with ivermectin or DEC making little difference to adverse events in people with lymphatic filariasis or in people in endemic communities. Adverse events were generally mild and systemic. Local adverse events were reported in two small trials that compared albendazole co‐administered with DEC to DEC alone (<a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>; <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>). <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a> observed no difference between groups, but <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a> detected a higher proportion of "sensitive reactions" in men in the DEC group compared to men given the albendazole and DEC combination. There do not appear to be safety concerns for albendazole when given at the dose or in the drug combinations recommended for lymphatic filariasis MDA programmes (<a href="./references#CD003753-bbs2-0099" title="World Health Organization. Preventive Chemotherapy in Human Helminthiasis: Coordinated Use of Anthelminthic Drugs in Control Interventions: A Manual for Health Professionals and Programme Managers. Geneva: World Health Organization, 2006. ">WHO 2006</a>). </p> </section> <section id="CD003753-sec-0137"> <h4 class="title">Long‐term effects</h4> <p>Multiple rounds of annual treatment with albendazole and either DEC or ivermectin are recommended in lymphatic filariasis elimination programmes in order to sustainably interrupt transmission. There is insufficient evidence to draw any meaningful conclusions on the long‐term impact of albendazole for lymphatic filariasis. The impact of albendazole on outcomes in the long term (at 24 or 36 months post‐treatment) was evaluated in four trials that compared albendazole added to DEC with DEC alone. </p> <p>In a small subgroup of randomized participants, <a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a> reported that there was no effect of adding albendazole for any of the parasitological outcomes measured after three annual rounds of treatment. <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a> and <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a> showed little or no effect of adding albendazole for parasitological outcomes at 24 or 36 months after a single dose of the treatments; and <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a>, a very small trial, reported a greater increase in antigen density at 36 months post‐treatment with the albendazole combination therapy. </p> </section> <section id="CD003753-sec-0138"> <h4 class="title">Certainty of the evidence</h4> <p>Thirteen trials, including one cluster‐RCT, with 8713 participants met the inclusion criteria. We assessed the certainty of the evidence for mf prevalence and antigenaemia prevalence outcomes as high for our main analysis, albendazole alone or added to a microfilaricidal drug. In individual comparisons, we graded the certainty of the evidence for mf prevalence as high for albendazole alone, and moderate for albendazole added to DEC and albendazole added to ivermectin. The other parasitological outcomes, mf density, antigen density, and adult worm prevalence detected by ultrasound, had low or very low certainty evidence for an effect of albendazole. </p> <p>All trials were described as randomized, but they had important limitations. Most included studies were designed primarily to assess the effectiveness of albendazole for treatment of individuals, and did not explicitly consider the effects on transmission in whole communities. The numbers of participants lost to or excluded from the follow‐up were also very high (above 20%) in almost half of the trials, which could lead to imbalances in the comparison groups. However, the numbers lost were generally comparable between treatment groups within the trials. </p> <p>Differences in design (mf‐positive participants only compared to positive and negative participants, variable outcome measurement and reporting, and follow‐up times) made it difficult to compare the trials. Most trials reported outcomes mainly for those who were mf‐positive or antigen‐positive at baseline. Selectively analysing subgroups of randomized participants may bias the conclusions of the study, and result in an overestimation or dilution of potential treatment effects. </p> <p>For parasite density data, the difference in outcome summary measure reported (i.e. geometric mean, arithmetic mean, log mean), the analysis methods used, and the lack of reporting of SDs or CIs in most trials made it impossible to include these results in a meta‐analysis. Studies should report measures of variance or CIs so that the amount of uncertainty in the point estimate is clear. We judged the analytical methods used by some trials to be at high risk of bias due to the method used to calculate the change from baseline (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>), or use of the arithmetic mean as the average estimate. For studies that reported no transformation onto the log scale for skewness in the data, using the arithmetic mean to measure skewed data is not appropriate. Tests of statistical significance were also not always carried out or reported. For these reasons, we downgraded the certainty of the evidence for density outcomes by two levels for imprecision; by one for risk of bias when data from <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> or <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> were included; and by one when there was also inconsistency between trials. </p> </section> </section> <section id="CD003753-sec-0139"> <h3 class="title" id="CD003753-sec-0139">Potential biases in the review process</h3> <section id="CD003753-sec-0140"> <h4 class="title">Statistical errors in analysis</h4> <p>We included one cluster‐RCT in the review (<a href="./references#CD003753-bbs2-0013" title="WamaeCN , NjengaSM , NgugiBM , MbuiJ , NjaanakeHK . Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Tropica2011;120(Supplement 1):S33‐8. ">Wamae 2011</a>), but the trial authors did not take adequate account of cluster randomization. The analyses for primary and secondary outcomes were not adjusted for clustering, and the trial authors reported results from subgroups of microfilaraemic and antigenaemic individuals. This could impact the interpretation of the trial, and we did not use these data in our analyses. However, we have reported all relevant outcomes not included in our analyses in <a href="./appendices#CD003753-sec-0151">Appendix 2</a>. </p> </section> <section id="CD003753-sec-0141"> <h4 class="title">Parasite density outcomes</h4> <p>Due to the poor reporting of parasite density outcomes we could not combine trials in a meta‐analysis. We attempted to contact several trial authors to clarify their methods or request CIs for the data (<a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>; <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>; <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a>; <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a>; <a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a>; <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>; <a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a>). We received a response from <a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a> and <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>, and are awaiting data from <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a>. We could not find an active email address for <a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a>. </p> <p>We therefore analysed density data by comparing the difference in percentage reduction between the intervention and control groups, with less weighting given to trials that reported the mean (as this does not account for potentially skewed data). We also considered the results of the statistical analyses reported by the authors. This could introduce bias, as authors assessed subgroups of the total randomized individuals and calculated the geometric mean and percentage reduction in geometric mean using different methods. Tests of statistical significance were not always carried out or reported. However, we judged the evidence to be low to very low certainty. </p> </section> <section id="CD003753-sec-0142"> <h4 class="title">Subgroup analyses</h4> <p>Many of the included trials had several dissimilar follow‐up intervals and reported on subgroups of participants for the outcomes. We analysed the longest follow‐up up to 12 months from each trial, and used the number randomized as the denominator where possible. This meant combining trials that analysed individuals who were all microfilaraemic or positive for adult worms with trials that analysed infected and uninfected individuals. We believed this would not bias the findings of our review. </p> <p>We did detect moderate heterogeneity when comparing albendazole plus ivermectin to ivermectin alone for mf prevalence, but this appeared to be explained by trial follow‐up periods, which ranged from two weeks to 12 months. </p> <p>We also conducted additional meta‐analyses to assess different follow‐up times (up to six, and at 12, 24 and 36 months), and stratified the analyses by the participants' baseline infection status to rule out any potential time‐dependent effects or other specific effects of albendazole. The number of participants in the subgroup analyses were generally small, but the results of these additional meta‐analyses were in broad agreement with our primary analyses assessing the longest follow‐up data. </p> </section> </section> <section id="CD003753-sec-0143"> <h3 class="title" id="CD003753-sec-0143">Agreements and disagreements with other studies or reviews</h3> <p>The findings from our review are in agreement with the findings from a literature review published in 2005, <a href="./references#CD003753-bbs2-0090" title="TischDJ , MichaelE , KazuraJW . Mass chemotherapy options to control lymphatic filariasis: a systematic review. Lancet Infectious Diseases2005;5(8):514‐23. ">Tisch 2005</a>, which conducted a systematic evaluation of data from publicly available drug trials to determine estimates of drug effect against <i>W bancrofti</i> mf in individuals and populations. <a href="./references#CD003753-bbs2-0090" title="TischDJ , MichaelE , KazuraJW . Mass chemotherapy options to control lymphatic filariasis: a systematic review. Lancet Infectious Diseases2005;5(8):514‐23. ">Tisch 2005</a> concluded that the use of albendazole with a microfilaricidal drug does not appear to augment the effectiveness of a single microfilaricidal drug, and the authors also emphasized the need for further research and clearer reporting of trials. However, the methods of this literature review differed from our Cochrane Review: it was not a protocol‐driven systematic review; effect estimates and precision around the effect estimate for outcomes were not determined using meta‐analyses; and the study quality was not assessed for included studies. </p> <p>The findings of our review are at odds with the original documents that led to the introduction of albendazole to filarial control programmes, including a WHO consultation on albendazole research findings in lymphatic filariasis (<a href="./references#CD003753-bbs2-0098" title="Filariasis Elimination Programme (CDS/FIL). Report from informal consultation on albendazole research findings in lymphatic filariasis 13‐14 October 1998. Geneva: World Health Organization WHO/FIL/98.1941998. ">WHO 1998</a>) and a narrative review (<a href="./references#CD003753-bbs2-0075" title="OttesenEA , IsmailMM , HortonJ . The role of albendazole in programmes to eliminate lymphatic filariasis. Parasitology Today1999;15(9):382‐6. ">Ottesen 1999</a>). The narrative review conducted by the WHO concluded that "single dose 2‐drug combinations of albendazole plus either ivermectin or DEC are superior in efficacy to single drug treatment for decreasing microfilaraemia in lymphatic filariasis", and that "Albendazole alone has a killing or sterilizing activity on lymphatic filarial adult worms" (<a href="./references#CD003753-bbs2-0098" title="Filariasis Elimination Programme (CDS/FIL). Report from informal consultation on albendazole research findings in lymphatic filariasis 13‐14 October 1998. Geneva: World Health Organization WHO/FIL/98.1941998. ">WHO 1998</a>). </p> <p>An expert opinion review and meta‐analysis by <a href="./references#CD003753-bbs2-0060" title="GyapongJO , KumaraswamiV , BiswasG , OttesenEA . Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opinion on Pharmacotherapy2005;6(2):179‐200. ">Gyapong 2005</a> favoured the two‐drug regimens over single microfilaricidal drugs for treating and preventing lymphatic filariasis. Their analyses differ from our analyses in a number of ways: it was not a protocol‐driven systematic review; the authors included scientific literature supplemented by reports and studies, and did not assess the quality of the studies; the authors only included studies where the participants were microfilaraemic; the statistical significance may also have been overstated in some analyses, since data from several studies were incorporated twice (by counting results at six and 12 months and combining them in the same meta‐analysis), which artificially narrows the 95% CIs. </p> <p>A narrative literature review by <a href="./references#CD003753-bbs2-0074" title="OlsenA . Efficacy and safety of drug combinations in the treatment of schistosomiasis, soil‐transmitted helminthiasis, lymphatic filariasis and onchocerciasis. Transactions of The Royal Society of Tropical Medicine and Hygiene2007;101(8):747‐58. ">Olsen 2007</a> presented evidence reported by individual studies, and concluded: “Results with ALB added to single‐drug therapy with IVM or DEC against lymphatic filariasis were inconclusive, but DEC and IVM in combination appeared to be superior to DEC or IVM alone.” Their analyses differ from ours, in that: it was not a protocol‐driven systematic review; it was a narrative summary of studies rather than a meta‐analysis of data; and the study quality was not assessed for included studies. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003753-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003753-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="‘Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003753-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>‘Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="‘Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003753-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>‘Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Albendazole alone or added to a microfilaricidal drug, Outcome 1 Microfilaraemia (mf) prevalence: longest follow‐up (up to 12 months)." data-id="CD003753-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Albendazole alone or added to a microfilaricidal drug, Outcome 1 Microfilaraemia (mf) prevalence: longest follow‐up (up to 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Albendazole alone or added to a microfilaricidal drug, Outcome 2 Antigenaemia prevalence: longest follow‐up (up to 12 months)." data-id="CD003753-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Albendazole alone or added to a microfilaricidal drug, Outcome 2 Antigenaemia prevalence: longest follow‐up (up to 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Albendazole alone or added to a microfilaricidal drug, Outcome 3 Adult worm prevalence by ultrasound: longest follow‐up (up to 12 months)." data-id="CD003753-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Albendazole alone or added to a microfilaricidal drug, Outcome 3 Adult worm prevalence by ultrasound: longest follow‐up (up to 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Albendazole alone or added to a microfilaricidal drug, Outcome 4 New clinical disease (new cases hydrocoele)." data-id="CD003753-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Albendazole alone or added to a microfilaricidal drug, Outcome 4 New clinical disease (new cases hydrocoele). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Albendazole alone or added to a microfilaricidal drug, Outcome 5 Pre‐existing clinical disease (net improvement)." data-id="CD003753-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Albendazole alone or added to a microfilaricidal drug, Outcome 5 Pre‐existing clinical disease (net improvement). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Albendazole alone or added to a microfilaricidal drug, Outcome 6 Adverse events." data-id="CD003753-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Albendazole alone or added to a microfilaricidal drug, Outcome 6 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Albendazole versus placebo, Outcome 1 Microfilaraemia (mf) prevalence: longest follow‐up (up to 12 months)." data-id="CD003753-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Albendazole versus placebo, Outcome 1 Microfilaraemia (mf) prevalence: longest follow‐up (up to 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Albendazole versus placebo, Outcome 2 Microfilaraemia (mf) prevalence: stratified by baseline infection (up to 6 months follow‐up)." data-id="CD003753-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Albendazole versus placebo, Outcome 2 Microfilaraemia (mf) prevalence: stratified by baseline infection (up to 6 months follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Albendazole versus placebo, Outcome 3 Microfilaraemia (mf) prevalence: stratified by baseline infection (12 months follow‐up)." data-id="CD003753-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Albendazole versus placebo, Outcome 3 Microfilaraemia (mf) prevalence: stratified by baseline infection (12 months follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Albendazole versus placebo, Outcome 4 Antigenaemia prevalence: longest follow‐up (up to 12 months)." data-id="CD003753-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Albendazole versus placebo, Outcome 4 Antigenaemia prevalence: longest follow‐up (up to 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Albendazole versus placebo, Outcome 5 Antigenaemia prevalence: stratified by baseline infection (6 months follow‐up)." data-id="CD003753-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Albendazole versus placebo, Outcome 5 Antigenaemia prevalence: stratified by baseline infection (6 months follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Albendazole versus placebo, Outcome 6 Antigenaemia prevalence: stratified by baseline infection (12 months follow‐up)." data-id="CD003753-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Albendazole versus placebo, Outcome 6 Antigenaemia prevalence: stratified by baseline infection (12 months follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Albendazole versus placebo, Outcome 7 Clinical disease." data-id="CD003753-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Albendazole versus placebo, Outcome 7 Clinical disease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Albendazole versus placebo, Outcome 8 Adverse events." data-id="CD003753-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Albendazole versus placebo, Outcome 8 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Albendazole plus DEC versus DEC, Outcome 1 Microfilaraemia (mf) prevalence: longest follow‐up (up to 12 months)." data-id="CD003753-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Albendazole plus DEC versus DEC, Outcome 1 Microfilaraemia (mf) prevalence: longest follow‐up (up to 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Albendazole plus DEC versus DEC, Outcome 2 Microfilaraemia (mf) prevalence: stratified by baseline infection (up to 6 months follow‐up)." data-id="CD003753-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Albendazole plus DEC versus DEC, Outcome 2 Microfilaraemia (mf) prevalence: stratified by baseline infection (up to 6 months follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Albendazole plus DEC versus DEC, Outcome 3 Microfilaraemia (mf) prevalence: stratified by baseline infection (12 months follow‐up)." data-id="CD003753-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Albendazole plus DEC versus DEC, Outcome 3 Microfilaraemia (mf) prevalence: stratified by baseline infection (12 months follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Albendazole plus DEC versus DEC, Outcome 4 Microfilaraemia (mf) prevalence: stratified by baseline infection (24 months follow‐up)." data-id="CD003753-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Albendazole plus DEC versus DEC, Outcome 4 Microfilaraemia (mf) prevalence: stratified by baseline infection (24 months follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Albendazole plus DEC versus DEC, Outcome 5 Microfilaraemia (mf) prevalence: stratified by baseline infection (36 months follow‐up)." data-id="CD003753-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Albendazole plus DEC versus DEC, Outcome 5 Microfilaraemia (mf) prevalence: stratified by baseline infection (36 months follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Albendazole plus DEC versus DEC, Outcome 6 Antigenaemia prevalence: longest follow‐up (up to 12 months)." data-id="CD003753-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Albendazole plus DEC versus DEC, Outcome 6 Antigenaemia prevalence: longest follow‐up (up to 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Albendazole plus DEC versus DEC, Outcome 7 Antigenaemia prevalence: stratified by baseline infection (6 months follow‐up)." data-id="CD003753-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Albendazole plus DEC versus DEC, Outcome 7 Antigenaemia prevalence: stratified by baseline infection (6 months follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Albendazole plus DEC versus DEC, Outcome 8 Antigenaemia prevalence: stratified by baseline infection (12 months follow‐up)." data-id="CD003753-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Albendazole plus DEC versus DEC, Outcome 8 Antigenaemia prevalence: stratified by baseline infection (12 months follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Albendazole plus DEC versus DEC, Outcome 9 Antigenaemia prevalence: stratified by baseline infection (24 months follow‐up)." data-id="CD003753-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Albendazole plus DEC versus DEC, Outcome 9 Antigenaemia prevalence: stratified by baseline infection (24 months follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Albendazole plus DEC versus DEC, Outcome 10 Antigenaemia prevalence: stratified by baseline infection (36 months follow‐up)." data-id="CD003753-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Albendazole plus DEC versus DEC, Outcome 10 Antigenaemia prevalence: stratified by baseline infection (36 months follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Albendazole plus DEC versus DEC, Outcome 11 Adult worm prevalence by ultrasound: longest follow‐up (up to 12 months)." data-id="CD003753-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Albendazole plus DEC versus DEC, Outcome 11 Adult worm prevalence by ultrasound: longest follow‐up (up to 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Albendazole plus DEC versus DEC, Outcome 12 Adult worm prevalence by ultrasound: stratified by baseline infection (6 month follow‐up)." data-id="CD003753-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Albendazole plus DEC versus DEC, Outcome 12 Adult worm prevalence by ultrasound: stratified by baseline infection (6 month follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Albendazole plus DEC versus DEC, Outcome 13 Adult worm prevalence by ultrasound: stratified by baseline infection (12 month follow‐up)." data-id="CD003753-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Albendazole plus DEC versus DEC, Outcome 13 Adult worm prevalence by ultrasound: stratified by baseline infection (12 month follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Albendazole plus DEC versus DEC, Outcome 14 Adult worm prevalence by ultrasound: stratified by baseline infection (24 month follow‐up)." data-id="CD003753-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 Albendazole plus DEC versus DEC, Outcome 14 Adult worm prevalence by ultrasound: stratified by baseline infection (24 month follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Albendazole plus DEC versus DEC, Outcome 15 Adverse events." data-id="CD003753-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 Albendazole plus DEC versus DEC, Outcome 15 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-003-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-003-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Albendazole plus DEC versus DEC, Outcome 16 Adverse events: stratified by type." data-id="CD003753-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 Albendazole plus DEC versus DEC, Outcome 16 Adverse events: stratified by type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-003-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Albendazole plus ivermectin versus ivermectin, Outcome 1 Microfilaraemia (mf) prevalence: longest follow‐up (up to 12 months)." data-id="CD003753-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Albendazole plus ivermectin versus ivermectin, Outcome 1 Microfilaraemia (mf) prevalence: longest follow‐up (up to 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Albendazole plus ivermectin versus ivermectin, Outcome 2 Microfilaraemia (mf) prevalence: stratified by baseline infection (up to 6 months follow‐up)." data-id="CD003753-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Albendazole plus ivermectin versus ivermectin, Outcome 2 Microfilaraemia (mf) prevalence: stratified by baseline infection (up to 6 months follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Albendazole plus ivermectin versus ivermectin, Outcome 3 Microfilaraemia (mf) prevalence: stratified by baseline infection (12 months follow‐up)." data-id="CD003753-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Albendazole plus ivermectin versus ivermectin, Outcome 3 Microfilaraemia (mf) prevalence: stratified by baseline infection (12 months follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Albendazole plus ivermectin versus ivermectin, Outcome 4 Antigenaemia prevalence: longest follow‐up (up to 12 months)." data-id="CD003753-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Albendazole plus ivermectin versus ivermectin, Outcome 4 Antigenaemia prevalence: longest follow‐up (up to 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Albendazole plus ivermectin versus ivermectin, Outcome 5 Antigenaemia prevalence: stratified by baseline infection (6 months follow‐up)." data-id="CD003753-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Albendazole plus ivermectin versus ivermectin, Outcome 5 Antigenaemia prevalence: stratified by baseline infection (6 months follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Albendazole plus ivermectin versus ivermectin, Outcome 6 Antigenaemia prevalence: stratified by baseline infection (12 months follow‐up)." data-id="CD003753-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Albendazole plus ivermectin versus ivermectin, Outcome 6 Antigenaemia prevalence: stratified by baseline infection (12 months follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Albendazole plus ivermectin versus ivermectin, Outcome 7 Clinical disease." data-id="CD003753-fig-0040" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Albendazole plus ivermectin versus ivermectin, Outcome 7 Clinical disease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003753-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/urn:x-wiley:14651858:media:CD003753:CD003753-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_t/tCD003753-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Albendazole plus ivermectin versus ivermectin, Outcome 8 Adverse events." data-id="CD003753-fig-0041" src="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Albendazole plus ivermectin versus ivermectin, Outcome 8 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/media/CDSR/CD003753/image_n/nCD003753-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003753-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Albendazole alone or added to a microfilaricidal drug for lymphatic filariasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Albendazole alone or added to a microfilaricidal drug for lymphatic filariasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with lymphatic filariasis or communities where lymphatic filariasis is endemic<br/> <b>Setting:</b> Brazil, Ghana, Haiti, India, Papua New Guinea, Tanzania, and Zanzibar </p> <p><b>Intervention:</b> albendazole alone or in combination with a microfilaricidal drug<br/> <b>Comparison:</b> placebo or a single microfilaricidal drug </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment or a single microfilaricidal drug</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with albendazole alone or in combination with a microfilaricidal drug</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microfilaraemia (mf) prevalence<br/> follow‐up: range 2 weeks to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>174 per 1000<br/> (154 to 196) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95<br/> (0.85 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5027<br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole makes little or no difference to mf prevalence.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mf density<br/> follow‐up: range 1 month to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>In the included studies the effects of treatment with albendazole varied. The difference between treatment groups ranged from a 81.7% greater reduction with albendazole to 13.6% greater reduction with a single microfilaricidal drug.<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1216<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b,c,d</sup> </p> <p><i>Due to risk of bias, inconsistency, and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if albendazole has an effect on mf density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mf density<br/> follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>In the included studies the effects of treatment with albendazole varied. The difference between treatment groups ranged from a 55.5% greater reduction with albendazole to a 15.8% greater reduction with a single microfilaricidal drug.<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1052<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>c,f</sup> </p> <p><i>Due to inconsistency and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if albendazole has an effect on mf density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigenaemia prevalence<br/> follow‐up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>435 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>452 per 1000<br/> (422 to 487) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04<br/> (0.97 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3774<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole makes little or no difference to antigenaemia prevalence.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigen density<br/> follow‐up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>In the included studies treatment with albendazole had little or no effect on antigen density. There was a 1.5% to 17.1% greater reduction with albendazole in all studies except one; this study reported a 64.4% greater reduction in antigen density due to a small reduction with albendazole (16.9%) but a large increase in the placebo group.<sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1374<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>i,j,k</sup> </p> <p><i>Due to risk of bias and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if albendazole has an effect on antigen density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult worm prevalence detected by ultrasound<br/> follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>268 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>311 per 1000<br/> (193 to 499) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.16<br/> (0.72 to 1.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>l,m,n</sup> </p> <p><i>Due to indirectness and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole may make little or no difference to adult worm prevalence detected by ultrasound. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>184 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>178 per 1000<br/> (155 to 208) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.97<br/> (0.84 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2894<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>o</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole makes little or no difference to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> Abbreviations: CI: confidence interval; RR: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Eight studies reported geometric means, one study reported log mean, and one study reported the arithmetic mean. An effect of albendazole (P &lt; 0.05) on the geometric mean mf density was reported in three analyses in two studies. No effect of albendazole (P &gt; 0.05) was reported in six studies that used the geometric mean.<br/> <sup>b</sup>Downgraded by one for risk of bias: we judged the analytical methods used by <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> and <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> to obtain the change in density from baseline to follow‐up to be at high risk of bias.<br/> <sup>c</sup>Downgraded by one for inconsistency: the direction and magnitude of effect reported varied in favour of both albendazole and a microfilaricidal drug alone. We judged the effects of albendazole to be inconsistent.<br/> <sup>d</sup>Downgraded by two for imprecision: the optimal information size was met. There was considerable variation in the effects of albendazole, ranging from a statistically significant effect of albendazole (P &lt; 0.05) to little no effect. Authors reported mf density using geometric means, log means, and arithmetic means. We judged that the range of values that the effect estimate might take would likely include a meaningful effect and no effect.<br/> <sup>e</sup>Six studies reported geometric means, one study reported the log mean, and two studies reported the arithmetic mean. Five studies that assessed the geometric mean reported no effect was detected in six analyses (P &gt; 0.05).<br/> <sup>f</sup>Downgraded by two for imprecision: the optimal information size was met. There was considerable variation in the effects of albendazole; ranging from estimates with apparently large but underpowered effects (P &gt; 0.05) to estimates with little or no effect. Authors reported mf density using geometric means, log means, and arithmetic means. Given the differences in these measures, we are unable to judge the precision of the estimate of effect across the studies.<br/> <sup>g</sup>Not downgraded for risk of bias: most information is from studies at low or unclear risk of bias. Four studies had high risk of bias for attrition, but participant numbers at follow‐up were generally comparable between groups. We judge plausible bias unlikely to seriously alter the results.<br/> <sup>h</sup>Three studies reported geometric means, one study reported the log mean, and one study reported the arithmetic mean. Five analyses in three studies reported no effect of albendazole (P &gt; 0.05).<br/> <sup>i</sup>Downgraded by one for risk of bias: we judged the analytical methods used by <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> to obtain the change in density from baseline to follow‐up to be at high risk of bias.<br/> <sup>j</sup>Not downgraded for inconsistency: little to no benefit of albendazole was seen consistently across the studies. We judged the direction and the magnitude of effect to be consistent across studies.<br/> <sup>k</sup>Downgraded by two for imprecision: the optimal information size was met. Little to no effect of albendazole was consistently reported across the studies. All studies that reported a test for differences reported no statistically significant effect on geometric mean antigen density (P &gt; 0.05). We judged that the range of values would probably include little or no effect and exclude appreciable benefit or harm, but with no effect estimate or measure of precision we judged this to be seriously imprecise.<br/> <sup>l</sup>Not downgraded for risk of bias: all studies had unclear risk of bias for random sequence generation. The study contributing the most (68.7%) to the effect estimate had high risk of bias for attrition, but the number of participants followed up was comparable between groups. We judged plausible bias unlikely to seriously alter the results.<br/> <sup>m</sup>Downgraded by one for indirectness: this outcome was assessed only in men and boys (three studies). Two studies included adult men only, and one very small study included adults and children. We judged the evidence for this outcome to have serious indirectness due to the lack of applicability to the wider population of interest.<br/> <sup>n</sup>Downgraded by one for imprecision: there were insufficient events to meet optimal information size. The 95% CI around the pooled estimate of effect includes both no effect and appreciable benefit and harm, using a 25% relative risk reduction (RRR).<br/> <sup>o</sup>Not downgraded for risk of bias: for participant and personnel blinding, two studies had unclear risk of bias and one study was at high risk of bias. A large safety study contributing the most to the overall effect estimate (52.6%) had low risk of bias for blinding. We judged plausible bias unlikely to seriously alter the results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Albendazole alone or added to a microfilaricidal drug for lymphatic filariasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003753-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Albendazole alone for lymphatic filariasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Albendazole alone for lymphatic filariasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with lymphatic filariasis or communities where lymphatic filariasis is endemic<br/> <b>Setting:</b> Ghana, Haiti and India<br/> <b>Intervention:</b> albendazole<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with albendazole</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microfilaraemia (mf) prevalence<br/> follow‐up: range 4 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>207 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>203 per 1000<br/> (168 to 246) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98<br/> (0.81 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1406<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole makes little or no difference to mf prevalence.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mf density<br/> follow‐up: range 4 months to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Trend favoured albendazole to a variable extent. Albendazole reduced the geometric mean mf density by 28.7% to 61.1%. Placebo reduced the geometric mean mf density up to 17.2%, but the density also increased by 20.6%.<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>d,e,f</sup> </p> <p><i>Due to risk of bias, inconsistency, and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if albendazole has an effect on mf density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mf density<br/> follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No trend. In one study that reported the geometric mean, albendazole reduced mf density by 68.5% and in the placebo group the reduction was 13%; however, the authors reported no significant difference with albendazole (P &gt; 0.05).<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>h,i</sup> </p> <p><i>Due to inconsistency and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if albendazole has an effect on mf density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigenaemia prevalence<br/> follow‐up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>355 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 per 1000<br/> (323 to 444) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.07<br/> (0.91 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1054<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole makes little or no difference to antigenaemia prevalence.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigen density<br/> follow‐up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Trend showed little or no effect of albendazole. Albendazole reduced the geometric mean antigen density by 3.2% to 16.9%, and the placebo group antigen density was reduced by 1.7% and also increased by 47.5%.<sup>j</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>371<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>k,l,m</sup> </p> <p><i>Due to risk of bias and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if albendazole has an effect on antigen density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult worm prevalence detected by ultrasound ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult worm prevalence detected by ultrasound was not measured for this comparison.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/> (65 to 157) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95<br/> (0.61 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>678<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>n,o</sup> </p> <p><i>Due to imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole probably makes little or no difference to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> Abbreviations: CI: confidence interval; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for risk of bias: most information is from studies at low or unclear risk of bias. Three studies had unclear or high risk of bias for attrition, but numbers of participants followed up were comparable between groups in each study. We judged plausible bias unlikely to seriously alter the results.<br/> <sup>b</sup>Not downgraded for imprecision: borderline sufficient events to meet optimal information size (289 total events), and the 95% CI around the pooled estimate of effect includes little or no effect and excludes clinically appreciable benefit and harm. We used a relative risk reduction (RRR) of 25% as a cut‐off for imprecision.<br/> <sup>c</sup>Of the three studies that reported the geometric mean; one study reported an effect of albendazole (P &lt; 0.05), one study reported no effect (P &gt; 0.05), and one study did not statistically test this. One study reporting the arithmetic mean suggested a large benefit with albendazole, but we judged this to be an inappropriate measure for skewed data.<br/> <sup>d</sup>Downgraded by one for risk of bias: we judged the analytical methods used by <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> and <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> to obtain the change in density from baseline to follow‐up to be at high risk of bias.<br/> <sup>e</sup>Downgraded by one for inconsistency: the benefit of albendazole and the magnitude of effect was inconsistent.<br/> <sup>f</sup>Downgraded by two for imprecision: the optimal information size was not met. There was considerable variation in the effects of albendazole on geometric mean mf density; ranging from an effect in one study (P &lt; 0.05), an apparently large effect in one study that was not statistically evaluated, and no effect in one study (P &gt; 0.05). One study reported the arithmetic mean. We judged that the range of values could include a meaningful effect and no effect.<br/> <sup>g</sup>One study reported the arithmetic mean and showed a large benefit with albendazole, but we judged it to be an inappropriate measure for skewed data.<br/> <sup>h</sup>Downgraded by one for inconsistency: two studies reported a greater reduction in mf density with albendazole, but the magnitude of effect was unclear. One study reported the geometric mean and reported no effect of albendazole (P &gt;0.05), and one study reported the arithmetic mean and did not test for differences.<br/> <sup>i</sup>Downgraded by two for imprecision: the optimal information size was not met. One study reported the geometric mean mf density and an apparently large but underpowered effect (P &gt; 0.05). One study suggested a large reduction in the arithmetic mean with albendazole and did not statistically evaluate the effect. We judged that the range of values could include a meaningful effect and no effect.<br/> <sup>j</sup>Both studies reported that there was no effect using albendazole (P &gt; 0.05).<br/> <sup>k</sup>Downgraded by one for risk of bias: we judged the analytical methods used by <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> to obtain the change in density from baseline to follow‐up to be at high risk of bias.<br/> <sup>l</sup>Not downgraded for inconsistency: we found little to no effect of albendazole consistently across the studies. We judged the direction and the magnitude of effect to be consistent across studies.<br/> <sup>m</sup>Downgraded by two for imprecision: the optimal information size was not met. Two studies reported geometric mean antigen density and no benefit of using albendazole (P &gt; 0.05). We judged that the range of values would likely include little or no effect and exclude appreciable benefit or harm, but we can not be certain with no effect estimate or measure of precision.<br/> <sup>n</sup>Not downgraded for indirectness: albendazole regimens differed, one study provided single dose 400 mg albendazole and one study provided daily dose 400 mg albendazole for seven days. However, we judge this does not have serious indirectness.<br/> <sup>o</sup>Downgraded by one for imprecision: insufficient events to meet optimal information size. The 95% CI around the pooled estimate of effect includes both no effect and appreciable benefit and harm, using a relative risk reduction (RRR) of 25%. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Albendazole alone for lymphatic filariasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003753-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Albendazole added to DEC for lymphatic filariasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Albendazole added to DEC for lymphatic filariasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with lymphatic filariasis or communities where lymphatic filariasis is endemic<br/> <b>Setting:</b> Brazil, Haiti, India and Papua New Guinea<br/> <b>Intervention:</b> albendazole plus DEC<br/> <b>Comparison:</b> DEC </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with DEC</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with albendazole plus DEC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microfilaraemia (mf) prevalence<br/> follow‐up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>262 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>236 per 1000<br/> (197 to 286) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.90<br/> (0.75 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1102<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b</sup> </p> <p><i>Due to imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole probably makes little or no difference to mf prevalence.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mf density<br/> follow‐up: range 1 months to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No trend. The difference between the albendazole plus DEC and the DEC groups percentage reductions from baseline ranged from a 30% greater reduction with albendazole plus DEC to a 13.6% greater reduction with DEC alone.<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>559<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>d,e,f</sup> </p> <p><i>Due to risk of bias, inconsistency, and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if albendazole has an effect on mf density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mf density<br/> follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Trend showed little or no effect of albendazole. The difference between the albendazole plus DEC and the DEC groups percentage reductions from baseline ranged from a 5.6% greater reduction with albendazole plus DEC to a 15.8% greater reduction with DEC alone.<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>535<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>h,i</sup> </p> <p><i>Due to imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole may make little or no difference to mf density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigenaemia prevalence<br/> follow‐up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>503 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>518 per 1000<br/> (463 to 574) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/> (0.92 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>954<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>j</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole makes little or no difference to antigenaemia prevalence.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigen density<br/> follow up: range 6 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Trend showed little or no effect of albendazole. The difference between the albendazole plus DEC and the DEC groups percentage reductions from baseline ranged from a 9.7% greater reduction in the geometric mean to a 10.7% greater reduction in the log mean with albendazole plus DEC.<sup>k</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>h,l,m</sup> </p> <p><i>Due to risk of bias and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if albendazole has an effect on antigen density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult worm prevalence detected by ultrasound<br/> follow up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>268 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>311 per 1000<br/> (193 to 499) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.16<br/> (0.72 to 1.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>n,o,p</sup> </p> <p><i>Due to indirectness and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole may make little or no difference to adult worm prevalence detected by ultrasound. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>240 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000<br/> (189 to 266) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.94<br/> (0.79 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1589<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>q</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole makes little or no difference to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> Abbreviations: CI: confidence interval; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for inconsistency: I<sup>2</sup> of 40% was explained through subgroup analysis. The heterogeneity was a result of one study which used a more intensive treatment regimen (daily dose for 12 days) compared to the other six studies (single dose). We therefore judged inconsistency does not seem to be a serious issue.<br/> <sup>b</sup>Downgraded by one for imprecision: insufficient events to meet optimal information size (276 total events). Using a relative risk reduction (RRR) of 25% as a cut‐off for imprecision, the 95% CI around the pooled estimate of effect includes no effect and no clinically appreciable harm, but the upper boundary of the CI represents a 25% RRR. We therefore judge that the 95% CI around the pooled estimate of effect could include clinically appreciable benefit if the optimal information size had been met.<br/> <sup>c</sup>One study reported an effect of adding albendazole to DEC (P &lt; 0.05) and four studies reported no effect (P &gt; 0.05). Five studies reported geometric means and one study reported the log mean.<br/> <sup>d</sup>Downgraded by one for risk of bias: we judged the analytical methods used by <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> to obtain the change in density from baseline to follow‐up to be at high risk of bias.<br/> <sup>e</sup>Downgraded by one for inconsistency: the direction and magnitude of effect reported varied in favour of both albendazole plus DEC and DEC alone. We judged the effects of adding albendazole to DEC to be inconsistent.<br/> <sup>f</sup>Downgraded by two for imprecision: the optimal information size was met. The effect of adding albendazole to DEC varied considerably. One trial reported an effect of adding albendazole (P &lt; 0.05) and no effect was reported in the others (P &gt; 0.05). We judged that the range of values would likely include a meaningful effect and no effect.<br/> <sup>g</sup>Four studies reporting the geometric mean reported no effect of adding albendazole to DEC (P &gt; 0.05). One study reported the log mean and one study reported the arithmetic mean, no effect was seen.<br/> <sup>h</sup>Not downgraded for inconsistency: the direction and magnitude of the effect was consistent; we found no benefit of adding albendazole to DEC consistently across the studies.<br/> <sup>i</sup>Downgraded by two for imprecision: the optimal information size was met. No effect of adding albendazole to DEC was consistently reported across the studies; all studies reported no effect on geometric mean mf density (P &gt; 0.05). We judged that the range of values would likely include little or no effect and exclude appreciable benefit or harm, but we can not be certain as there is no estimate of effect or measure of precision.<br/> <sup>j</sup>Not downgraded for risk of bias: most information was at low or unclear risk of bias. Three studies had high risk of bias for attrition, but the number of participants followed up was comparable between groups in the studies. We judged plausible bias unlikely to alter the results.<br/> <sup>k</sup>One study reported the geometric mean, one study reported the log mean and one study reported the arithmetic mean; two studies reported no effect of adding albendazole to DEC (P &gt; 0.05).<br/> <sup>l</sup>Downgraded by one for risk of bias: we judged the analytical methods used by <a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> to obtain the change in density from baseline to follow‐up to be at high risk of bias.<br/> <sup>m</sup>Downgraded by two for imprecision: the optimal information size was not met. Two studies reported no effect of albendazole added to DEC (P &gt; 0.05). One study reported geometric mean, one study reported log mean and one study reported arithmetic mean. Given the differences in these measures and small number of participants, we are unable to judge the precision of the estimate of effect across the studies.<br/> <sup>n</sup>Not downgraded for risk of bias: all studies had unclear risk of bias for random sequence generation. The study contributing the most (68.7%) to the effect estimate had high risk of bias for attrition, but the number of participants followed up was comparable between groups. We judged plausible bias unlikely to seriously alter the results.<br/> <sup>o</sup>Downgraded by one for indirectness: this outcome was assessed only in men and boys (three studies). Two studies included adult men only, and one study included adults and children. We judged the evidence for this outcome to have serious indirectness due to the lack of applicability to the wider population of interest.<br/> <sup>p</sup>Downgraded by one for imprecision: there were insufficient events to meet optimal information size (47 total events). The 95% CI around the pooled estimate of effect includes both no effect and appreciable benefit and harm, using a relative risk reduction (RRR) of 25%.<br/> <sup>q</sup>Not downgraded for risk of bias: for participant and personnel blinding, one study had unclear risk of bias and one study was at high risk of bias; however, a large safety study contributing the most to the overall effect estimate (73.1%) was at low risk of bias. We judged plausible bias unlikely to seriously alter the results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Albendazole added to DEC for lymphatic filariasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003753-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Albendazole added to ivermectin for lymphatic filariasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Albendazole added to ivermectin for lymphatic filariasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with lymphatic filariasis or communities where lymphatic filariasis is endemic<br/> <b>Setting:</b> Ghana, Haiti, Tanzania and Zanzibar<br/> <b>Intervention:</b> albendazole plus ivermectin<br/> <b>Comparison:</b> ivermectin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ivermectin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with albendazole plus ivermectin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microfilaraemia (mf) prevalence<br/> follow‐up: range 2 weeks to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>108 per 1000<br/> (70 to 169) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.84<br/> (0.54 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2519<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b,c</sup> </p> <p><i>Due to imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole probably makes little or no difference to mf prevalence.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mf density<br/> follow‐up: range 4 months to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No trend. The difference between the albendazole plus ivermectin and the ivermectin groups percentage reductions from baseline ranged from a 3% to 22.8% greater reduction with albendazole plus ivermectin.<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>372<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>e,f,g</sup> </p> <p><i>Due to risk of bias, inconsistency, and imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if albendazole has an effect on mf density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mf density<br/> follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Trend showed little or no effect of albendazole. The difference between the albendazole plus ivermectin and the ivermectin groups percentage reductions from baseline ranged from a 6.7% to 9.1% greater reduction with albendazole plus ivermectin.<sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>i,j,k</sup> </p> <p><i>Due to imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole may make little or no difference to mf density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigenaemia prevalence<br/> follow up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>462 per 1000<br/> (418 to 516) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04<br/> (0.94 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1766<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole makes little or no difference to antigenaemia prevalence.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigen density<br/> follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Trend showed little or no effect of albendazole. The difference between the albendazole plus ivermectin and the ivermectin groups percentage reductions from baseline ranged from a 10.9% to 17.1% greater reduction with albendazole plus ivermectin.<sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>733<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>i,j,l</sup> </p> <p><i>Due to imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole may make little or no difference to antigen density.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult worm prevalence detected by ultrasound ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult prevalence detected by ultrasound was not measured for this comparison.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>122 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>142 per 1000<br/> (94 to 212) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.16<br/> (0.77 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>627<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>m,n</sup> </p> <p><i>Due to imprecision</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albendazole probably makes little or no difference to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> Abbreviations: CI: confidence interval; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for risk of bias: most information is from studies at low or unclear risk of bias. Two studies had high risk and one had unclear risk of bias for attrition, but the number of participants followed up were comparable between groups in most of the studies. We judged plausible bias unlikely to seriously alter the results.<br/> <sup>b</sup>Not downgraded for inconsistency: although we found heterogeneity between studies (I<sup>2</sup> = 65%), a subgroup analysis for length of follow‐up showed no statistical variability when two studies with earlier follow‐up time points (two weeks and four months) and two studies with later follow‐up time points (12 months) were analysed as subgroups. Overall, we judged that the effect estimate is not inconsistent.<br/> <sup>c</sup>Downgraded by one for imprecision: the optimal information size was met. The 95% CI around the pooled estimate of effect includes both no effect and appreciable benefit and harm, using a relative risk reduction (RRR) of 25%.<br/> <sup>d</sup>One small study reported an effect of adding albendazole to ivermectin (P &lt; 0.05), one study reported no effect (P &gt; 0.05), and one study did not clearly report the outcome of the statistical analyses.<br/> <sup>e</sup>Downgraded by one for risk of bias: we judged the analytical methods used by <a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> to obtain the change in density from baseline to follow‐up to be at high risk of bias.<br/> <sup>f</sup>Downgraded by one for inconsistency: the magnitude of the effect of adding albendazole to ivermectin varied and we judged it to be inconsistent.<br/> <sup>g</sup>Downgraded by two for imprecision: the optimal information size was not met. The effect of adding albendazole to ivermectin showed considerable variability; ranging from an effect in one study (P &lt; 0.05) and little or no effect (P &gt; 0.05) in another. We judged that the range of values could include a meaningful effect and no effect.<br/> <sup>h</sup>One study reported no effect of adding albendazole to ivermectin (P &gt; 0.05), and one study did not clearly report the outcome of the statistical analyses.<br/> <sup>i</sup>Not downgraded for risk of bias: most information is from studies at low or unclear risk of bias. Two studies had high risk or unclear risk of bias for attrition, but losses between groups were generally comparable in the studies. We judged plausible bias unlikely to seriously alter the results.<br/> <sup>j</sup>Not downgraded for inconsistency: we judged the direction and magnitude of effect to be consistent across studies.<br/> <sup>k</sup>Downgraded by two for imprecision: the optimal information size was not met. Two studies reported little or no effect with albendazole; statistically evaluated in one study (P &gt; 0.05). We judged that the range of values would likely include little or no effect and exclude appreciable benefit or harm, but we can not be certain as there is no estimate of effect or measure of precision.<br/> <sup>l</sup>Downgraded by two for imprecision: the optimal information size was met. Two studies reported little or no effect of albendazole; statistically evaluated in one study (P &gt; 0.05). We judged that the range of values would likely include little or no effect and exclude appreciable benefit or harm, but we can not be certain as there is no estimate of effect or measure of precision.<br/> <sup>m</sup>Not downgraded for risk of bias: most information was at low and unclear risk of bias. The study had unclear risk of bias for participant and personnel blinding and unclear risk of bias for attrition. However, for this outcome 90% of individuals were followed up. We judged plausible bias unlikely to seriously alter the results.<br/> <sup>n</sup>Downgraded by one for imprecision: insufficient events to meet optimal information size (83 total events). The 95% CI around the pooled estimate of effect includes both no effect and appreciable harm, using a 25% relative risk reduction (RRR). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Albendazole added to ivermectin for lymphatic filariasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003753-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Mass drug administration (MDA) programmes for filariasis</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Endemic for</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Drug recommendation</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Lymphatic filariasis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Onchocerciasis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Loiasis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Albendazole</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ivermectin</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Diethylcarbamazine</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Regimen</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twice per year<sup>b,c</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annual<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twice per year<sup>b,c</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annual<sup>c</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annual<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annual</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>In areas where <i>L loa</i> is endemic, ivermectin must be used with caution as people with high <i>L loa</i> microfilaraemia are at greater risk of experiencing serious adverse effects (SAEs). Albendazole alone given twice per year is recommended when mass drug administration with ivermectin has not yet occurred. Where mass drug administration with ivermectin has already occurred for either lymphatic filariasis or onchocerciasis, ivermectin distribution can continue under current guidance on the use of ivermectin for onchocerciasis in areas co‐endemic for loiasis. For further information, see reference c.<br/> <sup>b</sup><a href="./references#CD003753-bbs2-0105" title="World Health Organization. Guideline: alternative mass drug administration regimens to eliminate lymphatic filariasis. Guideline: Alternative Mass Drug Administration Regimens to Eliminate Lymphatic Filariasis. Geneva: World Health Organization, 2017. ">WHO 2017a</a><br/> <sup>c</sup><a href="./references#CD003753-bbs2-0070" title="Mectizan® Expert Committee, The Technical Consultative Committee. Recommendations for the Treatment of Onchocerciasis with Mectizan® in Areas Co‐endemic for Onchocerciasis and Loiasis. Georgia (USA): Mectizan® Expert Committee/The Mectizan® Donation Program, 2004. ">Mectizan Expert Committee 2004</a><br/> <sup>d</sup>Annual treatment with the triple‐drug therapy of ivermectin, DEC and albendazole is recommended in specified settings. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Mass drug administration (MDA) programmes for filariasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003753-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Parasitaemia density data: reported statistical analysis</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study details </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Reported statistical analysis </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of people enrolled</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mf density outcome denominator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CFA density outcome denominator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Explicit about method used to accommodate people with zero counts </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Explicit about method used to calculate % reduction in density</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>If density increased post‐ treatment, authors set change to zero </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0001" title="AddissDG , BeachMJ , StreitTG , LutwickS , LeConteFH , LafontantJG , et al. Randomised placebo‐controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet1997;350(9076):480‐4. BeachMJ , StreitTG , AddissDG , ProspereR , RobertsJM , LammiePJ . Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian school children. American Journal of Tropical Medicine and Hygiene1999;60(3):479‐86. ">Beach 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infected and uninfected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infected and uninfected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All CFA‐positive<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All CFA‐positive<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> <p>(“n+1”)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All CFA‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All FDS‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All individuals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infected and uninfected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All CFA‐positive<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> <p>Calculation provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>e</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infected and uninfected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All CFA‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> <p>(“n+1”)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>e</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infected and uninfected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>e</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All individuals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GM and AM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> <p>(“n+1”)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infected and uninfected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All mf‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All CFA‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> <p>Calculation provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>e</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Abbreviations: AM: arithmetic mean; CFA: circulating filarial antigen; FDS: filarial dance sign; GM: geometric mean; LM: log mean; Mf: microfilariae; NA: not applicable; NR: not reported.<br/> <sup>a</sup>Mf density and percentage reduction in density were reported for all participants irrespective of their pre‐treatment infection status only at the 24‐month follow‐up. Details were not provided in the Methods, but the standard percentage change calculation was used.<br/> <sup>b</sup>Antigen density was reported as number of antigenaemic participants with high antigenaemia decreasing to low or to negative, and number with low antigenaemia converting to negative only at 24‐month follow‐up.<br/> <sup>c</sup>Authors provided further details on request; for mf density the "n+1" formula before log transforming values was used, and % reduction was calculated using method reported in <a href="./references#CD003753-bbs2-0030" title="AddissDG , EberhardML , LammiePJ , McNeeleyMB , LeeSH , McNeeleyDF , et al. Comparative efficacy of clearing‐dose and single high‐dose ivermectin and diethylcarbamazine against Wuchereria bancrofti microfilaremia. American Society of Tropical Medicine and Hygiene1993;48(2):178‐85. ">Addiss 1993</a>.<br/> <sup>d</sup>Authors also reported mf and CFA unit geometric mean densities for individuals who were negative for the markers at baseline and positive at 12 months; however, the change or reduction in population mf or CFA densities for all enrolled individuals was not reported.<br/> <sup>e</sup>Details were not provided in the Methods, but the standard percentage change calculation was used.<br/> <sup>f</sup>Authors used the arithmetic mean and only assessed participants who remained mf‐positive at follow‐ups; participants who had previously been mf‐positive but converted to negative were excluded from density calculations.<br/> <sup>g</sup>The last version of this review, <a href="./references#CD003753-bbs2-0113" title="AddissD , GambleCL , GarnerP , GelbandH , EjereHOD , CritchleyJA . Albendazole for lymphatic filariasis. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD003753.pub3] ">Addiss 2005</a>, reported further details were provided by <a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a> on request; this trial calculated a William's mean (a modified geometric mean to take into account zero counts). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Parasitaemia density data: reported statistical analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003753-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Microfilarial density: up to 6 months follow‐up</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Background drug </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of bias: analysis used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial (follow‐up)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Intervention (albendazole) </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Control </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Difference between groups post‐treatment </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing (% reduction)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing: mf density</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Dunyo-2000" target="_blank">Dunyo 2000</a><sup>a,b,c,d</sup> </p> <p>(6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1783 (95% CI 1215 to 2617) to 693 (95% CI 335 to 1431)</p> <p>(61.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2277 (95% CI 1576 to 3289) to 2745 (95% CI 1505 to 5007)</p> <p>(20.6% increase)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.7%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>High risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Beach-1999" target="_blank">Beach 1999</a><sup>a,d,e</sup> </p> <p>(4 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.1 to 5.1</p> <p>(28.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.3 to 5.3</p> <p>(17.2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Fox-2005" target="_blank">Fox 2005</a><sup>a,d,e</sup> </p> <p>(6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.1 (95% CI 10.3 to 14.2) to 4.4 (95% CI 3.7 to 5.3)</p> <p>(34.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.3 (95% CI 14.5 to 20.6) to 11.2 (95% CI 9.2 to 13.7)</p> <p>(10.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>* (P &lt; 0.05)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>* (P &lt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Gayen-2013" target="_blank">Gayen 2013</a><sup>a,f,g</sup> </p> <p>(4 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3942.32 to 821.88</p> <p>(79%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4460.7 to 4390.7</p> <p><i>(1.6%)</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>DEC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Pani-2002" target="_blank">Pani 2002</a><sup>a,d,f</sup> </p> <p>(6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.4, post‐treatment NR</p> <p><i>(81%)</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.3, post‐treatment NR</p> <p><i>(74.7%)</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Dreyer-2006" target="_blank">Dreyer 2006</a><sup>d,f</sup> </p> <p>(1 month)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.9 to 12.7</p> <p>(53.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129.5 to 18.8</p> <p>(67.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−13.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.83)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Rizzo-2007" target="_blank">Rizzo 2007</a><sup>a,d,f</sup> </p> <p>(6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232.6 to 17.7</p> <p>(92.4%)</p> <p>[2.36 (95% CI 2.16 to 2.57) to 1.27 (95% CI 0.94 to 1.60)]<sup>i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182.6 to 10.5</p> <p>(94.2%)</p> <p>[2.26 (95% CI 2.04 to 2.49) to 1.09 (95% CI 0.74 to 1.43)]<sup>i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Bockarie-2007" target="_blank">Bockarie 2007</a><sup>d,f</sup> </p> <p>(6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.4 to 4.46</p> <p><i>(82.4%)</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.4 to 7.49</p> <p><i>(69.3%)</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.21)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-De-Britto-2015" target="_blank">De Britto 2015</a><sup>a,f,j</sup> </p> <p>(6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.26 (± 0.57) to 0.15 (± NR)</p> <p>(<i>99.2%</i>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.22 (± 0.52) to 0.83 (± NR)</p> <p>(<i>96%</i>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Fox-2005" target="_blank">Fox 2005</a><sup>a,d,e</sup> </p> <p>(6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.4 (95% CI 11.4 to 15.8) to 0.76 (95% CI 0.7 to 0.9)</p> <p>(80.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.9 (95% CI 11.0 to 15.2) to 2.8 (95% CI 2.3 to 3.4)</p> <p>(50.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>* (P = 0.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>* (P &lt;0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Ivermectin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Dunyo-2000" target="_blank">Dunyo 2000</a><sup>a,b,c,d</sup> </p> <p>(6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1585 (95% CI 1069 to 2350) to 110 (95% CI 50 to 239)</p> <p>(93.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2055 (95% CI 1389 to 3041) to 204 (95% CI 91 to 451)</p> <p>(90.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.71)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Simonsen-2004" target="_blank">Simonsen 2004</a><sup>a,b,d</sup> </p> <p>(6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>812.6 to 29.8</p> <p>(96.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>763.5 to 150</p> <p>(80.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>k</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>k</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1801091632054409485919135577293%26format=REVMAN#STD-Beach-1999" target="_blank">Beach 1999</a><sup>a,d,e</sup> </p> <p>(4 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.7 to 0.3</p> <p>(98.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5 to 1.5</p> <p>(76.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>*** (P &lt; 0.001)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>* (P &lt; 0.05)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Microfilariae (mf) density data and significance testing for differences between groups at baseline and follow‐up, as reported by study authors. We calculated the percentage reduction when this was not reported by the authors (values are italicized), and also the difference between the percentage reductions in the intervention and control groups. We judged the risk of bias as high when studies used analytical methods that could affect the interpretation of the data, and low or unclear risk when there was no obvious analytical issues.<br/> Abbreviations: CI: confidence interval; mf: microfilariae; NR: not reported; NS: not significant; * (P &lt; 0.05): significant; *** (P &lt; 0.001): significant; ±: standard deviation.<br/> <sup>a</sup>Only participants positive for mf at baseline.<br/> <sup>b</sup>Measured in 100 µL blood using counting chamber, and expressed as mf/mL.<br/> <sup>c</sup>Only in those individuals with over 100 mf/mL blood before treatment.<br/> <sup>d</sup>Reported as geometric mean.<br/> <sup>e</sup>Measured in 20 µL thick smear.<br/> <sup>f</sup>Measured in 1 mL blood by membrane filtration, and expressed as mf/mL.<br/> <sup>g</sup>Reported as arithmetic mean.<br/> <sup>h</sup>Authors reported "a significant difference between the control and the treated groups (P &lt; 0.05)" using paired t‐test for analysis; however, this statistical test is inappropriate for comparing different groups.<br/> <sup>i</sup>Data within square brackets [ ] indicates log mean intensity data and CIs provided by authors of <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>.<br/> <sup>j</sup>Reported as log mean.<br/> <sup>k</sup>Authors reported statistical analysis by paired t‐test and repeated‐measures ANOVA for correlated samples, and use of pairwise contrast tests to examine differences between groups at specific time points; results of pairwise tests for differences between groups do not appear to be reported. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Microfilarial density: up to 6 months follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003753-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Microfilarial density: 12 months follow‐up</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Background drug</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of bias: analysis used</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Intervention (albendazole)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Difference between groups post‐treatment </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing: % reduction</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing: mf density</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>798 to 251</p> <p>(68.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>971 to 845</p> <p>(13%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0008" title="GayenP , NayakA , SainiP , MukherjeeN , MaitraS , SarkarP , et al. A double‐blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Tropica2013;125(2):150‐6. ">Gayen 2013</a><sup>a,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3942.32 to 432.64</p> <p>(89%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4460.7 to 4245</p> <p>(<i>4.8%</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>DEC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a><sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.4, post‐treatment NR</p> <p>(95.4%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.3, post‐treatment NR</p> <p>(89.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0005" title="DreyerG , AddissD , WilliamsonJ , NorõesJ . Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Transactions of the Royal Society of Tropical Medicine and Hygiene2006;100(12):1118‐25. ">Dreyer 2006</a><sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.9 to 6.1</p> <p>(69.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129.5 to 4.8</p> <p>(85.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−15.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.21)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.87)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a><sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232.6 to 5.2</p> <p>(<i>97.8%</i>) </p> <p>[2.36 (95% CI 2.16 to 2.57) to 0.74 (95% CI 0.44 to 1.03)]<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182.6 to 3.6</p> <p>(<i>98%</i>) </p> <p>[2.26 (95% CI 2.04 to 2.49) to 0.65 (95% CI 0.35 to 0.95)]<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a><sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.4 to 3.47</p> <p>(<i>86.3%</i>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.4 to 4.27</p> <p>(<i>82.5%</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.6)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a><sup>a,d,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.26 (± 0.57) to 0.07 (± NR)</p> <p>(<i>99.4%</i>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.22 (± 0.52) to 0.52 (± NR)</p> <p>(<i>98%</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a><sup>a,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR to 249.2 (± 276.1)</p> <p>(NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR to 245.9 (± 314.8)</p> <p>(NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ivermectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>614 to 78</p> <p>(87.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>640 to 124</p> <p>(80.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.80)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>812.6 to 59.4</p> <p>(92.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>763.5 to 124.9</p> <p>(83.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>i</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Microfilariae (mf) density data and significance testing for differences between groups at baseline and follow‐up, as reported by study authors. We calculated the percentage reduction when this was not reported by the authors (values are italicized), and also the difference between the percentage reductions in the intervention and control groups. We judged the risk of bias as high when studies used analytical methods that could affect the interpretation of the data, and low or unclear risk when there was no obvious analytical issues. </p> <p>Abbreviations: mf: microfilariae; NR: not reported; NS: not significant; ±: standard deviation; CI: confidence interval.<br/> <sup>a</sup>Only participants positive for mf at baseline.<br/> <sup>b</sup>Measured in 100 µL blood using counting chamber, and expressed as mf/mL.<br/> <sup>c</sup>Reported as geometric mean.<br/> <sup>d</sup>Measured in 1 mL blood by membrane filtration, and expressed as mf/mL.<br/> <sup>e</sup>Reported as arithmetic mean.<br/> <sup>f</sup>Authors reported "a significant difference between the control and the treated groups (P &lt; 0.05)" using paired t‐test for analysis; however, this statistical test is inappropriate for comparing different groups.<br/> <sup>g</sup>Data within square brackets [ ] indicates log mean intensity data and CIs provided by authors of <a href="./references#CD003753-bbs2-0011" title="RizzoJA , BeloC , LinsR , DreyerG . Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year‐long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine‐albendazole. Annals of Tropical Medicine and Parasitology2007;101(5):423‐33. ">Rizzo 2007</a>.<br/> <sup>h</sup>Reported as log mean.<br/> <sup>i</sup>Authors reported statistical analysis by paired t‐test and repeated‐measures ANOVA for correlated samples, and use of pairwise contrast tests to examine differences between groups at specific time points; results of pairwise tests for differences between groups do not appear to be reported. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Microfilarial density: 12 months follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003753-tbl-0009"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Antigen density: longest follow‐up (up to 12 months)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Background drug</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of bias: analysis used</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial</b> </p> <p><b>(follow‐up)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Intervention (albendazole)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Difference between groups post‐treatment </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing: % reduction</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing: CFA density</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a><sup>a,b</sup> </p> <p>(12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1370 to 1139</p> <p>(16.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1869 to 2757</p> <p>(47.5% increase)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a><sup>a,c</sup> </p> <p>(6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2640 (95% CI 2279 to 3058) to 2428 (95% CI 2071 to 2847)</p> <p>(3.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2298 (95% CI 1951 to 2706) to 2479 (95% CI 2105 to 2919)</p> <p>(1.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>DEC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0004" title="DeBrittoRL , VanamailP , SankariT , VijayalakshmiG , DasLK , PaniSP . Enhanced efficacy of sequential administration of albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Tropical Biomedicine2015;32(2):198‐209. ">De Britto 2015</a><sup>a,d</sup> </p> <p>(12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.88 (± 0.48) to 2.89 (± NR) (<i>89.8%</i>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.58 (± 0.69) to 2.9 (± NR) (<i>79.1%</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.750)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0007" title="FoxLM , FurnessBW , HaserJK , DesireD , BrissauJM , MilordMD , et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. American Journal of Tropical Medicine and Hygiene2005;73(1):115‐21. ">Fox 2005</a><sup>a,c</sup> </p> <p>(6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2116 (95% CI 1798 to 2490) to 1350 (95% CI 1176 to 1549)</p> <p>(26.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2194 (95% CI 1842 to 2613) to 1597 (95% CI 1375 to 1855)</p> <p>(17%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a><sup>e</sup> </p> <p>(12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.47 (± 0.18) to 0.08 (± 0.15) (<i>83%</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39 (± 0.21) to 0.07 (± 0.15) (<i>82.1%</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ivermectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0006" title="DunyoSK , NkrumahFK , SimonsenPE . A randomized double‐blind placebo‐controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(2):205‐11. DunyoSK , NkrumahFK , SimonsenPE . Single‐dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(4):437‐43. DunyoSK , SimonsenPE . Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow‐up after re‐treatment with the combination. Transactions of the Royal Society for Tropical Medicine and Hygiene2002;96(2):189‐92. ">Dunyo 2000</a><sup>a,b</sup> </p> <p>(12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1404 to 834</p> <p>(40.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1689 to 1187</p> <p>(29.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.80)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0012" title="SimonsenPE , MagesaSM , DunyoSK , Malecela‐LazaroMN , MichaelE . The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania. Transactions of the Royal Soceity of Tropical Medicine and Hygiene2004;98(8):462‐72. ">Simonsen 2004</a><sup>a,b</sup> </p> <p>(12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>247</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1338.4 to 986.6</p> <p>(26.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>266</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1026.3 to 931.6</p> <p>(9.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>f</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Circulating filarial antigen (CFA) density data and significance testing for differences between groups at baseline and follow‐up, as reported by study authors. We calculated the percentage reduction when this was not reported by the authors (values are italicized), and also the difference between the percentage reductions in the intervention and control groups. We judged the risk of bias as high when studies used analytical methods that could affect the interpretation of the data, and low or unclear risk when there was no obvious analytical issues. </p> <p>Abbreviations: CFA: circulating filarial antigen; CI: confidence interval; DEC: diethylcarbamazine; mf: microfilariae; NR: not reported; NS: not significant; ±: standard deviation.<br/> <sup>a</sup>Only participants positive for CFA at baseline.<br/> <sup>b</sup>Measured in fingerprick blood, expressed as CFA unit geometric mean intensity.<br/> <sup>c</sup>Measured in fingerprick blood, expressed as geometric mean CFA units/mL.<br/> <sup>d</sup>Volume of blood not reported, expressed as log mean CFA units.<br/> <sup>e</sup>Measured in 50 µL blood, expressed as arithmetic mean CFA optical density value.<br/> <sup>f</sup>Authors reported statistical analysis by paired t‐test and repeated‐measures ANOVA for correlated samples, and use of pairwise contrast tests to examine differences between groups at specific time points; results of pairwise tests for differences between groups do not appear to be reported. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Antigen density: longest follow‐up (up to 12 months)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003753-tbl-0010"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Microfilarial density: 24 months and 36 months follow‐up</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Background drug</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of bias:</b> </p> <p><b>Analysis used</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial</b> </p> <p><b>(follow‐up)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Intervention (albendazole)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Difference between groups post‐treatment </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing: % reduction</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing: mf density</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>DEC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low or unclear risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0002" title="BockarieMJ , TavulL , IbamI , KastensW , HazlettF , TischDJ , et al. Efficacy of single‐dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. American Journal of Tropical Medicine and Hygiene2007;76(1):62‐6. ">Bockarie 2007</a><sup>a,b</sup> </p> <p>(24 months)<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR to 0.5</p> <p>(83.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>381</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR to 0.7</p> <p>(87.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−3.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P = 0.53)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>High risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a><sup>d,e</sup> </p> <p>(24 months)<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 (± 57) to <i>0.52</i> (± NR) (<i>99.5%</i>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133 (± 157) to <i>0.94</i> (± NR) </p> <p>(<i>99.3%</i>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS (P &gt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a><sup>d,e</sup> </p> <p>(24 months)<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR to 109.5 (± 143.3) (NR)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR to 99.5 (± 119.3)</p> <p>(NR)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a><sup>d,e</sup> </p> <p>(36 months)<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 (± 57) to 0</p> <p>(<i>100%</i>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133 (± 157) to 0</p> <p>(<i>100%</i>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0009" title="KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. Parasitology Research2017;116(10):2683–94. KshirsagarNA , GogtayNJ , GargBS , DeshmukhPR , RajgorDD , KadamVS , et al. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co‐administration in a field study in an area endemic for lymphatic filariasis in India. Transactions of the Royal Society of Tropical Medicine and Hygiene2004;98(4):205‐17. ">Kshirsagar 2004</a><sup>d,e</sup> </p> <p>(36 months)<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR to 57.6 (± 56.0)</p> <p>(NR)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR to 60.3 (± 61.5)</p> <p>(NR)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Microfilariae (mf) density (mf/mL) data and significance testing for differences between groups at baseline and follow‐up, as reported by study authors. We calculated the percentage reduction when this was not reported by the authors (values are italicized), and also the difference between the percentage reductions in the intervention and control groups. We judged the risk of bias as high when studies used analytical methods that could affect the interpretation of the data, and low or unclear risk when there was no obvious analytical issues. </p> <p>Abbreviations: DEC: diethylcarbamazine; mf: microfilariae; NR: not reported; NS: not significant; ±: standard deviation.<br/> <sup>a</sup>All evaluable participants irrespective of baseline mf status.<br/> <sup>b</sup>Reported as geometric mean.<br/> <sup>c</sup>After one annual dose albendazole plus DEC and DEC provided.<br/> <sup>d</sup>Only participants positive for mf at baseline.<br/> <sup>e</sup>Reported as arithmetic mean.<br/> <sup>f</sup>After two annual doses albendazole plus DEC and DEC provided.<br/> <sup>g</sup>After three annual doses albendazole plus DEC and DEC provided. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Microfilarial density: 24 months and 36 months follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003753-tbl-0011"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Antigen density: 24 months and 36 months follow‐up</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Background drug</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of bias: analysis used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial (follow‐up)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Intervention (albendazole)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Difference between groups post‐treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline to follow‐up (% reduction)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing: % reduction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significance testing: CFA density</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>DEC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a><sup>a,b</sup> </p> <p>(24 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 to 0.48</p> <p>(4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39 to 0.44</p> <p>(12.8% increase)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003753-bbs2-0010" title="HotiSL , PaniSP , VanamailP , AthisayaMK , DasLK , DasPK . Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. National Medical Journal of India2010;23(2):72‐6. PaniS , Subramanyam ReddyG , DasL , VanamailP , HotiS , RameshJ , et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co‐administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital‐based study. Filaria Journal2002;1(1):1. ">Pani 2002</a><sup>a,b</sup> </p> <p>(36 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 to 1.2</p> <p>(140% increase)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39 to 0.79</p> <p>(102.6% increase)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−37.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Circulating filarial antigen (CFA) density data and significance testing for differences between groups at baseline and follow‐up, as reported by study authors. Data was reported as the arithmetic mean and presented by the authors in graphs only; we extracted this information using WebPlotDigitizer software. We calculated the percentage reduction after treatment, and the difference between the percentage reductions in the intervention and control groups. We judged the risk of bias as high when studies used analytical methods that could affect the interpretation of the data, and low or unclear risk when there was no obvious analytical issues. </p> <p>Abbreviations: CFA: circulating filarial antigen; DEC: diethylcarbamazine; mf: microfilariae; NR: not reported.<br/> <sup>a</sup>Only participants positive for mf at baseline.<br/> <sup>b</sup>Volume of blood not reported, expressed as arithmetic mean CFA optical density value. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Antigen density: 24 months and 36 months follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/full#CD003753-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003753-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Albendazole alone or added to a microfilaricidal drug</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Microfilaraemia (mf) prevalence: longest follow‐up (up to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5027</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.85, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Albendazole versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.81, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Albendazole plus DEC versus DEC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.75, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Albendazole plus ivermectin versus ivermectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.80, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Antigenaemia prevalence: longest follow‐up (up to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.97, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Albendazole versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.91, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Albendazole plus DEC versus DEC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>954</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.92, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Albendazole plus ivermectin versus ivermectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.94, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adult worm prevalence by ultrasound: longest follow‐up (up to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.72, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Albendazole plus DEC versus DEC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.72, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 New clinical disease (new cases hydrocoele) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.23, 8.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Albendazole versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.06, 15.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Albendazole plus ivermectin versus ivermectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [0.17, 19.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Pre‐existing clinical disease (net improvement) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Albendazole versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Albendazole plus ivermectin versus ivermectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2894</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.84, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Albendazole versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>678</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.61, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Albendazole plus DEC versus DEC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1589</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.79, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Albendazole plus ivermectin versus ivermectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.77, 1.74]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Albendazole alone or added to a microfilaricidal drug</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003753-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Albendazole versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Microfilaraemia (mf) prevalence: longest follow‐up (up to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.81, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Microfilaraemia (mf) prevalence: stratified by baseline infection (up to 6 months follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 All mf positive at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.90, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Infected and uninfected individuals at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>783</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.73, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Microfilaraemia (mf) prevalence: stratified by baseline infection (12 months follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 All mf positive at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.86, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Infected and uninfected individuals at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.71, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Antigenaemia prevalence: longest follow‐up (up to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.91, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Antigenaemia prevalence: stratified by baseline infection (6 months follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Infected and uninfected individuals at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Antigenaemia prevalence: stratified by baseline infection (12 months follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 All adult worm positive (CFA) at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Infected and uninfected individuals at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Clinical disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 New cases hydrocoele</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Net improvement (lymphoedema)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Total improvement (hydrocoele)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>678</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.61, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Albendazole versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003753-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Albendazole plus DEC versus DEC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Microfilaraemia (mf) prevalence: longest follow‐up (up to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.75, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Microfilaraemia (mf) prevalence: stratified by baseline infection (up to 6 months follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.70, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 All mf positive at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.57, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 All adult worm positive (CFA or ultrasound) at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.74, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Infected and uninfected individuals at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.32, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Microfilaraemia (mf) prevalence: stratified by baseline infection (12 months follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 All mf positive at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.54, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 All adult worm positive (CFA or ultrasound) at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.70, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Infected and uninfected individuals at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.78, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Microfilaraemia (mf) prevalence: stratified by baseline infection (24 months follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 All mf positive at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.06, 13.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 All adult worm positive (CFA) at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.46, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Infected and uninfected individuals at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>868</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.71, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Microfilaraemia (mf) prevalence: stratified by baseline infection (36 months follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Infected and uninfected individuals at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Antigenaemia prevalence: longest follow‐up (up to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>954</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.92, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Antigenaemia prevalence: stratified by baseline infection (6 months follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 All mf positive at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.38, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 All adult worm positive (CFA) at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.95, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Infected and uninfected individuals at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.84, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Antigenaemia prevalence: stratified by baseline infection (12 months follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 All mf positive at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.22, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 All adult worm positive (CFA) at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.92, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Infected and uninfected individuals at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.83, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Antigenaemia prevalence: stratified by baseline infection (24 months follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.96, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 All mf positive at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.91, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Infected and uninfected individuals at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.95, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Antigenaemia prevalence: stratified by baseline infection (36 months follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.92, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 All mf positive at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.95, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Infected and uninfected individuals at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.84, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adult worm prevalence by ultrasound: longest follow‐up (up to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.72, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adult worm prevalence by ultrasound: stratified by baseline infection (6 month follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 All mf positive at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 All adult worm positive (ultrasound) at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Infected and uninfected individuals at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adult worm prevalence by ultrasound: stratified by baseline infection (12 month follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 All mf positive at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.37, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 All adult worm positive (ultrasound) at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.69, 3.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Infected and uninfected individuals at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.53, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adult worm prevalence by ultrasound: stratified by baseline infection (24 month follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.62, 2.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 All mf positive at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [0.09, 40.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Infected and uninfected individuals at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.59, 2.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1589</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.79, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse events: stratified by type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Any</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1589</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.79, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Interferred with daily activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.67, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Localized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.05, 5.43]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Albendazole plus DEC versus DEC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003753-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Albendazole plus ivermectin versus ivermectin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Microfilaraemia (mf) prevalence: longest follow‐up (up to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.54, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Microfilaraemia (mf) prevalence: stratified by baseline infection (up to 6 months follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 All mf positive at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.50, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Infected and uninfected individuals at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1929</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.23, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Microfilaraemia (mf) prevalence: stratified by baseline infection (12 months follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 All mf positive at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.88, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Infected and uninfected individuals at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.88, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Antigenaemia prevalence: longest follow‐up (up to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.94, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Antigenaemia prevalence: stratified by baseline infection (6 months follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 All adult worm positive (CFA) at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Infected and uninfected individuals at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Antigenaemia prevalence: stratified by baseline infection (12 months follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 All adult worm positive (CFA) at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.98, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Infected and uninfected individuals at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.94, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Clinical disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 New cases hydrocoele</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Net improvement (lymphoedema)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Net improvement (hydrocoele)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Albendazole plus ivermectin versus ivermectin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003753.pub4/references#CD003753-tbl-0015">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003753.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003753-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003753-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003753-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD003753-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD003753-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003753-note-0020">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003753\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003753\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003753\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003753\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003753\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003753\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003753\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003753\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003753\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003753\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003753\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003753\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003753\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003753\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003753\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003753\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003753\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003753\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003753.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003753.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003753.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003753.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003753.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715891692"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003753.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715891696"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003753.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d922a89649368',t:'MTc0MDcxNTg5Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 